CA2682761C - Methods for rapid multiplexed amplification of target nucleic acids - Google Patents
Methods for rapid multiplexed amplification of target nucleic acids Download PDFInfo
- Publication number
- CA2682761C CA2682761C CA2682761A CA2682761A CA2682761C CA 2682761 C CA2682761 C CA 2682761C CA 2682761 A CA2682761 A CA 2682761A CA 2682761 A CA2682761 A CA 2682761A CA 2682761 C CA2682761 C CA 2682761C
- Authority
- CA
- Canada
- Prior art keywords
- biochip
- sec
- reaction
- nucleic acid
- reactions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract description 112
- 108020004707 nucleic acids Proteins 0.000 title abstract description 111
- 102000039446 nucleic acids Human genes 0.000 title abstract description 111
- 230000003321 amplification Effects 0.000 title description 55
- 238000003199 nucleic acid amplification method Methods 0.000 title description 55
- 238000000034 method Methods 0.000 title description 45
- 238000000018 DNA microarray Methods 0.000 claims abstract description 144
- 238000006243 chemical reaction Methods 0.000 claims description 252
- 239000000758 substrate Substances 0.000 claims description 56
- 238000004891 communication Methods 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 14
- 230000005257 nucleotidylation Effects 0.000 abstract description 31
- 208000003028 Stuttering Diseases 0.000 abstract description 25
- 239000000243 solution Substances 0.000 description 75
- 238000003752 polymerase chain reaction Methods 0.000 description 72
- 108020004414 DNA Proteins 0.000 description 63
- 108091092878 Microsatellite Proteins 0.000 description 57
- 239000000523 sample Substances 0.000 description 51
- 230000001351 cycling effect Effects 0.000 description 37
- 108090000790 Enzymes Proteins 0.000 description 27
- 102000004190 Enzymes Human genes 0.000 description 27
- 108700028369 Alleles Proteins 0.000 description 26
- 238000001816 cooling Methods 0.000 description 25
- 238000010438 heat treatment Methods 0.000 description 25
- 239000012530 fluid Substances 0.000 description 23
- 238000012163 sequencing technique Methods 0.000 description 21
- 238000000137 annealing Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 17
- -1 poly(methyl methacrylate) Polymers 0.000 description 15
- 238000000926 separation method Methods 0.000 description 15
- 238000005382 thermal cycling Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 229920003023 plastic Polymers 0.000 description 12
- 239000004033 plastic Substances 0.000 description 12
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 238000010839 reverse transcription Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 239000004926 polymethyl methacrylate Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102000007325 Amelogenin Human genes 0.000 description 4
- 108010007570 Amelogenin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 210000004712 air sac Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 238000007403 mPCR Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 210000004381 amniotic fluid Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 238000001821 nucleic acid purification Methods 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 238000001921 nucleic acid quantification Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012782 phase change material Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'ādeoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- HSPHKCOAUOJLIO-UHFFFAOYSA-N 6-(aziridin-1-ylamino)-1h-pyrimidin-2-one Chemical compound N1C(=O)N=CC=C1NN1CC1 HSPHKCOAUOJLIO-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100451539 Arabidopsis thaliana HSD4 gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 239000004429 Calibre Substances 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 102100021766 E3 ubiquitin-protein ligase RNF138 Human genes 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101100305525 Homo sapiens RNF138 gene Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 229920005479 LuciteĀ® Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 229920005439 PerspexĀ® Polymers 0.000 description 1
- 229920005372 PlexiglasĀ® Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 241000769240 Polyozellus multiplex Species 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 241000205192 Pyrococcus woesei Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-L benzyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-L 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005323 electroforming Methods 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004374 forensic analysis Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- XTGGILXPEMRCFM-UHFFFAOYSA-N morpholin-4-yl carbamate Chemical compound NC(=O)ON1CCOCC1 XTGGILXPEMRCFM-UHFFFAOYSA-N 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920002939 poly(N,N-dimethylacrylamides) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 239000006226 wash reagent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/50273—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means or forces applied to move the fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502753—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6402—Atomic fluorescence; Laser induced fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6452—Individual samples arranged in a regular 2D-array, e.g. multiwell plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
- G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
- G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44743—Introducing samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44782—Apparatus specially adapted therefor of a plurality of samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44791—Microapparatus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0684—Venting, avoiding backpressure, avoid gas bubbles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
- B01L2200/143—Quality control, feedback systems
- B01L2200/147—Employing temperature sensors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0654—Lenses; Optical fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/069—Absorbents; Gels to retain a fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0819—Microarrays; Biochips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0887—Laminated structure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/16—Surface properties and coatings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
- B01L2300/1822—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using Peltier elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1838—Means for temperature control using fluid heat transfer medium
- B01L2300/1844—Means for temperature control using fluid heat transfer medium using fans
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1894—Cooling means; Cryo cooling
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0415—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic
- B01L2400/0421—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic electrophoretic flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
- G01N2021/6441—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks with two or more labels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/06—Illumination; Optics
- G01N2201/061—Sources
- G01N2201/06113—Coherent sources; lasers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2575—Volumetric liquid transfer
Abstract
A fast, multiplexed PCR system is described that can rapidly generate amplified nucleic acid products, for example, a full STR profile, from a target nucleic acid. Such systems include, for example, microfluidic biochips and a custom built thermal cycler, which are also described. The resulting STR profiles can satisfy forensic guidelines for signal strength, inter-loci peak height balance, heterozygous peak height ratio, incomplete non-template nucleotide addition, and stutter.
Description
METHODS FOR RAPID MULTIPLEXED AMPLIFICATION OF TARGET NUCLEIC ACIDS
FIELD OF THE INVENTION
The present invention generally relates to methods for the rapid amplification of one or more loci within a nucleic acid sample, as well as thermal cyclers and systems useful for performing the methods.
BACKGROUND OF THE INVENTION
The polymerase chain reaction (PCR) is an enzymatic reaction that facilitates rapid exponential amplification of nucleic acid sequences in vitro. In forensics, PCR can be utilized to identify individuals based on the amplification of small regions of the human genome containing a class of repeated DNA known as Short Tandem Repeats (STRs). The unit length of a given STR repeat ranges between 2-10 base pairs, and STRs generally fall within non-coding and flanking sequences but occasionally within coding regions (Edwards et al., Am. J. Hum. Genet. 1991, 49, 746-756). There are several hundred thousand STR loci in the human genome, occurring on average every 6-10 kb (Beckman and Weber, Genomics 1992, 12, 627-631) and appearing to be highly polymorphic (Edwards et al., Trans. Assoc.
Am. Physicians 1989, 102, 185-194). STR analysis has become a major tool in the forensic armamentarium with a growing set of applications including paternity testing, human identification in mass disasters, and routine typing of children.
While several commercially available STR kits have been developed for synthesizing the desired PCR products with high specificity, there are significant areas in which current STR technologies can be improved. Most importantly, the average time to complete multiplex PCR using commercial STR typing kits is approximately 2.14 hours;
the time-consuming and labor-intensive nature of these assays has contributed to backlogs in forensic laboratories. While the advent of automated instrumentation to simultaneously process multiple samples has helped to alleviate a significant bottleneck in typing throughput, the increasing number of samples to be analyzed will require further acceleration of the process. Furthermore, there is a need to increase the sensitivity of STR
assays as well as to improve the detection of the amplified products (Gill, Croat. Med. J. 2001, 42, 229-32).
Currently available STR kits contain nine to sixteen loci and work is underway in the field to increase the number of loci that can be detected. Certain applications of STR
analysis in the field can be conducted using 4 or more loci.
PCR can also be applied in a wide range of clinical settings. For example, PCR
can be utilized to diagnose bacterial infections such as those caused by Group A
Streptococci, methicillin resistant S. aureus, and vancomycin resistant Enterococci and is generally more sensitive than culture-based diagnostic techniques. Fungal infections can be similarly diagnosed. PCR can be used to diagnose respiratory viruses (e.g., respiratory syncytial virus, adenovirus, and influenza and parainfluenza viruses), genito-urinary viruses (e.g., herpes simplex virus and typing human papilloma viruses), meningitis (e.g., herpes simplex virus, Epstein-Barr virus, varicella-zoster virus, and enteroviruses), and hepatitis (e.g., hepatitis B
and C). PCR is also useful in preimplantation genetic diagnosis including the assessment of aneuploidy as well as the diagnosis of inherited diseases. From oncology to rheumatology and from hematology to gastroenterology, it would be difficult to find an area of medicine not impacted by PCR.
PCR has also been applied in a variety of non-clinical settings including veterinary identification (analogous to human STR typing), veterinary diagnostics, assessment of food safety, detection of agricultural pathogens and pharmacogenomics. An application of growing importance concerns the identification of biological weapons agents in clinical and environmental samples. Real-time PCR, a close relative of PCR that allows quantitation of the amount of product present in a reaction following each amplification cycle, is utilized in essentially the same applications as PCR itself (see, Espy et al., Clinical Microbiology Reviews 2006, 19, 1656-256).
Most commercially available thermal cycling instruments are limited in that they receive temperature feedback directly from and control the block temperature as opposed to the PCR solution temperature. As a consequence, the temperature profile of the solution,
FIELD OF THE INVENTION
The present invention generally relates to methods for the rapid amplification of one or more loci within a nucleic acid sample, as well as thermal cyclers and systems useful for performing the methods.
BACKGROUND OF THE INVENTION
The polymerase chain reaction (PCR) is an enzymatic reaction that facilitates rapid exponential amplification of nucleic acid sequences in vitro. In forensics, PCR can be utilized to identify individuals based on the amplification of small regions of the human genome containing a class of repeated DNA known as Short Tandem Repeats (STRs). The unit length of a given STR repeat ranges between 2-10 base pairs, and STRs generally fall within non-coding and flanking sequences but occasionally within coding regions (Edwards et al., Am. J. Hum. Genet. 1991, 49, 746-756). There are several hundred thousand STR loci in the human genome, occurring on average every 6-10 kb (Beckman and Weber, Genomics 1992, 12, 627-631) and appearing to be highly polymorphic (Edwards et al., Trans. Assoc.
Am. Physicians 1989, 102, 185-194). STR analysis has become a major tool in the forensic armamentarium with a growing set of applications including paternity testing, human identification in mass disasters, and routine typing of children.
While several commercially available STR kits have been developed for synthesizing the desired PCR products with high specificity, there are significant areas in which current STR technologies can be improved. Most importantly, the average time to complete multiplex PCR using commercial STR typing kits is approximately 2.14 hours;
the time-consuming and labor-intensive nature of these assays has contributed to backlogs in forensic laboratories. While the advent of automated instrumentation to simultaneously process multiple samples has helped to alleviate a significant bottleneck in typing throughput, the increasing number of samples to be analyzed will require further acceleration of the process. Furthermore, there is a need to increase the sensitivity of STR
assays as well as to improve the detection of the amplified products (Gill, Croat. Med. J. 2001, 42, 229-32).
Currently available STR kits contain nine to sixteen loci and work is underway in the field to increase the number of loci that can be detected. Certain applications of STR
analysis in the field can be conducted using 4 or more loci.
PCR can also be applied in a wide range of clinical settings. For example, PCR
can be utilized to diagnose bacterial infections such as those caused by Group A
Streptococci, methicillin resistant S. aureus, and vancomycin resistant Enterococci and is generally more sensitive than culture-based diagnostic techniques. Fungal infections can be similarly diagnosed. PCR can be used to diagnose respiratory viruses (e.g., respiratory syncytial virus, adenovirus, and influenza and parainfluenza viruses), genito-urinary viruses (e.g., herpes simplex virus and typing human papilloma viruses), meningitis (e.g., herpes simplex virus, Epstein-Barr virus, varicella-zoster virus, and enteroviruses), and hepatitis (e.g., hepatitis B
and C). PCR is also useful in preimplantation genetic diagnosis including the assessment of aneuploidy as well as the diagnosis of inherited diseases. From oncology to rheumatology and from hematology to gastroenterology, it would be difficult to find an area of medicine not impacted by PCR.
PCR has also been applied in a variety of non-clinical settings including veterinary identification (analogous to human STR typing), veterinary diagnostics, assessment of food safety, detection of agricultural pathogens and pharmacogenomics. An application of growing importance concerns the identification of biological weapons agents in clinical and environmental samples. Real-time PCR, a close relative of PCR that allows quantitation of the amount of product present in a reaction following each amplification cycle, is utilized in essentially the same applications as PCR itself (see, Espy et al., Clinical Microbiology Reviews 2006, 19, 1656-256).
Most commercially available thermal cycling instruments are limited in that they receive temperature feedback directly from and control the block temperature as opposed to the PCR solution temperature. As a consequence, the temperature profile of the solution,
2 which is critical to the success of the PCR, is likely to be grossly different from the desired profile.
Moreover, much of the literature on increasing PCR speed and sensitivity has focused on amplification of one particular locus at a time ("singleplex assays") and only limited success has been reported in simultaneous amplification of multiple loci ("multiplex assays") as required for forensic STR typing, clinical diagnostic and non-clinical applications. For example, a 160 nL chamber coupled to an integrated heater has been shown to be capable of amplification and separation of 4 STRs contained in a Y-STR assay in 80 minutes with a detection limit of 20 copies of template DNA. (Liu et al., Anal. Chem. 2007, 79, 1881-1889).
Increased PCR sensitivity due to reduced PCR reaction volume has also been reported for the PowerPlex 16 System, although no attempt was made to increase reaction speed (Schmidt et al., Int. J. Legal Med. 2006, 120, 42-48). However, neither report provided for the significantly shorter amplification times needed in the art. Hopwood et al., (International Congress Series 1288 (2006) 639-641) report a one hundred minute amplification using a set of 11 STR primers. With respect to clinical diagnostics, a panel of seven common respiratory viruses was amplified using a nanochip system in a PCR assay requiring 97.5 minutes (Takahashi et al., J. Clin. Microbiol 2008, doi:10.1128/JCM.01947-07).
Many of the applications of PCR (and real time PCR) such as forensic human identification by STR typing, clinical diagnostics, and biological weapons agent detection are extremely time sensitive and many of the applications are best performed in a multiplex setting. In addition, many of these applications are utilized in settings in which limited sample is available (e.g., a small number of pathogens from a clinical or environmental sample or a small number of human cells from a forensic sample) and sensitivity of the reaction is critical.
Notably, Horsman et al., (J.Forensic Sci., 2007, 52, 784-799) Id. at 792 stated that "PCR has been a common pursuit among analytical microchip researchers, as demonstrated by the wealth of literature on the topic. However, for forensic DNA analysis, there remain a number of avenues for development. Extensive work has not been shown using the commercially available forensic STR kits or, further, multiple STR
amplifications on a single device. When fully developed, however, microchip PCR will undoubtedly be a considerable time and cost savings to the forensic community." Therefore, there exists a need in the art for rapid and sensitive methods to successfully provide simultaneous amplification of a plurality of loci within a nucleic acid sample for a broad range of applications.
Moreover, much of the literature on increasing PCR speed and sensitivity has focused on amplification of one particular locus at a time ("singleplex assays") and only limited success has been reported in simultaneous amplification of multiple loci ("multiplex assays") as required for forensic STR typing, clinical diagnostic and non-clinical applications. For example, a 160 nL chamber coupled to an integrated heater has been shown to be capable of amplification and separation of 4 STRs contained in a Y-STR assay in 80 minutes with a detection limit of 20 copies of template DNA. (Liu et al., Anal. Chem. 2007, 79, 1881-1889).
Increased PCR sensitivity due to reduced PCR reaction volume has also been reported for the PowerPlex 16 System, although no attempt was made to increase reaction speed (Schmidt et al., Int. J. Legal Med. 2006, 120, 42-48). However, neither report provided for the significantly shorter amplification times needed in the art. Hopwood et al., (International Congress Series 1288 (2006) 639-641) report a one hundred minute amplification using a set of 11 STR primers. With respect to clinical diagnostics, a panel of seven common respiratory viruses was amplified using a nanochip system in a PCR assay requiring 97.5 minutes (Takahashi et al., J. Clin. Microbiol 2008, doi:10.1128/JCM.01947-07).
Many of the applications of PCR (and real time PCR) such as forensic human identification by STR typing, clinical diagnostics, and biological weapons agent detection are extremely time sensitive and many of the applications are best performed in a multiplex setting. In addition, many of these applications are utilized in settings in which limited sample is available (e.g., a small number of pathogens from a clinical or environmental sample or a small number of human cells from a forensic sample) and sensitivity of the reaction is critical.
Notably, Horsman et al., (J.Forensic Sci., 2007, 52, 784-799) Id. at 792 stated that "PCR has been a common pursuit among analytical microchip researchers, as demonstrated by the wealth of literature on the topic. However, for forensic DNA analysis, there remain a number of avenues for development. Extensive work has not been shown using the commercially available forensic STR kits or, further, multiple STR
amplifications on a single device. When fully developed, however, microchip PCR will undoubtedly be a considerable time and cost savings to the forensic community." Therefore, there exists a need in the art for rapid and sensitive methods to successfully provide simultaneous amplification of a plurality of loci within a nucleic acid sample for a broad range of applications.
3 SUMMARY OF THE INVENTION
The instruments, biochips, methods and systems of the invention provide the capability of heating and cooling a PCR solution rapidly, controllably, and reproducibly through monitoring and controlling the thermal cycler based on, at least in part, the actual temperature of the solution. The inventive instruments, biochips, methods and systems disclosed herein provide the ability to monitor and/or accurately control the reaction temperature of a solution within a biochip to avoid over- or under-heating through the specific incorporation of thermosensors that are not present in commercial thermal cyclers.
The ability to rapidly heat and cool reaction solutions to such temperatures allows ramping and settling times to be minimized and incubation time at the desired temperature to dominate the total step time. Further, the instruments, biochips, methods and systems of the invention provided herein impart the ability to rapidly alter and equilibrate the temperature of a reaction solution, thereby greatly increasing the speed at which an amplification reaction may proceed.
Fast multiplex PCR amplification times as short as seventeen minutes have been achieved using instruments, biochips, methods and systems of the invention.
Additional time reductions are possible based on the teachings of this invention. Further, the fast PCR
methods of the invention are effective over a wide dynamic range, are extremely sensitive and are compatible with a wide range of commercially available enzymes and reagents. For forensic applications, the instruments, biochips, methods and systems of the invention enable significant reductions in the time required to generate full profiles that satisfy interpretation guidelines for STR analysis.
In a first aspect, the invention provides thermal cyclers comprising a temperature control element (TCE) wherein a first surface of said TCE is adapted to receive a sample chamber containing a solution and a sensing chamber containing a thermosensor, wherein the thermosensor provides feedback to the TCE to set or maintain the sample at a desired temperature. In a second aspect, the invention provides thermal cyclers further comprising a second thermosensor positioned to monitor the temperature of the first surface of the TCE.
In a second aspect, the invention provides systems comprising a biochip comprising one or a plurality of reaction chambers comprising a portion of the biochip having a volume, wherein each reaction chamber further comprises a microfluidic inlet channel and a microfluidic outlet channel, wherein each reaction chamber is less than 200 tim from a contact surface of the biochip substrate; the system further comprising a thermal cycler,
The instruments, biochips, methods and systems of the invention provide the capability of heating and cooling a PCR solution rapidly, controllably, and reproducibly through monitoring and controlling the thermal cycler based on, at least in part, the actual temperature of the solution. The inventive instruments, biochips, methods and systems disclosed herein provide the ability to monitor and/or accurately control the reaction temperature of a solution within a biochip to avoid over- or under-heating through the specific incorporation of thermosensors that are not present in commercial thermal cyclers.
The ability to rapidly heat and cool reaction solutions to such temperatures allows ramping and settling times to be minimized and incubation time at the desired temperature to dominate the total step time. Further, the instruments, biochips, methods and systems of the invention provided herein impart the ability to rapidly alter and equilibrate the temperature of a reaction solution, thereby greatly increasing the speed at which an amplification reaction may proceed.
Fast multiplex PCR amplification times as short as seventeen minutes have been achieved using instruments, biochips, methods and systems of the invention.
Additional time reductions are possible based on the teachings of this invention. Further, the fast PCR
methods of the invention are effective over a wide dynamic range, are extremely sensitive and are compatible with a wide range of commercially available enzymes and reagents. For forensic applications, the instruments, biochips, methods and systems of the invention enable significant reductions in the time required to generate full profiles that satisfy interpretation guidelines for STR analysis.
In a first aspect, the invention provides thermal cyclers comprising a temperature control element (TCE) wherein a first surface of said TCE is adapted to receive a sample chamber containing a solution and a sensing chamber containing a thermosensor, wherein the thermosensor provides feedback to the TCE to set or maintain the sample at a desired temperature. In a second aspect, the invention provides thermal cyclers further comprising a second thermosensor positioned to monitor the temperature of the first surface of the TCE.
In a second aspect, the invention provides systems comprising a biochip comprising one or a plurality of reaction chambers comprising a portion of the biochip having a volume, wherein each reaction chamber further comprises a microfluidic inlet channel and a microfluidic outlet channel, wherein each reaction chamber is less than 200 tim from a contact surface of the biochip substrate; the system further comprising a thermal cycler,
4 comprising a temperature control element (TCE) wherein a first surface of the TCE is adapted to receive a substrate containing a sample, and a thermosensor positioned to measure the temperature of sample in the substrate and provide feedback to the TCE to set or maintain the sample at a desired temperature said thermal cycler in thermal communication with the contact surface of the biochip substrate.
In a third aspect, the invention provides systems comprising a biochip, comprising one or a plurality of reaction chambers, wherein each reaction chamber comprising a portion of the biochip having a volume, further comprising a microfluidic inlet channel and a microfluidic outlet channel, wherein each reaction chamber is less than 100 itm from a contact surface of the biochip substrate; and a thermal cycler, comprising a temperature control element (TCE) wherein a first surface of the TCE is adapted to receive a substrate containing a sample, and a thermosensor positioned to measure the temperature of sample in the substrate and provide feedback to the TCE to set or maintain the sample at a desired temperature, said thermal cycler in thermal communication with the contact surface of the biochip substrate.
In a fourth aspect, the invention provides methods for simultaneously amplifying of a plurality of loci in a nucleic acid solution comprising providing one or a plurality of reaction chambers wherein each reaction chamber comprises (i) a nucleic acid solution comprising at least one copy of at least one target nucleic acid to be amplified; (ii) one or more buffers; (iii) one or more salts; (iv) a primer set corresponding to each of the plurality of loci to be amplified; (v) a nucleic acid polymerase; and (vi) nucleotides, sequentially thermally cycling the temperature of the nucleic acid solution in each reaction chamber between a denaturing state, an annealing state, and an extension state for a predetermined number of cycles at heating and a cooling rates of about 4 ĀØ 150 C/sec, to yield a plurality of amplified loci in each reaction chamber in about 97 minutes or less.
In a fifth aspect, the invention provides methods for simultaneously amplifying of a plurality of loci in a nucleic acid solution comprising providing one or a plurality of reaction chambers wherein each reaction chamber comprises (i) a nucleic acid solution comprising at least one copy of at least one target nucleic acid to be amplified; (ii) one or more buffers; (iii) one or more salts; (iv) a primer set corresponding to each of the plurality of loci to be amplified; (v) a nucleic acid polymerase; and (vi) nucleotides, sequentially thermally cycling the temperature of the nucleic acid solution in each reaction chamber for a predetermined
In a third aspect, the invention provides systems comprising a biochip, comprising one or a plurality of reaction chambers, wherein each reaction chamber comprising a portion of the biochip having a volume, further comprising a microfluidic inlet channel and a microfluidic outlet channel, wherein each reaction chamber is less than 100 itm from a contact surface of the biochip substrate; and a thermal cycler, comprising a temperature control element (TCE) wherein a first surface of the TCE is adapted to receive a substrate containing a sample, and a thermosensor positioned to measure the temperature of sample in the substrate and provide feedback to the TCE to set or maintain the sample at a desired temperature, said thermal cycler in thermal communication with the contact surface of the biochip substrate.
In a fourth aspect, the invention provides methods for simultaneously amplifying of a plurality of loci in a nucleic acid solution comprising providing one or a plurality of reaction chambers wherein each reaction chamber comprises (i) a nucleic acid solution comprising at least one copy of at least one target nucleic acid to be amplified; (ii) one or more buffers; (iii) one or more salts; (iv) a primer set corresponding to each of the plurality of loci to be amplified; (v) a nucleic acid polymerase; and (vi) nucleotides, sequentially thermally cycling the temperature of the nucleic acid solution in each reaction chamber between a denaturing state, an annealing state, and an extension state for a predetermined number of cycles at heating and a cooling rates of about 4 ĀØ 150 C/sec, to yield a plurality of amplified loci in each reaction chamber in about 97 minutes or less.
In a fifth aspect, the invention provides methods for simultaneously amplifying of a plurality of loci in a nucleic acid solution comprising providing one or a plurality of reaction chambers wherein each reaction chamber comprises (i) a nucleic acid solution comprising at least one copy of at least one target nucleic acid to be amplified; (ii) one or more buffers; (iii) one or more salts; (iv) a primer set corresponding to each of the plurality of loci to be amplified; (v) a nucleic acid polymerase; and (vi) nucleotides, sequentially thermally cycling the temperature of the nucleic acid solution in each reaction chamber for a predetermined
5
6 number of cycles at heating and a cooling rates of about 4 ĀØ 150 C/sec, to yield a plurality of amplified loci in each reaction chamber in about 97 minutes or less.
In a sixth aspect, the invention provides methods for simultaneously amplifying 5 or more loci in a nucleic acid solution comprising providing one or a plurality of reaction chambers wherein each reaction chamber comprises (i) a nucleic acid solution comprising at least one copy of at least one target nucleic acid to be amplified; (ii) one or more buffers; (iii) one or more salts; (iv) a primer set corresponding to the 5 or more loci to be amplified; (v) a nucleic acid polymerase; and (vi) nucleotides, sequentially thermally cycling the temperature of the nucleic acid solution in each reaction chamber between a denaturing state, an annealing state, and an extension state for a predetermined number of cycles at heating and a cooling rates of about 4 ĀØ 150 C/sec, to yield 5 or more amplified loci in each reaction chamber.
In a seventh aspect, the invention provides integrated biochips systems comprising a biochip comprising at least two reaction chambers in microfludic communication, wherein a first reaction chamber is in thermal communication with a thermal cycler, comprising: a.
temperature control element (TCE) wherein a first surface of the TCE is adapted to receive a substrate containing a sample, and a thermosensor positioned to measure the temperature of sample in the substrate and provide feedback to the TCE to set or maintain the sample at a desired temperature wherein a contact surface of the biochip is in thermal communication with the first surface of the thermal cycler; and a second reaction chamber in fluid connection with the first reaction chamber and adapted for nucleic acid extraction, nucleic acid purification, pre-PCR nucleic acid cleanup, post-PCR cleanup, pre-sequencing cleanup, sequencing, post-sequencing cleanup, nucleic acid separation, nucleic acid detection, reverse transcription, pre-reverse transcription cleanup, post-reverse transcription cleanup, nucleic acid ligation, nucleic acid hybridization, or quantification, wherein the first reaction chamber is less than 200 Am from a contact surface of the biochip.
Specific preferred embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure IA is a photograph of an embodiment of the thermal cycler of the invention.
Figure 1B is a photograph showing an embodiment of a 16-lane microfluidic biochip for use with the thermal cycler shown in Figure 1A.
Figure 2A is a graph showing the temperature profiles of block and reaction solution for one thermal cycle of the standard STR cycling protocol described herein (total cycling time: 145.1 minutes).
Figure 2B is a graph showing the temperature profiles of block and reaction solution for one thermal cycle of the fast cycling protocol described herein (total cycling time: 19.56 minutes).
Figure 3 is a graph showing temperature profiles of the heat pump and the reaction solution for one thermal cycle for a thermal cycler of the invention using fast cycling conditions (total cycling time: 17.3 minutes).
Figure 4A is a graph showing the STR profile generated in biochip reactions according to the invention using 0.5 ng template DNA.
Figure 4B is a graph showing the STR profile generated in tube reactions according to the invention using 0.5 ng template DNA.
Figure 5A is a graph showing the effect of DNA template level on signal strength in biochip reactions.
Figure 5B is a graph showing the effect of DNA template level on signal strength in tube reactions.
Figure 6A is a graph showing the effect of DNA template level on heterozygous peak height ratio (PHR) in biochip reactions.
Figure 6B is a graph showing the effect of DNA template level on PHR in tube reactions.
Figure 7A is a graph showing the effect of DNA template level on non-template nucleotide addition (NTA) in biochip reactions.
Figure 7B is a graph showing the effect of DNA template level on NTA in tube reactions Figure 8A is a graph showing the effect of DNA template level on stutter in biochip reactions.
Figure 8B is a graph showing the effect of DNA template level on stutter in tube reactions Figure 9A is a graph showing the profile for biochip (top) and tube reaction (bottom) generated with the COfilerTm primer set using lng template DNA.
In a sixth aspect, the invention provides methods for simultaneously amplifying 5 or more loci in a nucleic acid solution comprising providing one or a plurality of reaction chambers wherein each reaction chamber comprises (i) a nucleic acid solution comprising at least one copy of at least one target nucleic acid to be amplified; (ii) one or more buffers; (iii) one or more salts; (iv) a primer set corresponding to the 5 or more loci to be amplified; (v) a nucleic acid polymerase; and (vi) nucleotides, sequentially thermally cycling the temperature of the nucleic acid solution in each reaction chamber between a denaturing state, an annealing state, and an extension state for a predetermined number of cycles at heating and a cooling rates of about 4 ĀØ 150 C/sec, to yield 5 or more amplified loci in each reaction chamber.
In a seventh aspect, the invention provides integrated biochips systems comprising a biochip comprising at least two reaction chambers in microfludic communication, wherein a first reaction chamber is in thermal communication with a thermal cycler, comprising: a.
temperature control element (TCE) wherein a first surface of the TCE is adapted to receive a substrate containing a sample, and a thermosensor positioned to measure the temperature of sample in the substrate and provide feedback to the TCE to set or maintain the sample at a desired temperature wherein a contact surface of the biochip is in thermal communication with the first surface of the thermal cycler; and a second reaction chamber in fluid connection with the first reaction chamber and adapted for nucleic acid extraction, nucleic acid purification, pre-PCR nucleic acid cleanup, post-PCR cleanup, pre-sequencing cleanup, sequencing, post-sequencing cleanup, nucleic acid separation, nucleic acid detection, reverse transcription, pre-reverse transcription cleanup, post-reverse transcription cleanup, nucleic acid ligation, nucleic acid hybridization, or quantification, wherein the first reaction chamber is less than 200 Am from a contact surface of the biochip.
Specific preferred embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure IA is a photograph of an embodiment of the thermal cycler of the invention.
Figure 1B is a photograph showing an embodiment of a 16-lane microfluidic biochip for use with the thermal cycler shown in Figure 1A.
Figure 2A is a graph showing the temperature profiles of block and reaction solution for one thermal cycle of the standard STR cycling protocol described herein (total cycling time: 145.1 minutes).
Figure 2B is a graph showing the temperature profiles of block and reaction solution for one thermal cycle of the fast cycling protocol described herein (total cycling time: 19.56 minutes).
Figure 3 is a graph showing temperature profiles of the heat pump and the reaction solution for one thermal cycle for a thermal cycler of the invention using fast cycling conditions (total cycling time: 17.3 minutes).
Figure 4A is a graph showing the STR profile generated in biochip reactions according to the invention using 0.5 ng template DNA.
Figure 4B is a graph showing the STR profile generated in tube reactions according to the invention using 0.5 ng template DNA.
Figure 5A is a graph showing the effect of DNA template level on signal strength in biochip reactions.
Figure 5B is a graph showing the effect of DNA template level on signal strength in tube reactions.
Figure 6A is a graph showing the effect of DNA template level on heterozygous peak height ratio (PHR) in biochip reactions.
Figure 6B is a graph showing the effect of DNA template level on PHR in tube reactions.
Figure 7A is a graph showing the effect of DNA template level on non-template nucleotide addition (NTA) in biochip reactions.
Figure 7B is a graph showing the effect of DNA template level on NTA in tube reactions Figure 8A is a graph showing the effect of DNA template level on stutter in biochip reactions.
Figure 8B is a graph showing the effect of DNA template level on stutter in tube reactions Figure 9A is a graph showing the profile for biochip (top) and tube reaction (bottom) generated with the COfilerTm primer set using lng template DNA.
7 Figure 9B is a graph showing the profile for biochip (top) and tube reaction (bottom) generated with the IdentifilerTm primer set using lng template DNA.
Figure 10 is a graph showing the profile for an embodiment of a sequencing reaction, as described in Example 5, DETAILED DESCRIPTION OF THE INVENTION
In order to achieve fast multiplexed nucleic acid amplification, such as PCR, the invention provides thermal cycling instrumentation, reaction vessels, and reaction conditions that can be used to amplify a plurality of loci within a target nucleic acid sample. As is illustrated by the examples provided herein, fast thermal cycling methods of the invention can be performed in microfluidic biochips using the thermal cycler of the invention and the methods described herein.
The methods provided by the invention are capable of rapid multiplex amplification in applications in addition to those utilizing the biochips and thermal cyclers described herein.
For example, the use of thin walled tubes in conventional thermal cyclers (for example block based thermal cyclers and the Roche LightCyclerTm) and the use of amplification methods other than temperature cycled PCR (for example isothermal PCR or rolling circle amplification) are specifically contemplated.
The methods, biochips, and thermal cyclers provided by the invention are capable of amplifying a plurality of loci in under 100 minutes within a given nucleic acid solution present at amounts of at least 0.006 ng of human genomic DNA (the approximate amount of DNA in a single nucleated human cell) containing the target nucleic acid locus or loci). In other embodiments the amplification occurs in less than 90 min., less than 80 min., less than 70 min., less than 60 min., less than 50 min., less than 40 min., less than 30 min., less than 20 min., less that 17.7 min., less than 15 min., less than 10 min., or less than 5 min..
In other embodiments, a plurality of loci within a bacterial, viral, fungal, animal, or plant-derived genome can be amplified starting from at least one copy of the target nucleic acid locus or loci. For example, a sample to be analyzed can comprise less than 1000 copies, less than 400 copies, less than 200 copies, less than 100 copies, less than 50 copies, less than 30 copies, less than 10 copies or at least 1 copy of a target nucleic acid prior to the multiplexed amplification reaction. In addition, less than a single genome equivalent of DNA
can be utilized for amplification if the target nucleic acid locus is present in more than one copy in the genome. Generally, at least two loci, and up to approximately 250 loci can be
Figure 10 is a graph showing the profile for an embodiment of a sequencing reaction, as described in Example 5, DETAILED DESCRIPTION OF THE INVENTION
In order to achieve fast multiplexed nucleic acid amplification, such as PCR, the invention provides thermal cycling instrumentation, reaction vessels, and reaction conditions that can be used to amplify a plurality of loci within a target nucleic acid sample. As is illustrated by the examples provided herein, fast thermal cycling methods of the invention can be performed in microfluidic biochips using the thermal cycler of the invention and the methods described herein.
The methods provided by the invention are capable of rapid multiplex amplification in applications in addition to those utilizing the biochips and thermal cyclers described herein.
For example, the use of thin walled tubes in conventional thermal cyclers (for example block based thermal cyclers and the Roche LightCyclerTm) and the use of amplification methods other than temperature cycled PCR (for example isothermal PCR or rolling circle amplification) are specifically contemplated.
The methods, biochips, and thermal cyclers provided by the invention are capable of amplifying a plurality of loci in under 100 minutes within a given nucleic acid solution present at amounts of at least 0.006 ng of human genomic DNA (the approximate amount of DNA in a single nucleated human cell) containing the target nucleic acid locus or loci). In other embodiments the amplification occurs in less than 90 min., less than 80 min., less than 70 min., less than 60 min., less than 50 min., less than 40 min., less than 30 min., less than 20 min., less that 17.7 min., less than 15 min., less than 10 min., or less than 5 min..
In other embodiments, a plurality of loci within a bacterial, viral, fungal, animal, or plant-derived genome can be amplified starting from at least one copy of the target nucleic acid locus or loci. For example, a sample to be analyzed can comprise less than 1000 copies, less than 400 copies, less than 200 copies, less than 100 copies, less than 50 copies, less than 30 copies, less than 10 copies or at least 1 copy of a target nucleic acid prior to the multiplexed amplification reaction. In addition, less than a single genome equivalent of DNA
can be utilized for amplification if the target nucleic acid locus is present in more than one copy in the genome. Generally, at least two loci, and up to approximately 250 loci can be
8 simultaneously amplified within each target nucleic acid in a sample according to the methods described herein. Further, at least two loci and up to approximately 250 loci can be simultaneously amplified in a plurality of target nucleic acids according to the methods described herein.
The target nucleic acids utilized herein can be any nucleic acid, for example, human nucleic acids, bacterial nucleic acids, or viral nucleic acids. The target nucleic acid sample can be, for example, a nucleic acid sample from one or more cells, tissues, or bodily fluids such as blood, urine, semen, lymphatic fluid, cerebrospinal fluid, or amniotic fluid, or other biological samples, such as tissue culture cells, buccal swabs, mouthwashes, stool, tissues slices, biopsy aspiration, and archeological samples such as bone or mummified tissue.
Target nucleic acids can be, for example, DNA, RNA, or the DNA product of RNA
subjected to reverse transcription. Target samples can be derived from any source including, but not limited to, eukaryotes, plants, animals, vertebrates, fish, mammals, humans, non-humans, bacteria, microbes, viruses, biological sources, serum, plasma, blood, urine, semen, lymphatic fluid, cerebrospinal fluid, amniotic fluid, biopsies, needle aspiration biopsies, cancers, tumors, tissues, cells, cell lysates, crude cell lysates, tissue lysates, tissue culture cells, buccal swabs, mouthwashes, stool, mummified tissue, forensic sources, autopsies, archeological sources, infections, nosocomial infections, production sources, drug preparations, biological molecule productions, protein preparations, lipid preparations, carbohydrate preparations, inanimate objects, air, soil, sap, metal, fossils, excavated materials, and/or other terrestrial or extra-terrestrial materials and sources. The sample may also contain mixtures of material from one source or different sources. For example, nucleic acids of an infecting bacterium or virus can be amplified along with human nucleic acids when nucleic acids from such infected cells or tissues are amplified using the disclosed methods. Types of useful target samples include eukaryotic samples, plant samples, animal samples, vertebrate samples, fish samples, mammalian samples, human samples, non-human samples, bacterial samples, microbial samples, viral samples, biological samples, serum samples, plasma samples, blood samples, urine samples, semen samples, lymphatic fluid samples, cerebrospinal fluid samples, amniotic fluid samples, biopsy samples, needle aspiration biopsy samples, cancer samples, tumor samples, tissue samples, cell samples, cell lysate samples, crude cell lysate samples, tissue lysate samples, tissue culture cell samples, buccal swab samples, mouthwash samples, stool samples, mummified tissue samples, autopsy samples, archeological samples, infection samples, nosocomial infection samples, production samples, drug preparation samples,
The target nucleic acids utilized herein can be any nucleic acid, for example, human nucleic acids, bacterial nucleic acids, or viral nucleic acids. The target nucleic acid sample can be, for example, a nucleic acid sample from one or more cells, tissues, or bodily fluids such as blood, urine, semen, lymphatic fluid, cerebrospinal fluid, or amniotic fluid, or other biological samples, such as tissue culture cells, buccal swabs, mouthwashes, stool, tissues slices, biopsy aspiration, and archeological samples such as bone or mummified tissue.
Target nucleic acids can be, for example, DNA, RNA, or the DNA product of RNA
subjected to reverse transcription. Target samples can be derived from any source including, but not limited to, eukaryotes, plants, animals, vertebrates, fish, mammals, humans, non-humans, bacteria, microbes, viruses, biological sources, serum, plasma, blood, urine, semen, lymphatic fluid, cerebrospinal fluid, amniotic fluid, biopsies, needle aspiration biopsies, cancers, tumors, tissues, cells, cell lysates, crude cell lysates, tissue lysates, tissue culture cells, buccal swabs, mouthwashes, stool, mummified tissue, forensic sources, autopsies, archeological sources, infections, nosocomial infections, production sources, drug preparations, biological molecule productions, protein preparations, lipid preparations, carbohydrate preparations, inanimate objects, air, soil, sap, metal, fossils, excavated materials, and/or other terrestrial or extra-terrestrial materials and sources. The sample may also contain mixtures of material from one source or different sources. For example, nucleic acids of an infecting bacterium or virus can be amplified along with human nucleic acids when nucleic acids from such infected cells or tissues are amplified using the disclosed methods. Types of useful target samples include eukaryotic samples, plant samples, animal samples, vertebrate samples, fish samples, mammalian samples, human samples, non-human samples, bacterial samples, microbial samples, viral samples, biological samples, serum samples, plasma samples, blood samples, urine samples, semen samples, lymphatic fluid samples, cerebrospinal fluid samples, amniotic fluid samples, biopsy samples, needle aspiration biopsy samples, cancer samples, tumor samples, tissue samples, cell samples, cell lysate samples, crude cell lysate samples, tissue lysate samples, tissue culture cell samples, buccal swab samples, mouthwash samples, stool samples, mummified tissue samples, autopsy samples, archeological samples, infection samples, nosocomial infection samples, production samples, drug preparation samples,
9 biological molecule production samples, protein preparation samples, lipid preparation samples, carbohydrate preparation samples, inanimate object samples, air samples, soil samples, sap samples, metal samples, fossil samples, excavated material samples, and/or other terrestrial or extra-terrestrial samples. Types of forensics samples include blood, dried blood, bloodstains, buccal swabs, fingerprints, touch samples (e.g., epithelial cells left on the lip of a drinking glass, the inner rim of a baseball cap, or cigarette butts), chewing gum, gastric contents, saliva, nail scrapings, soil, sexual assault samples, hair, bone, skin, and solid tissue. Types of environmental samples include unfiltered and filtered air and water, soil, swab samples from surfaces, envelopes, and powders.
For example, the methods herein can provide amplified nucleic acid samples whose analysis yields data suitable for forensic interpretation, and in particular, data that satisfies forensic interpretation guidelines. Such guidelines include signal strength, inter-loci peak height balance, heterozygous peak height ratio (PHR), incomplete non-template nucleotide addition (NTA), and stutter (Scientific Working Group on DNA Analysis Methods, Short Tandem Repeat (STR) Interpretation Guidelines. Forensic Science Communications, 2000, 2(3)).
The phrase "fluid communication" as used herein, refers to two chambers, or other components or regions containing a fluid, connected together so that a fluid can flow between the two chambers, components, or regions. Therefore, two chambers that are in "fluid communication" can, for example, be connected together by a microfluidic channel between the two chambers, such that a fluid can flow freely between the two chambers.
Such microfluidic channels can optionally include one or more valves therein which can be closed or occluded, in order to block and/or otherwise control fluid communication between the chambers.
The term "poly(methyl methacrylate) or "PlVIMA," as used herein, means the synthetic polymers of methyl methacrylate, including but not limited to, those sold under the tradenames Plexiglas, Limacryirm, R-Cast, Perspex', Plazcrylrm, Acrylex TM, ACrylitemi, ACrylplastml, AltuglasTm, PolycastTm and Lucite, as well as those polymers described in US Patent Nos. 5,561,208, 5,462,995, and 5,334,424.
The term "polycarbonate" as used herein means a polyester of carbonic acid and glycol or a divalent phenol. Examples of such glycols or divalent phenols are p-xylyene glycol, 2,2-bis(4-oxyphenyl)propane, bis(4-oxyphenyl)methane, 1,1-bis(4-oxyphenyl)ethane, 1,1-bis(oxyphenyl)butane, 1,1-bis(oxyphenyl)cyclohexane, 2,2-bis(oxyphenyl)butane, and mixtures thereof, including but not limited to, those sold under the tradenames Calibre', MalcrolonTm, PanliteTm, MalcroclearTm, CyrolonTM, LexanTm and Tuffak TM.
As used herein the term "nucleic acid" is intended to encompass single- and double-stranded DNA and RNA, as well as any and all forms of alternative nucleic acid containing modified bases, sugars, and backbones. The term "nucleic acid" thus will be understood to include, but not be limited to, single- or double-stranded DNA
or RNA (and forms thereof that can be partially single-stranded or partially double-stranded), cDNA, aptamers, peptide nucleic acids ("PNA"), 2'-5' DNA (a synthetic material with a shortened backbone that has a base-spacing that matches the A conformation of DNA; 2'-5' DNA will not normally hybridize with DNA in the B form, but it will hybridize readily with RNA), and locked nucleic acids ("LNA"). Nucleic acid analogues include known analogues of natural nucleotides that have similar or improved binding, hybridization of base-pairing properties.
"Analogous" forms of purines and pyrimidines are well known in the art, and include, but are not limited to aziridinylcytosine, 4-acetylcytosine, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethy1-2-thiouracil, 5-carboxymethylaminomethyluracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethy1-2-thiouracil, beta-D-mannosylqueosine, 5-methoxyuracil, 2-methylthio-N-6-isopentenyladenine, uracil-5-oxyacetic acid methylester, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid, and 2,6-diaminopurine. DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs), methylphosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup, 1997, Biochemistry 36:8692-8698), and benzylphosphonate linkages, as discussed in US 6,664,057; see also OLIGONUCLEOTIDES AND ANALOGUES, A
PRACTICAL
APPROACH, edited by F. Eckstein, IRL Press at Oxford University Press (1991);
Antisense Strategies, Annals of the New York Academy of Sciences, Volume 600, Eds.
Baserga and Denhardt (NYAS 1992); Milligan, 1993, J. Med. Chem. 36:1923-1937; Antisense Research and Applications (1993, CRC Press). The nucleic acids herein can be extracted from cells or synthetically prepared according to any means known to those skilled in the art; for example, the nucleic acids can be chemically synthesized or transcribed or reverse transcribed from cDNA or mRNA, among other sources.
The term "via" as used herein means a through-hole formed in a solid material to allow fluidic connection between the top and bottom surfaces of the material.
The terms "locus" and "loci" (plural) as used herein mean one or more specific positions on one or more nucleic acids (e.g., one or more chromosomes), as defined herein.
The terms "STR locus" and "STR loci" as used herein means a nucleotide sequence consisting of a repeating pattern of two or more nucleotides at a given locus of a target nucleic acid. The repeating pattern can range in length from 2 to 10 base pairs (bp), and is typically in the non-coding intron region.
According to one aspect of the invention, a thermal cycler is provided having the capability of heating and cooling a reaction solution rapidly, controllably, and reproducibly.
An example of an embodiment of the thermal cycler of the invention is shown in Figure 1A.
The ability to rapidly heat and cool the reaction solution temperatures allows ramping and settling times to be minimized and incubation time at the desired temperature to dominate the total step time, enabling minimization of multiplex cycling times.
High heating and cooling rates can be achieved by utilizing a temperature control element (TCE), either alone or in fluid communication with a heat sink. A TCE
comprises a means for heating and cooling, a thermosensor, a controller that receives signals from the thermosensor, and a power supply. In a preferred embodiment, a first surface of the TCE
can be adapted to receive a sample chamber containing a solution and a sensing chamber containing an additional thermosensor. In this setting, the thermosensor is positioned within the sensing chamber mounted to the TCE such that it simulates the conditions within the sample chamber. This sensing chamber is fabricated such that it has the same material stack-up as the sample chamber. A thermocouple mounted within the temperature sensor is embedded in the structure at an analogous position to that of the sample in the sample chamber. This sensor reports the effective temperature of the solutions in the sample chamber. Commercially-available Type-T or Type-K thermocouples (from Omega Engineering, Stamford, CT) are most applicable but other types of thermocouple and thermosensor may be used including thermisters, semiconductors, and infrared.
The thermosensor within the sensing chamber provides feedback to the TCE to set or maintain the sample at the desired temperature. In this way, the sample temperature can be measured indirectly and controlled without inserting a thermosensor into the reaction chamber itself.
Alternatively, a thermosensor can be placed directly into the reaction chamber and used to set and maintain sample temperature, eliminating the need for the sensing chamber.
As one skilled in the art will appreciate, other types of sensors such as pressure sensors may be utilized according to the teachings of this invention.
The first surface of the TCE can be adapted to accept an essentially flat substrate by, for example, forming a recess in the first surface for accepting a substrate (e.g., a biochip, infra). Alternatively, the TCE can be adapted to accept one or more thin-walled tubes, defined as tubes with wall diameters with regions less than 200 1.1M thick.
Preferably, the heat sink is a high efficiency heat sink, such as, but not limited to, fan-cooled heat sinks with copper bases and cooling fins. More preferably, the heat sink can be a fan cooled copper base and fins having a thermal resistance of about 0.4 C/W or less. A
particular and non-limiting example of a high efficiency heat sink is E1U-N7BCC-03-GP
(Coolermaster, Taiwan ROC).
The thermal cycler of the invention may further comprise a thermosensor positioned to monitor the temperature of the first surface of the TCE. Additional thermosensors can be added as desired to achieve further improvement in sample temperature control.
The supplementary temperatures that can be monitored include those on multiple regions on and within the substrate, multiple regions on and within the heat sink, cooling air input and output, sample input and output, and ambient.
Good thermal communication between the TCE and the heat sink is desired. When the two mating surfaces are properly prepared, intimate physical contact is sufficient to provide adequate thermal transfer between the two components. Thermal interface materials (TIMs) between the TCE and heat sink can be used to enhance thermal coupling.
Such TIIVIs include but are not limited to adhesives, greases, phase-change materials (PCMs), metal thermal interface materials, ceramic thermal interface materials, soft metal alloys, indium, alumina nano-layer coatings, submicron films, glycol, water, oils, antifreeze, epoxy compounds, and others. Specific examples include Arctic Silver or Ceramique (Arctic Silver, Visalia, CA; compounds that have thermal resistances of < 0.007 C-in2/W), compressible heat spring HSD4 (Indium Corp, Utica, NY), HITIIERM (GrafTech International Holdings Inc., Lakewood, OH), or directly bonding of the TCE to the surface of the heat sink. Thermal contact can be further enhanced by physical clamping the components together with a average force of more than 2 psi, or more than 5 psi, or more than 10 psi, or more than 30 psi, or more than 60 psi or more than 100 psi or more than 200 psi, or by direct bonding of the surfaces.
Thermal transfer between the TCE and a substrate in contact therewith can be increased with respect to block thermal cyclers, such as the Eppendorf MastercyclerTm ep gradient S thermal cycler (which provide heat energy via a silver block with high thermal conductivity and low specific heat capacity), by placing the substrate directly on the TCE.
Suitable TCEs include, but are not limited to, a high heating and cooling capacity heat pump, and high power output Peltier devices; examples of Peltier devices are (Ferrotec, Bedford NH), XLT2393 (Marlow, Dallas TX). When utilized as a part of the TCE
for thermal cyclers of the invention, Peltier devices are advantageously powered by an H-bridge. An example of an H-bridge device is the 5R7-001 (Oven Industries).
When Peltier devices are used as a part of the TCE for thermal cyclers of the invention, it is advantageous to power the Peltier devices by an H-bridge with pulse width modulation for heating and cooling. Temperature feedback from the thermosensor which measures the sample temperature drives the TCE to set and maintain the desired sample temperature. Closed-loop temperature control algorithms for control of the TCE
include, but are not limited to, PID control and fuzzy logic control.
Said thermal controllers comprise a control algorithm that provides the capacity for rapid transition from one target temperature state to another target temperature state. This transition can be divided into 3 distinct phases. In phase 1, there is a large difference between the actual temperature and target temperature (for example 1 to 20 C or higher). In this phase, ramping takes place at or near the maximum rate of the TCE device. In phase 2, the transition phase, the actual temperature and target temperature are closer (less than approximately 1 to 20 C). In this case the controller must reduce the power to the TCE in order to prevent overshoot of the solution temperature and allow for rapid achievement of target temperature with minimal deviations and oscillations. In phase 3, the target temperature has been achieved and the controller moderates power to the thermal cycler to maintain the solution within a narrow range about the target temperature.
Measurement of the temperature with the sensor provides more accurate feedback of the actual temperature and also allows the temperature of the TCE surface temperature to be overdriven.
Each of the above 3 phases may be further subdivided into multiple sub-phases to provide for faster response time, more accurate temperature control, increased stability, and increased tolerance to external variability.
In one example, the temperature of the substrate can be measured by placing a thin thermocouple into a channel on the substrate surface. In another example, the second thermosensor can be housed in an enclosure, formed from essentially the same material as the substrate being utilized, that holds the second thermosensor essentially the same distance from the TCE as a reaction chamber on a substrate in contact with the TCE.
Such a second thermosensor can generally be separate from the substrate (i.e., a stand-alone sensor), and can be placed next to the substrate on the first surface of the TCE.
The heat sink may, optionally, further comprise a variable speed cooling fan and/or a second heating element for controlling the temperature of the heat sink, where each additional element of the heat sink is in communication with the second control element.
This allows the cooling efficiency of the heat sink to be adjusted, in particular to keep the heat sink temperature essentially constant and independent of environmental temperature changes. The heater can also precondition the heat sink to essentially the operating temperature.
To facilitate thermal coupling of a reaction solution in a substrate and the TCE, uniform thermal communication of a contact surface of the substrate with the first surface of the TCE can be provided by applying a force to the substrate to secure it thereto while the thermal cycler is in operation. Such forces are preferably applied by means that only temporarily hold the substrate to the first surface of the TCE and can be readily removed upon completion of thermal cycling. For example, a chip compression element (CCE) can be situated above the first surface of the TCE to allow the substrate to be placed between. The chip compression element can then be engaged to hold the substrate in place during operation of the thermal cycler, and released to allow removal of the substrate. Proper integration of the CCE, TCE and heat sink allows the CCE to improve thermal coupling between and among all three of these components.
The portion of the CCE in contact with a substrate can be formed from a low thermal mass insulating material, including, but not limited to, a foam, for example WF71 Rohcell foam (Inspec foams, Magnolia, AR). For embodiments discussed herein the Rohacell is preferred. It has a specific heat capacity of 1.4-1.6 (J/gK) [or less thermal mass] and a thermal conductivity of 0.0345 W/mK (or less).
Biochip compression elements include, but are not limited to, one or more clamps, springs, compressible foam, or a pressurized air bladder which can be inflated to provide force to hold the substrate onto the first surface of the TCE. Preferably, the chip compression element provides a substantially uniform force of about 5 to about 250 psia to a surface of the substrate, and more preferably, about 20 to about 50 psia to hold the substrate to the first surface of the TCE. Notably, thermal communication between the contact surface of the biochip substrate and the TCE can be provided in the absence of a thermal coupling solutions such as thermal grease or glycol, although such can be utilized as necessary.
The biochip compression elements provide a force on the biochip-thermoelectric cooler-heat sink. This force serves to ensure good thermal contact and hence heat transfer between the biochip and the top surface of the TCE.
In one embodiment, the low thermal mass insulator is an air bladder and is utilized to provide the low thermal mass and insulating properties. In another embodiment, the low thermal mass insulator is a foam pad. The clamping force can be applied to the foam pad by a pneumatic cylinder, or closed cell foam pads under compression or air pressure from an air bladder. In the latter case, the air bladder provides both the insulation and the compressive force.
As described above, the thermal cycler can have a heating and/or cooling rate at the first surface of the TCE surface about 4 ĀØ 150 C per second, and preferably about 8 ĀØ 150 C/sec, and more preferably about 10 ĀØ 150 C/sec. The thermal cycler can also have a heating or cooling rate at a solution within a reaction chamber of a substrate in uniform thermal communication with the first surface of the TCE (e.g., a biochip) of about 4 ĀØ 150 C
per second and preferably about 8 ĀØ 150 C/sec, and more preferably about 10 ĀØ
150 C/sec.
Further, the thermal cycler of the invention can have a temperature stability of +/- 1.0 C, and preferably +/- 0.50 C, and more preferably +/- 0.25 C.
Biochip, An embodiment of a biochip (i.e., a substrate for use with the thermal cycler of the invention) according to another aspect of the invention is shown for the sake of illustration in Figure 1B as having 16 microfluidic systems, each comprising an inlet and an outlet in fluid communication with each of the reaction chambers formed within the biochip.
However, such disclosure is not intended to be limiting, rather, one skilled in the art will readily recognize that the biochip can contain alternate numbers of microfluidic systems (infra) including biochips with one system and biochips with two or more systems. The term "plurality" as used herein, means two or more, four or more, eight or more, 16 or more, 32 or more, 48 or more, 64 or more, 96 or more, 128 or more, or 2 ĀØ 16, 2 ĀØ 32, 2 ĀØ
48, 2 ĀØ 64, 2 ĀØ
96, 2 ĀØ 128, 8 ĀØ 128, 8 - 64, or 8 ĀØ 32 microfluidic channels.
The biochip can comprise a substrate layer and a cover layer, where a portion of one or a plurality of microfluidic systems, comprising grooves and/or shaped depressions, are patterned into the substrate layer. A series of vias (i.e., through holes and/or inlets or outlets) can be formed in the cover layer to provide fluidic access to the microfluidic channels and reaction chambers, and can be located at any location about the biochip.
Alternatively, vias can be formed in the substrate layer instead of the cover layer to achieve the same functionality. The top surface of the substrate layer can be bonded with the bottom surface of the cover layer to complete the microfluidic systems. Techniques for fabricating polymer-based microfluidic systems are reviewed extensively by Becker and Gartner (Becker, 2000, Electrophoresis 21, 12-26 and Becker, 2008, Electrophoresis 390, 89).
Biochips can be fabricated using materials such as unsaturated, partially unsaturated or saturated cyclic olefin copolymers "COC ", unsaturated, partially unsaturated, or saturated cyclic olefin polymers "COP", poly(methyl) methacrylate "PMMA", polycarbonate "PC", polypropylene "PP", polyethylene "PE", polyetheretherketone "PEEK", poly(dimethylsiloxane) "PDMA", polyimide "P1". It is important to select a plastic with a glass transition temperature greater than that of the maximal temperature to be utilized in the amplification reaction. Any number of these processes and materials can be used to fabricate the biochips described herein. In particular, the biochips can be prepared by injection molding of a plastic substrate, for example, a COC
or COP based polymers (currently sold under the tradenames TopasTm, ZeonexTm, ZeonorTM, and ApelTm). In this fabrication methodology, an injection mold and mold insert consisting of the negative of the features to be formed is fabricated by machining and subsequent surface polishing. Together, the mold and insert allow the substrate layers to be fabricated and the formed substrate to comprise the channels, reaction chamber features and vias.
The substrate and cover layers can be diffusion bonded by the application of heat and pressure.
Altematively, the biochips can be prepared by hot embossing of thin thermoplastic films with a master die of the negative of the structure to be produced. The mastcr die can bc prepared by using electroforming to replicate the device prepared in a solid substrate. The solid substrate can be glass sheets that are patterned by standard photolithographic and chemical etching methods known to those skilled in the art. The substrate and cover layers are diffusion bonded by the application of heat and pressure.
The substrate and cover layers of the biochip can be constructed from a variety of plastic substrates including, but not limited to, polyethylene, poly(acrylates) (e.g., poly(methyl methacrylate)), poly(carbonate)s, and unsaturated, partially unsaturated or saturated cyclic olefin polymers (COP), or an unsaturated, partially unsaturated, or saturated cyclic olefin copolymers (COC). The thickness of plastic substrate and cover layers utilized in the present process is kept thin to minimize the mass thereof to thereby maximize thermal transfer between the thermal cycler and the reaction solution contained in each reaction chamber during their use. The plastic substrate and cover layers can each, independently, have a thickness of less than 2 mm, less than 1 mm, less than 750 pm, less than 650 pm, less than 500 Am, less than 400 pm, less than 300 p.m, less than 200 Am, or less than 100 pm; or plastic substrate and cover layers can each, independently, comprise a plastic having a thickness ranging from 25 ĀØ 2000 pm, 25 ĀØ 1000, 25 ĀØ 750 pm, 25 ĀØ 650 mm, 25 ĀØ
500 p.m, 25 ĀØ 400 p.m, 25 ĀØ 300 pm, 25 ĀØ 200 pm, or 25 ĀØ 100 pm. Preferably, at least one of the substrate and cover layers has a thickness of less than about 200 pm to maximize thermal transfer to the reaction solution contained in the reaction chambers of the biochip. More preferably, a contact surface of the biochip which is in contact with the first surface of the TCE has a thickness of less than about 200 pm.
Each reaction chamber can be formed to have a volume of, for example, less than 100 AL. Preferably, each reaction chamber has a volume of less than about 50 AL, or less than about 40 AL, or less than about 30 AL, or less than about 25 AL, or less than about 20 pL, or less than about 15 AL, or less than about 10 AL, or less than about 5 AL or less than about 1 AL, or less than about 0.1 AL. Alternatively, each reaction chamber can be formed to have a volume ranging from about 0.1 AL to about 100 AL. Preferably, each reaction chamber has a volume ranging from about 0.1 AL to about 10 AL or about 10 AL to about 50 AL.
The reaction chambers are generally not coated with a polymer or silane coating.
Reaction chambers may be designed to have an inlet and an outlet channel.
Alternatively, a single channel may be used for inlet and outlet.
The biochip design of the invention leverages the benefits of microfluidics including having a high surface to volume ratio and reduced diffusion times to maximize heat transfer, and uniform heating and cooling. The use of microfluidic technology also provides benefits with respect to a fully-integrated forensic analysis instrument. Further, biochips fabricated by diffusion bonding, and without the use of adhesives to bond the various layers (e.g. COC
layers), were tested and demonstrated to be capable of withstanding from 100 to 1500 psi of pressure before failure based on the requirements of the desired application.
For example, the biochips of the present invention withstand 450 psi, sufficient for the desired thermal cycling applications.
It is noted that the specific embodiments of the biochips of the invention set forth herein substantially lack any heating elements integrated into the biochip for heating and/or cooling the reaction chambers. Thermal cycling of the reaction chambers on the biochip is provided externally, for example, by the thermal cycler of the invention.
Heating elements can be integrated into the biochips of the present invention, however.
In operation, one portion of the biochip can receive one or more reaction solutions, each independently comprising one or more reagents (e.g., for PCR) and or nucleic acid samples, through one or more inlets in fluid communication with one or more reaction chambers formed within the biochip. Simultaneous amplification of a plurality of samples can be performed by injecting each of the nucleic acid samples in a separate separation reaction chamber. An injector for simultaneously injecting a plurality samples into the plurality of sample or buffer wells can be provided with the biochip to enable simultaneous multiple sample amplification. Such injectors provide, for example, one sample of the plurality of samples to one reaction chamber of the plurality of reaction chambers. Injectors can introduce the samples to the channels according to any methods known to those skilled in the art, for example, by electrophoretic transport, pneumatic actuation or liquid actuation through a needle or tube or channel that connects the sample to the reaction chamber.
Following amplification (and optionally, nucleic acid extraction and quantification) the amplified nucleic acid product can be passed (e.g., to a Genebench-Fkrm 100) through one or more outlets in fluid communication with the reaction chambers for fragment separation and generation of STR profiles.
The relatively low cost of plastic manufacture allows the biochips of the invention to be disposable, eliminating the labor required to reuse the biochip and essentially eliminating the possibility of contamination. A single-use disposable would be particularly advantageous for low copy number analyses in that no possibility of contamination (other than initial sample collection) would exist. In settings where neither contamination nor labor are major considerations, reusable plastic and glass biochips may be utilized.
Integration Methods Using microfluidics allows fabrication of features to perform more than one function on a single biochip. These functions can include nucleic acid extraction, nucleic acid purification, pre-PCR nucleic acid cleanup, post-PCR cleanup, pre-sequencing cleanup, sequencing, post-sequencing cleanup, nucleic acid separation, nucleic acid detection, reverse transcription, pre-reverse transcription cleanup, post-reverse transcription cleanup, nucleic acid ligation, nucleic acid hybridization and quantification. Two or more of these functions can be connected microfluidically to enable sequential processing of a sample;
this coupling is termed integration.
One form of microfluidic DNA extraction can be achieved by inserting a purification medium between an input and output channel. This purification medium can be silica fiber based and use chaotropic-salt reagents to lyse the biological sample, expose the DNA and bind the DNA to the purification media. The lysate is then transported via the input channel through the purification medium to bind the DNA. Bound DNA is washed by an ethanol based buffer to remove contaminants. This can be accomplished by flowing wash reagents via the input channel through the purification membrane. Bound DNA is then eluted from the membrane by flowing an appropriate low salt buffer (see, e.g., Boom, US
5,234,809) via the input channel through the purification membrane and out the output channel.
One approach to DNA quantification in a microfluidic format is based upon real-time PCR. In this method of quantification, a reaction chamber is fabricated between an input and output channel. The reaction chamber is coupled to a thermal cycler and an optical excitation and detection system is coupled to the reaction chamber to allow fluorescence from the reaction solution to be measured. The amount of DNA in the sample is correlated to the intensity of the fluorescence from the reaction chamber per cycle (see, e.g., Heid et al., Genotne Research 1996, 6, 986-994).
For further information about integration in microfluidic formats, see the U.S. Patent application entitled "INTEGRATED NUCLEIC ACID ANALYSIS" filed on even day herewith (Attorney Docket No. 07-801-US).
For further information about separation and detection in microfluidic formats see the U.S.
Patent application entitled "Plastic Microfluidic Separation and Detection Platforms" filed on even day herewith (Attorney Docket No. 07-865-US).
Microfluidic drives of the invention are means for transporting fluids within the reaction chambers of the integrated biochips. One type of microfluidic drive is effected by incorporated a membrane pump which transports the fluid by sequential application of positive and negative pressure to the membrane. Alternatively, a positive displacement pump can be connected to the input of the microfluidic chamber. A displacement of the pump forces the fluid through the microfluidic channel.
Integration can make use of microfluidic valves to gate fluid flow within the biochip.
Valving can be accomplished with passive or active structures. Passive valving structures include capillary valves that stop fluid flow by utilizing capillary pressure.
Fluids can flow through the capillary valving structure by the application of a pressure that is sufficiently large enough to overcome the capillary forces. Active valving structures include membrane valves which use flexible or semi-rigid structures at a point between two channels. The application of pressure on the membrane causes it to close the channel. The application of a vacuum to the membrane lifts it from the channel, allowing passage of fluids.
Amplification Methods In yet another aspect, the invention provides methods for simultaneously amplifying a plurality of nucleic acid loci in one or more target nucleic acids via rapid polymerase chain reaction (PCR). Such methods comprise providing one or a plurality of reaction solutions to one or a plurality of reaction chambers, wherein each reaction solution comprises (i) at least one copy of at least one target nucleic acid, wherein each target nucleic acid is the same or different and each target nucleic acid independently comprises a plurality loci to be amplified; (ii) one or more buffers; (iii) one or more salts; (iv) a primer set corresponding to the plurality of loci to be amplified; (v) a nucleic acid polymerase; and (vi) nucleotides. Each of the reaction solutions, for example, each of the target nucleic acids, can be the same or different as necessary, for example, to run multiple simultaneous analyses on the same nucleic acid sample, or to simultaneously run multiple nucleic acid samples.
Each reaction chamber may be contained within a biochip of the invention as described above or thin-walled reaction tubes. Thin-walled reaction tubes preferably have a wall thickness of less than about 200 Am. Preferably, thin-walled reaction tubes preferably have a wall thickness of less than about 100 ttm.
Primers for PCR amplification are oligonucleotide sequences that are specifically designed to hybridize to loci of the target DNA. These primers serve as starting points for polymerase extensions. To facilitate analysis of amplified fragments, labeled primers can also be used in PCR reactions. Labeled primers are oligonucleotide sequences that are coupled to a detectable moiety; a non-limiting example thereof is a fluorescent dye. When PCR is carried out with fluorescently labeled primers, amplicons with a fluorescent label are generated. The methods for performing fast PCR are compatible with both labeled and unlabeled primers, and fast multiplexed PCR have been demonstrated.
Primer sets can be any known to those skilled in the art for the amplification of a plurality of loci with a target nucleic acid, as described above. For example, primers useful in amplification of one or more loci in a human nucleic acid sample are described in US5,582,989; US5,843,660; US6,221,598; US6,479,235; US6,531,282; and US7,008,771;
and US Patent Application Publication Nos. 2003/0180724; 2003/0186272; and 2004/0137504.
Further, primers useful in amplification of one or more loci in a viral nucleic acid sample are described in, for example, US7,312,036; US6,958,210; US6,849,407;
US6,790,952, and US6,472,155 .
Examples of primers useful in amplification of one or more loci in a bacterial nucleic acid sample are described in US7,326,779; US7,205,111; US7,074,599;
US7,074,598;
US6,664,080; and US5,994,066.
Salts and buffers include those familiar to those skilled in the art, including those comprising MgC12, and Tris-HC1 and KC1, respectfully. Buffers may contain additives such as surfactants (e.g., Tweens), dimethyl sulfoxide (DMSO), glycerol, bovine serum albumin (BSA) and polyethylene glycol (PEG), as well as others familiar to those skilled in the art.
Nucleotides are generally deoxyribonucleoside triphosphates, such as deoxyadenosine triphosphate (dATP), deoxycytidine triphophate (dCTP), deoxyguanosine triphosphate (dGTP) and deoxythymidine triphosphate (dTTP) are also added to the synthesis mixture in adequate amount for amplification of the target nucleic acid.
The solutions can be optionally heated to and held at a first temperature for a first period of time suitable for hot-start activation of the nucleic acid polymerases. Generally, the first period of time is less than about 90 seconds. The first temperature can be about 95 to about 99 C. Polymerases with hot start mechanisms that can be activated in 60 seconds or less include those utilizing antibody mediated hot-start and aptmer mediated hot start mechanisms. Alternatively, hot-start polymerases need not be utilized in the present invention.
Subsequently, the temperature of the reaction solutions are sequentially cycled between a denaturing state, an annealing state, and an extension state for a predetermined number of cycles. Generally, the one or a plurality of reaction solutions are cooled from the denaturing state to the =leafing state at a first cooling rate of about 1 to about 150 C/sec, or about 1 to about 100 C/sec; or about 1 to about 80 C/sec; or about 1 to about 60 C/sec; or about 1 to about 40 C/sec; or about 1 to about 30 C/sec; or about 1 to about 20 C/sec;
about 4 to about 150 C/sec, or about 4 to about 100 C/sec; or about 4 to about 80 C/sec; or about 4 to about 60 C/sec; or about 4 to about 40 C/sec; or about 4 to about 30 C/sec; or about 4 to about 20 C/sec; or about 10 to about 150 C/sec; or about 10 to about 100 C/sec;
or about 10 to about 80 C/sec; or about 10 to about 60 C/sec; of about 10 to about 40 C/sec; or about 10 to about 30 C/sec; or about 10 to about 20 C/sec. The one or a plurality of reaction solutions can be heated from the annealing state to the extension state at a first heating rate of about 1 to about 150 C/sec, or about 1 to about 100 C/sec;
or about 1 to about 80 C/sec; or about 1 to about 60 C/sec; or about 1 to about 40 C/sec;
about 1 to about 30 C/sec; about 1 to about 20 C/sec; 4 to about 150 C/sec, or about 4 to about 100 C/sec; or about 4 to about 80 C/sec; or about 4 to about 60 C/sec; or about 4 to about 40 C/sec; about 4 to about 30 C/sec; about 4 to about 20 C/sec; or about 10 to about 150 C/sec; or about 10 to about 100 C/sec; or about 10 to about 80 C/sec; or about 10 to about 60 C/sec; of about 10 to about 40 C/sec; or about 10 to about 30 C/sec; or about 10 to about 20 C/sec; and/or the one or a plurality of reaction solutions are heated from the extension state to the denaturing state at a second heating rate of about 1 to about 150 C/sec, or about 1 to about 100 C/sec; or about 1 to about 80 C/sec; or about 1 to about 60 C/sec;
or about 1 to about 40 C/sec; about 1 to about 30 C/sec; about 1 to about 20 C/sec; about 4 to about 150 C/sec, or about 4 to about 100 C/sec; or about 4 to about 80 C/sec; or about 4 to about 60 C/sec; or about 4 to about 40 C/sec; about 4 to about 30 C/sec;
about 4 to about 20 C/sec; or about 10 to about 150 C/sec; or about 10 to about 100 C/sec; or about
For example, the methods herein can provide amplified nucleic acid samples whose analysis yields data suitable for forensic interpretation, and in particular, data that satisfies forensic interpretation guidelines. Such guidelines include signal strength, inter-loci peak height balance, heterozygous peak height ratio (PHR), incomplete non-template nucleotide addition (NTA), and stutter (Scientific Working Group on DNA Analysis Methods, Short Tandem Repeat (STR) Interpretation Guidelines. Forensic Science Communications, 2000, 2(3)).
The phrase "fluid communication" as used herein, refers to two chambers, or other components or regions containing a fluid, connected together so that a fluid can flow between the two chambers, components, or regions. Therefore, two chambers that are in "fluid communication" can, for example, be connected together by a microfluidic channel between the two chambers, such that a fluid can flow freely between the two chambers.
Such microfluidic channels can optionally include one or more valves therein which can be closed or occluded, in order to block and/or otherwise control fluid communication between the chambers.
The term "poly(methyl methacrylate) or "PlVIMA," as used herein, means the synthetic polymers of methyl methacrylate, including but not limited to, those sold under the tradenames Plexiglas, Limacryirm, R-Cast, Perspex', Plazcrylrm, Acrylex TM, ACrylitemi, ACrylplastml, AltuglasTm, PolycastTm and Lucite, as well as those polymers described in US Patent Nos. 5,561,208, 5,462,995, and 5,334,424.
The term "polycarbonate" as used herein means a polyester of carbonic acid and glycol or a divalent phenol. Examples of such glycols or divalent phenols are p-xylyene glycol, 2,2-bis(4-oxyphenyl)propane, bis(4-oxyphenyl)methane, 1,1-bis(4-oxyphenyl)ethane, 1,1-bis(oxyphenyl)butane, 1,1-bis(oxyphenyl)cyclohexane, 2,2-bis(oxyphenyl)butane, and mixtures thereof, including but not limited to, those sold under the tradenames Calibre', MalcrolonTm, PanliteTm, MalcroclearTm, CyrolonTM, LexanTm and Tuffak TM.
As used herein the term "nucleic acid" is intended to encompass single- and double-stranded DNA and RNA, as well as any and all forms of alternative nucleic acid containing modified bases, sugars, and backbones. The term "nucleic acid" thus will be understood to include, but not be limited to, single- or double-stranded DNA
or RNA (and forms thereof that can be partially single-stranded or partially double-stranded), cDNA, aptamers, peptide nucleic acids ("PNA"), 2'-5' DNA (a synthetic material with a shortened backbone that has a base-spacing that matches the A conformation of DNA; 2'-5' DNA will not normally hybridize with DNA in the B form, but it will hybridize readily with RNA), and locked nucleic acids ("LNA"). Nucleic acid analogues include known analogues of natural nucleotides that have similar or improved binding, hybridization of base-pairing properties.
"Analogous" forms of purines and pyrimidines are well known in the art, and include, but are not limited to aziridinylcytosine, 4-acetylcytosine, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethy1-2-thiouracil, 5-carboxymethylaminomethyluracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethy1-2-thiouracil, beta-D-mannosylqueosine, 5-methoxyuracil, 2-methylthio-N-6-isopentenyladenine, uracil-5-oxyacetic acid methylester, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid, and 2,6-diaminopurine. DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs), methylphosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup, 1997, Biochemistry 36:8692-8698), and benzylphosphonate linkages, as discussed in US 6,664,057; see also OLIGONUCLEOTIDES AND ANALOGUES, A
PRACTICAL
APPROACH, edited by F. Eckstein, IRL Press at Oxford University Press (1991);
Antisense Strategies, Annals of the New York Academy of Sciences, Volume 600, Eds.
Baserga and Denhardt (NYAS 1992); Milligan, 1993, J. Med. Chem. 36:1923-1937; Antisense Research and Applications (1993, CRC Press). The nucleic acids herein can be extracted from cells or synthetically prepared according to any means known to those skilled in the art; for example, the nucleic acids can be chemically synthesized or transcribed or reverse transcribed from cDNA or mRNA, among other sources.
The term "via" as used herein means a through-hole formed in a solid material to allow fluidic connection between the top and bottom surfaces of the material.
The terms "locus" and "loci" (plural) as used herein mean one or more specific positions on one or more nucleic acids (e.g., one or more chromosomes), as defined herein.
The terms "STR locus" and "STR loci" as used herein means a nucleotide sequence consisting of a repeating pattern of two or more nucleotides at a given locus of a target nucleic acid. The repeating pattern can range in length from 2 to 10 base pairs (bp), and is typically in the non-coding intron region.
According to one aspect of the invention, a thermal cycler is provided having the capability of heating and cooling a reaction solution rapidly, controllably, and reproducibly.
An example of an embodiment of the thermal cycler of the invention is shown in Figure 1A.
The ability to rapidly heat and cool the reaction solution temperatures allows ramping and settling times to be minimized and incubation time at the desired temperature to dominate the total step time, enabling minimization of multiplex cycling times.
High heating and cooling rates can be achieved by utilizing a temperature control element (TCE), either alone or in fluid communication with a heat sink. A TCE
comprises a means for heating and cooling, a thermosensor, a controller that receives signals from the thermosensor, and a power supply. In a preferred embodiment, a first surface of the TCE
can be adapted to receive a sample chamber containing a solution and a sensing chamber containing an additional thermosensor. In this setting, the thermosensor is positioned within the sensing chamber mounted to the TCE such that it simulates the conditions within the sample chamber. This sensing chamber is fabricated such that it has the same material stack-up as the sample chamber. A thermocouple mounted within the temperature sensor is embedded in the structure at an analogous position to that of the sample in the sample chamber. This sensor reports the effective temperature of the solutions in the sample chamber. Commercially-available Type-T or Type-K thermocouples (from Omega Engineering, Stamford, CT) are most applicable but other types of thermocouple and thermosensor may be used including thermisters, semiconductors, and infrared.
The thermosensor within the sensing chamber provides feedback to the TCE to set or maintain the sample at the desired temperature. In this way, the sample temperature can be measured indirectly and controlled without inserting a thermosensor into the reaction chamber itself.
Alternatively, a thermosensor can be placed directly into the reaction chamber and used to set and maintain sample temperature, eliminating the need for the sensing chamber.
As one skilled in the art will appreciate, other types of sensors such as pressure sensors may be utilized according to the teachings of this invention.
The first surface of the TCE can be adapted to accept an essentially flat substrate by, for example, forming a recess in the first surface for accepting a substrate (e.g., a biochip, infra). Alternatively, the TCE can be adapted to accept one or more thin-walled tubes, defined as tubes with wall diameters with regions less than 200 1.1M thick.
Preferably, the heat sink is a high efficiency heat sink, such as, but not limited to, fan-cooled heat sinks with copper bases and cooling fins. More preferably, the heat sink can be a fan cooled copper base and fins having a thermal resistance of about 0.4 C/W or less. A
particular and non-limiting example of a high efficiency heat sink is E1U-N7BCC-03-GP
(Coolermaster, Taiwan ROC).
The thermal cycler of the invention may further comprise a thermosensor positioned to monitor the temperature of the first surface of the TCE. Additional thermosensors can be added as desired to achieve further improvement in sample temperature control.
The supplementary temperatures that can be monitored include those on multiple regions on and within the substrate, multiple regions on and within the heat sink, cooling air input and output, sample input and output, and ambient.
Good thermal communication between the TCE and the heat sink is desired. When the two mating surfaces are properly prepared, intimate physical contact is sufficient to provide adequate thermal transfer between the two components. Thermal interface materials (TIMs) between the TCE and heat sink can be used to enhance thermal coupling.
Such TIIVIs include but are not limited to adhesives, greases, phase-change materials (PCMs), metal thermal interface materials, ceramic thermal interface materials, soft metal alloys, indium, alumina nano-layer coatings, submicron films, glycol, water, oils, antifreeze, epoxy compounds, and others. Specific examples include Arctic Silver or Ceramique (Arctic Silver, Visalia, CA; compounds that have thermal resistances of < 0.007 C-in2/W), compressible heat spring HSD4 (Indium Corp, Utica, NY), HITIIERM (GrafTech International Holdings Inc., Lakewood, OH), or directly bonding of the TCE to the surface of the heat sink. Thermal contact can be further enhanced by physical clamping the components together with a average force of more than 2 psi, or more than 5 psi, or more than 10 psi, or more than 30 psi, or more than 60 psi or more than 100 psi or more than 200 psi, or by direct bonding of the surfaces.
Thermal transfer between the TCE and a substrate in contact therewith can be increased with respect to block thermal cyclers, such as the Eppendorf MastercyclerTm ep gradient S thermal cycler (which provide heat energy via a silver block with high thermal conductivity and low specific heat capacity), by placing the substrate directly on the TCE.
Suitable TCEs include, but are not limited to, a high heating and cooling capacity heat pump, and high power output Peltier devices; examples of Peltier devices are (Ferrotec, Bedford NH), XLT2393 (Marlow, Dallas TX). When utilized as a part of the TCE
for thermal cyclers of the invention, Peltier devices are advantageously powered by an H-bridge. An example of an H-bridge device is the 5R7-001 (Oven Industries).
When Peltier devices are used as a part of the TCE for thermal cyclers of the invention, it is advantageous to power the Peltier devices by an H-bridge with pulse width modulation for heating and cooling. Temperature feedback from the thermosensor which measures the sample temperature drives the TCE to set and maintain the desired sample temperature. Closed-loop temperature control algorithms for control of the TCE
include, but are not limited to, PID control and fuzzy logic control.
Said thermal controllers comprise a control algorithm that provides the capacity for rapid transition from one target temperature state to another target temperature state. This transition can be divided into 3 distinct phases. In phase 1, there is a large difference between the actual temperature and target temperature (for example 1 to 20 C or higher). In this phase, ramping takes place at or near the maximum rate of the TCE device. In phase 2, the transition phase, the actual temperature and target temperature are closer (less than approximately 1 to 20 C). In this case the controller must reduce the power to the TCE in order to prevent overshoot of the solution temperature and allow for rapid achievement of target temperature with minimal deviations and oscillations. In phase 3, the target temperature has been achieved and the controller moderates power to the thermal cycler to maintain the solution within a narrow range about the target temperature.
Measurement of the temperature with the sensor provides more accurate feedback of the actual temperature and also allows the temperature of the TCE surface temperature to be overdriven.
Each of the above 3 phases may be further subdivided into multiple sub-phases to provide for faster response time, more accurate temperature control, increased stability, and increased tolerance to external variability.
In one example, the temperature of the substrate can be measured by placing a thin thermocouple into a channel on the substrate surface. In another example, the second thermosensor can be housed in an enclosure, formed from essentially the same material as the substrate being utilized, that holds the second thermosensor essentially the same distance from the TCE as a reaction chamber on a substrate in contact with the TCE.
Such a second thermosensor can generally be separate from the substrate (i.e., a stand-alone sensor), and can be placed next to the substrate on the first surface of the TCE.
The heat sink may, optionally, further comprise a variable speed cooling fan and/or a second heating element for controlling the temperature of the heat sink, where each additional element of the heat sink is in communication with the second control element.
This allows the cooling efficiency of the heat sink to be adjusted, in particular to keep the heat sink temperature essentially constant and independent of environmental temperature changes. The heater can also precondition the heat sink to essentially the operating temperature.
To facilitate thermal coupling of a reaction solution in a substrate and the TCE, uniform thermal communication of a contact surface of the substrate with the first surface of the TCE can be provided by applying a force to the substrate to secure it thereto while the thermal cycler is in operation. Such forces are preferably applied by means that only temporarily hold the substrate to the first surface of the TCE and can be readily removed upon completion of thermal cycling. For example, a chip compression element (CCE) can be situated above the first surface of the TCE to allow the substrate to be placed between. The chip compression element can then be engaged to hold the substrate in place during operation of the thermal cycler, and released to allow removal of the substrate. Proper integration of the CCE, TCE and heat sink allows the CCE to improve thermal coupling between and among all three of these components.
The portion of the CCE in contact with a substrate can be formed from a low thermal mass insulating material, including, but not limited to, a foam, for example WF71 Rohcell foam (Inspec foams, Magnolia, AR). For embodiments discussed herein the Rohacell is preferred. It has a specific heat capacity of 1.4-1.6 (J/gK) [or less thermal mass] and a thermal conductivity of 0.0345 W/mK (or less).
Biochip compression elements include, but are not limited to, one or more clamps, springs, compressible foam, or a pressurized air bladder which can be inflated to provide force to hold the substrate onto the first surface of the TCE. Preferably, the chip compression element provides a substantially uniform force of about 5 to about 250 psia to a surface of the substrate, and more preferably, about 20 to about 50 psia to hold the substrate to the first surface of the TCE. Notably, thermal communication between the contact surface of the biochip substrate and the TCE can be provided in the absence of a thermal coupling solutions such as thermal grease or glycol, although such can be utilized as necessary.
The biochip compression elements provide a force on the biochip-thermoelectric cooler-heat sink. This force serves to ensure good thermal contact and hence heat transfer between the biochip and the top surface of the TCE.
In one embodiment, the low thermal mass insulator is an air bladder and is utilized to provide the low thermal mass and insulating properties. In another embodiment, the low thermal mass insulator is a foam pad. The clamping force can be applied to the foam pad by a pneumatic cylinder, or closed cell foam pads under compression or air pressure from an air bladder. In the latter case, the air bladder provides both the insulation and the compressive force.
As described above, the thermal cycler can have a heating and/or cooling rate at the first surface of the TCE surface about 4 ĀØ 150 C per second, and preferably about 8 ĀØ 150 C/sec, and more preferably about 10 ĀØ 150 C/sec. The thermal cycler can also have a heating or cooling rate at a solution within a reaction chamber of a substrate in uniform thermal communication with the first surface of the TCE (e.g., a biochip) of about 4 ĀØ 150 C
per second and preferably about 8 ĀØ 150 C/sec, and more preferably about 10 ĀØ
150 C/sec.
Further, the thermal cycler of the invention can have a temperature stability of +/- 1.0 C, and preferably +/- 0.50 C, and more preferably +/- 0.25 C.
Biochip, An embodiment of a biochip (i.e., a substrate for use with the thermal cycler of the invention) according to another aspect of the invention is shown for the sake of illustration in Figure 1B as having 16 microfluidic systems, each comprising an inlet and an outlet in fluid communication with each of the reaction chambers formed within the biochip.
However, such disclosure is not intended to be limiting, rather, one skilled in the art will readily recognize that the biochip can contain alternate numbers of microfluidic systems (infra) including biochips with one system and biochips with two or more systems. The term "plurality" as used herein, means two or more, four or more, eight or more, 16 or more, 32 or more, 48 or more, 64 or more, 96 or more, 128 or more, or 2 ĀØ 16, 2 ĀØ 32, 2 ĀØ
48, 2 ĀØ 64, 2 ĀØ
96, 2 ĀØ 128, 8 ĀØ 128, 8 - 64, or 8 ĀØ 32 microfluidic channels.
The biochip can comprise a substrate layer and a cover layer, where a portion of one or a plurality of microfluidic systems, comprising grooves and/or shaped depressions, are patterned into the substrate layer. A series of vias (i.e., through holes and/or inlets or outlets) can be formed in the cover layer to provide fluidic access to the microfluidic channels and reaction chambers, and can be located at any location about the biochip.
Alternatively, vias can be formed in the substrate layer instead of the cover layer to achieve the same functionality. The top surface of the substrate layer can be bonded with the bottom surface of the cover layer to complete the microfluidic systems. Techniques for fabricating polymer-based microfluidic systems are reviewed extensively by Becker and Gartner (Becker, 2000, Electrophoresis 21, 12-26 and Becker, 2008, Electrophoresis 390, 89).
Biochips can be fabricated using materials such as unsaturated, partially unsaturated or saturated cyclic olefin copolymers "COC ", unsaturated, partially unsaturated, or saturated cyclic olefin polymers "COP", poly(methyl) methacrylate "PMMA", polycarbonate "PC", polypropylene "PP", polyethylene "PE", polyetheretherketone "PEEK", poly(dimethylsiloxane) "PDMA", polyimide "P1". It is important to select a plastic with a glass transition temperature greater than that of the maximal temperature to be utilized in the amplification reaction. Any number of these processes and materials can be used to fabricate the biochips described herein. In particular, the biochips can be prepared by injection molding of a plastic substrate, for example, a COC
or COP based polymers (currently sold under the tradenames TopasTm, ZeonexTm, ZeonorTM, and ApelTm). In this fabrication methodology, an injection mold and mold insert consisting of the negative of the features to be formed is fabricated by machining and subsequent surface polishing. Together, the mold and insert allow the substrate layers to be fabricated and the formed substrate to comprise the channels, reaction chamber features and vias.
The substrate and cover layers can be diffusion bonded by the application of heat and pressure.
Altematively, the biochips can be prepared by hot embossing of thin thermoplastic films with a master die of the negative of the structure to be produced. The mastcr die can bc prepared by using electroforming to replicate the device prepared in a solid substrate. The solid substrate can be glass sheets that are patterned by standard photolithographic and chemical etching methods known to those skilled in the art. The substrate and cover layers are diffusion bonded by the application of heat and pressure.
The substrate and cover layers of the biochip can be constructed from a variety of plastic substrates including, but not limited to, polyethylene, poly(acrylates) (e.g., poly(methyl methacrylate)), poly(carbonate)s, and unsaturated, partially unsaturated or saturated cyclic olefin polymers (COP), or an unsaturated, partially unsaturated, or saturated cyclic olefin copolymers (COC). The thickness of plastic substrate and cover layers utilized in the present process is kept thin to minimize the mass thereof to thereby maximize thermal transfer between the thermal cycler and the reaction solution contained in each reaction chamber during their use. The plastic substrate and cover layers can each, independently, have a thickness of less than 2 mm, less than 1 mm, less than 750 pm, less than 650 pm, less than 500 Am, less than 400 pm, less than 300 p.m, less than 200 Am, or less than 100 pm; or plastic substrate and cover layers can each, independently, comprise a plastic having a thickness ranging from 25 ĀØ 2000 pm, 25 ĀØ 1000, 25 ĀØ 750 pm, 25 ĀØ 650 mm, 25 ĀØ
500 p.m, 25 ĀØ 400 p.m, 25 ĀØ 300 pm, 25 ĀØ 200 pm, or 25 ĀØ 100 pm. Preferably, at least one of the substrate and cover layers has a thickness of less than about 200 pm to maximize thermal transfer to the reaction solution contained in the reaction chambers of the biochip. More preferably, a contact surface of the biochip which is in contact with the first surface of the TCE has a thickness of less than about 200 pm.
Each reaction chamber can be formed to have a volume of, for example, less than 100 AL. Preferably, each reaction chamber has a volume of less than about 50 AL, or less than about 40 AL, or less than about 30 AL, or less than about 25 AL, or less than about 20 pL, or less than about 15 AL, or less than about 10 AL, or less than about 5 AL or less than about 1 AL, or less than about 0.1 AL. Alternatively, each reaction chamber can be formed to have a volume ranging from about 0.1 AL to about 100 AL. Preferably, each reaction chamber has a volume ranging from about 0.1 AL to about 10 AL or about 10 AL to about 50 AL.
The reaction chambers are generally not coated with a polymer or silane coating.
Reaction chambers may be designed to have an inlet and an outlet channel.
Alternatively, a single channel may be used for inlet and outlet.
The biochip design of the invention leverages the benefits of microfluidics including having a high surface to volume ratio and reduced diffusion times to maximize heat transfer, and uniform heating and cooling. The use of microfluidic technology also provides benefits with respect to a fully-integrated forensic analysis instrument. Further, biochips fabricated by diffusion bonding, and without the use of adhesives to bond the various layers (e.g. COC
layers), were tested and demonstrated to be capable of withstanding from 100 to 1500 psi of pressure before failure based on the requirements of the desired application.
For example, the biochips of the present invention withstand 450 psi, sufficient for the desired thermal cycling applications.
It is noted that the specific embodiments of the biochips of the invention set forth herein substantially lack any heating elements integrated into the biochip for heating and/or cooling the reaction chambers. Thermal cycling of the reaction chambers on the biochip is provided externally, for example, by the thermal cycler of the invention.
Heating elements can be integrated into the biochips of the present invention, however.
In operation, one portion of the biochip can receive one or more reaction solutions, each independently comprising one or more reagents (e.g., for PCR) and or nucleic acid samples, through one or more inlets in fluid communication with one or more reaction chambers formed within the biochip. Simultaneous amplification of a plurality of samples can be performed by injecting each of the nucleic acid samples in a separate separation reaction chamber. An injector for simultaneously injecting a plurality samples into the plurality of sample or buffer wells can be provided with the biochip to enable simultaneous multiple sample amplification. Such injectors provide, for example, one sample of the plurality of samples to one reaction chamber of the plurality of reaction chambers. Injectors can introduce the samples to the channels according to any methods known to those skilled in the art, for example, by electrophoretic transport, pneumatic actuation or liquid actuation through a needle or tube or channel that connects the sample to the reaction chamber.
Following amplification (and optionally, nucleic acid extraction and quantification) the amplified nucleic acid product can be passed (e.g., to a Genebench-Fkrm 100) through one or more outlets in fluid communication with the reaction chambers for fragment separation and generation of STR profiles.
The relatively low cost of plastic manufacture allows the biochips of the invention to be disposable, eliminating the labor required to reuse the biochip and essentially eliminating the possibility of contamination. A single-use disposable would be particularly advantageous for low copy number analyses in that no possibility of contamination (other than initial sample collection) would exist. In settings where neither contamination nor labor are major considerations, reusable plastic and glass biochips may be utilized.
Integration Methods Using microfluidics allows fabrication of features to perform more than one function on a single biochip. These functions can include nucleic acid extraction, nucleic acid purification, pre-PCR nucleic acid cleanup, post-PCR cleanup, pre-sequencing cleanup, sequencing, post-sequencing cleanup, nucleic acid separation, nucleic acid detection, reverse transcription, pre-reverse transcription cleanup, post-reverse transcription cleanup, nucleic acid ligation, nucleic acid hybridization and quantification. Two or more of these functions can be connected microfluidically to enable sequential processing of a sample;
this coupling is termed integration.
One form of microfluidic DNA extraction can be achieved by inserting a purification medium between an input and output channel. This purification medium can be silica fiber based and use chaotropic-salt reagents to lyse the biological sample, expose the DNA and bind the DNA to the purification media. The lysate is then transported via the input channel through the purification medium to bind the DNA. Bound DNA is washed by an ethanol based buffer to remove contaminants. This can be accomplished by flowing wash reagents via the input channel through the purification membrane. Bound DNA is then eluted from the membrane by flowing an appropriate low salt buffer (see, e.g., Boom, US
5,234,809) via the input channel through the purification membrane and out the output channel.
One approach to DNA quantification in a microfluidic format is based upon real-time PCR. In this method of quantification, a reaction chamber is fabricated between an input and output channel. The reaction chamber is coupled to a thermal cycler and an optical excitation and detection system is coupled to the reaction chamber to allow fluorescence from the reaction solution to be measured. The amount of DNA in the sample is correlated to the intensity of the fluorescence from the reaction chamber per cycle (see, e.g., Heid et al., Genotne Research 1996, 6, 986-994).
For further information about integration in microfluidic formats, see the U.S. Patent application entitled "INTEGRATED NUCLEIC ACID ANALYSIS" filed on even day herewith (Attorney Docket No. 07-801-US).
For further information about separation and detection in microfluidic formats see the U.S.
Patent application entitled "Plastic Microfluidic Separation and Detection Platforms" filed on even day herewith (Attorney Docket No. 07-865-US).
Microfluidic drives of the invention are means for transporting fluids within the reaction chambers of the integrated biochips. One type of microfluidic drive is effected by incorporated a membrane pump which transports the fluid by sequential application of positive and negative pressure to the membrane. Alternatively, a positive displacement pump can be connected to the input of the microfluidic chamber. A displacement of the pump forces the fluid through the microfluidic channel.
Integration can make use of microfluidic valves to gate fluid flow within the biochip.
Valving can be accomplished with passive or active structures. Passive valving structures include capillary valves that stop fluid flow by utilizing capillary pressure.
Fluids can flow through the capillary valving structure by the application of a pressure that is sufficiently large enough to overcome the capillary forces. Active valving structures include membrane valves which use flexible or semi-rigid structures at a point between two channels. The application of pressure on the membrane causes it to close the channel. The application of a vacuum to the membrane lifts it from the channel, allowing passage of fluids.
Amplification Methods In yet another aspect, the invention provides methods for simultaneously amplifying a plurality of nucleic acid loci in one or more target nucleic acids via rapid polymerase chain reaction (PCR). Such methods comprise providing one or a plurality of reaction solutions to one or a plurality of reaction chambers, wherein each reaction solution comprises (i) at least one copy of at least one target nucleic acid, wherein each target nucleic acid is the same or different and each target nucleic acid independently comprises a plurality loci to be amplified; (ii) one or more buffers; (iii) one or more salts; (iv) a primer set corresponding to the plurality of loci to be amplified; (v) a nucleic acid polymerase; and (vi) nucleotides. Each of the reaction solutions, for example, each of the target nucleic acids, can be the same or different as necessary, for example, to run multiple simultaneous analyses on the same nucleic acid sample, or to simultaneously run multiple nucleic acid samples.
Each reaction chamber may be contained within a biochip of the invention as described above or thin-walled reaction tubes. Thin-walled reaction tubes preferably have a wall thickness of less than about 200 Am. Preferably, thin-walled reaction tubes preferably have a wall thickness of less than about 100 ttm.
Primers for PCR amplification are oligonucleotide sequences that are specifically designed to hybridize to loci of the target DNA. These primers serve as starting points for polymerase extensions. To facilitate analysis of amplified fragments, labeled primers can also be used in PCR reactions. Labeled primers are oligonucleotide sequences that are coupled to a detectable moiety; a non-limiting example thereof is a fluorescent dye. When PCR is carried out with fluorescently labeled primers, amplicons with a fluorescent label are generated. The methods for performing fast PCR are compatible with both labeled and unlabeled primers, and fast multiplexed PCR have been demonstrated.
Primer sets can be any known to those skilled in the art for the amplification of a plurality of loci with a target nucleic acid, as described above. For example, primers useful in amplification of one or more loci in a human nucleic acid sample are described in US5,582,989; US5,843,660; US6,221,598; US6,479,235; US6,531,282; and US7,008,771;
and US Patent Application Publication Nos. 2003/0180724; 2003/0186272; and 2004/0137504.
Further, primers useful in amplification of one or more loci in a viral nucleic acid sample are described in, for example, US7,312,036; US6,958,210; US6,849,407;
US6,790,952, and US6,472,155 .
Examples of primers useful in amplification of one or more loci in a bacterial nucleic acid sample are described in US7,326,779; US7,205,111; US7,074,599;
US7,074,598;
US6,664,080; and US5,994,066.
Salts and buffers include those familiar to those skilled in the art, including those comprising MgC12, and Tris-HC1 and KC1, respectfully. Buffers may contain additives such as surfactants (e.g., Tweens), dimethyl sulfoxide (DMSO), glycerol, bovine serum albumin (BSA) and polyethylene glycol (PEG), as well as others familiar to those skilled in the art.
Nucleotides are generally deoxyribonucleoside triphosphates, such as deoxyadenosine triphosphate (dATP), deoxycytidine triphophate (dCTP), deoxyguanosine triphosphate (dGTP) and deoxythymidine triphosphate (dTTP) are also added to the synthesis mixture in adequate amount for amplification of the target nucleic acid.
The solutions can be optionally heated to and held at a first temperature for a first period of time suitable for hot-start activation of the nucleic acid polymerases. Generally, the first period of time is less than about 90 seconds. The first temperature can be about 95 to about 99 C. Polymerases with hot start mechanisms that can be activated in 60 seconds or less include those utilizing antibody mediated hot-start and aptmer mediated hot start mechanisms. Alternatively, hot-start polymerases need not be utilized in the present invention.
Subsequently, the temperature of the reaction solutions are sequentially cycled between a denaturing state, an annealing state, and an extension state for a predetermined number of cycles. Generally, the one or a plurality of reaction solutions are cooled from the denaturing state to the =leafing state at a first cooling rate of about 1 to about 150 C/sec, or about 1 to about 100 C/sec; or about 1 to about 80 C/sec; or about 1 to about 60 C/sec; or about 1 to about 40 C/sec; or about 1 to about 30 C/sec; or about 1 to about 20 C/sec;
about 4 to about 150 C/sec, or about 4 to about 100 C/sec; or about 4 to about 80 C/sec; or about 4 to about 60 C/sec; or about 4 to about 40 C/sec; or about 4 to about 30 C/sec; or about 4 to about 20 C/sec; or about 10 to about 150 C/sec; or about 10 to about 100 C/sec;
or about 10 to about 80 C/sec; or about 10 to about 60 C/sec; of about 10 to about 40 C/sec; or about 10 to about 30 C/sec; or about 10 to about 20 C/sec. The one or a plurality of reaction solutions can be heated from the annealing state to the extension state at a first heating rate of about 1 to about 150 C/sec, or about 1 to about 100 C/sec;
or about 1 to about 80 C/sec; or about 1 to about 60 C/sec; or about 1 to about 40 C/sec;
about 1 to about 30 C/sec; about 1 to about 20 C/sec; 4 to about 150 C/sec, or about 4 to about 100 C/sec; or about 4 to about 80 C/sec; or about 4 to about 60 C/sec; or about 4 to about 40 C/sec; about 4 to about 30 C/sec; about 4 to about 20 C/sec; or about 10 to about 150 C/sec; or about 10 to about 100 C/sec; or about 10 to about 80 C/sec; or about 10 to about 60 C/sec; of about 10 to about 40 C/sec; or about 10 to about 30 C/sec; or about 10 to about 20 C/sec; and/or the one or a plurality of reaction solutions are heated from the extension state to the denaturing state at a second heating rate of about 1 to about 150 C/sec, or about 1 to about 100 C/sec; or about 1 to about 80 C/sec; or about 1 to about 60 C/sec;
or about 1 to about 40 C/sec; about 1 to about 30 C/sec; about 1 to about 20 C/sec; about 4 to about 150 C/sec, or about 4 to about 100 C/sec; or about 4 to about 80 C/sec; or about 4 to about 60 C/sec; or about 4 to about 40 C/sec; about 4 to about 30 C/sec;
about 4 to about 20 C/sec; or about 10 to about 150 C/sec; or about 10 to about 100 C/sec; or about
10 to about 80 C/sec; or about 10 to about 60 C/sec; of about 10 to about 40 C/sec; or about 10 to about 30 C/sec; or about 10 to about 20 C/sec. Finally, the reaction solutions are held at a final state to provide one or a plurality of amplified nucleic acid products.
Denaturing states can range generally include from about 90 to 99 C for times ranging from about 1 to 30 seconds. The actual times and temperatures are enzyme, primer and target dependent. For the Applied Biosystems (AB) multiplexed STR kit for amplifying human genomic DNA, about 95 C for about 5 sec. being preferred.
The annealing temperature and time influence the specificity and efficiency of primer binding to a particular locus within a target nucleic acid and are particularly important for multiplexed PCR reactions. The correct binding of a complete set of primer pairs during the annealing step can allow production of multiplexed amplification of a plurality of loci, for example, one or a plurality of full STR profiles with acceptable PI-IR and inter-locus signal strength balance. For a given primer pair, annealing states can range from about 50 C to 70 C and times from about 1 to 30 seconds. The actual times and temperatures are enzyme, primer, and target dependent. For the AB multiplexed STR kit for amplifying human genomic DNA, about 59 C for 15 seconds is preferred.
Extension temperature and time primarily impact the allele product yield and are an inherent property of the enzyme under study. It should be noted that the extension rates reported by the manufacturer are often provided for singleplex reactions;
extension rates for multiplex reactions can be much slower. For a given enzyme, extension states can range from about 60 to 75 C and times from about 1 to 30 seconds. The actual times and temperatures are enzyme, primer, and target dependent. For the AB multiplexed STR kit for amplifying human genomic DNA, about 72 C for about 5 seconds is preferred.
Preferably, for continuing a predetermined number of cycles, the reaction solution is heated from the extension state to the denaturing state at a third rate of about 1 to about 150 C/sec, or about 1 to about 100 C/sec; or about 1 to about 80 C/sec; or about 1 to about 60 C/sec; or about 1 to about 40 C/sec; or about 1 to about 30 C/sec; or about 1 to about 20 C/sec; 4 to about 150 C/sec, or about 4 to about 100 C/sec; or about 4 to about 80 C/sec; or about 4 to about 60 C/sec; or about 4 to about 40 C/sec; or about 4 to about 30 C/sec; or about 4 to about 20 C/sec; or about 10 to about 150 C/sec; or about 10 to about 100 C/sec; or about 10 to about 80 C/sec; or about 10 to about 60 C/sec; of about 10 to about 40 C/sec; or about 10 to about 30 C/sec; or about 10 to about 20 C/sec. Generally, the predetermined number of cycles is chosen to be about 10 to about 50 cycles, although fewer or more cycles may be used as necessary.
Final extension times can be reduced significantly until incomplete NTA begins to increase. For a given enzyme, final extension temperatures can range from about 60 to 75 C
and times from about 0 to 300 seconds. The actual times and temperatures are enzyme, primer, and target dependent. For the AB multiplexed STR kit for amplifying human genomic DNA, about 72 C for about 90 seconds is preferred.
In addition to the 3-step thermal cycling approach set forth above, this process is also amenable to 2-step thermal cycling approaches. In this approach, the reaction solutions are sequentially cycled between a denaturing state, and an annealing/extension state for a predetermined number of cycles. This approach utilizes primers designed to anneal at the extension temperature, allowing the annealing and extension steps to share the same temperature. The reduced number of temperature transition results in a further reduction in the cycle time.
In certain embodiments, a plurality of amplified nucleic acid products can be obtained in about 5 to about 20 minutes. In certain other embodiments, a plurality of amplified nucleic acid products can be obtained in about 5 to 10 minutes, about 1 to 5 minutes, or less than 5 minutes. Each amplified nucleic acid product can be generated starting from less than about ng of a target nucleic acid. Preferably, amplified nucleic acid products can be generated starting from less than about 5 ng or less than about 2 ng of nucleic acid, or less than about 1 ng of nucleic acid, or less than about 0.5 ng of nucleic acid, or less than about 0.2 ng of nucleic acid, or less than about 0.1 ng of nucleic acid, or less than about 0.05 ng of nucleic acid, or less than about 0.006 ng of nucleic acid.
In other embodiments, such as the identification of biological weapons agents in clinical or environmental samples or the diagnosis of bacterial, viral, or fungal infections in humans, plants, and animals, amplified nucleic acid products can be generated starting from at least one copy of a target nucleic acid. For example, a sample to be analyzed can comprise less than 1000 copies (e.g., 1 ĀØ 1000 copies), less than 400 copies, less than 200 copies, less than 100 copies, less than 50 copies, less than 30 copies, less than 10 copies or 1 copy of a target nucleic acid prior to the multiplexed amplification reaction.
In addition, less than a single genome equivalent of DNA can be utilized for amplification if the target nucleic acid locus is present in more than one copy in the genome.
In any of the preceding methods, the thermal cycling can be performed for a predetermined number of cycles to achieve sufficient amplification of the loci in the target nucleic acid as can be readily determined by one skilled in the art. For example, the predetermined number of cycles can range between about 10 and about 50 cycles, and preferably between about 20 and 50 cycles. Further, in any of the preceding methods, at least 2 loci of one or a plurality of nucleic acids can be simultaneously amplified.
Depending on the desired application, greater than four, 5 to 10, 10 to 20, 20 to 30 or about 10 to 250 loci are simultaneously amplified For example, for amplification of STR loci, 10-20 loci may be preferred.
Preferably, the temperature of the reaction solutions is cycled by a thermal cycler of the invention (supra). While it can be possible to utilize commercial block thermal cyclers for fast thermal cycling by the compensating for lagging response of the PCR
solution by setting the block temperature higher than the desired solution temperature on heating steps and setting the block temperature lower than the desired solution temperature on cooling steps, this mode of operation is cumbersome to implement as the temperature setpoints required to compensate for the slow ramping response must be determined empirically.
Furthermore, as feedback and control are still performed by the block and no monitoring of the solution temperature takes place, the repeatability and reproducibility of the profile can be influenced by external factors including the changes in the room temperature.
Hence, the temperature profile of the solution is not reproducible.
Many commercially available polymerases can be adapted for use in fast PCR
applications using the approaches described here. Typically, the nucleic acid polymerase has an extension rate of at least 100 bases/sec. A large number of polymerases available for PCR
amplification including Thermus aquaticus (Taq), Pyrococcus furiosus (Pfu), Pyrococcus woesei (Pwo), Thermas flavus (Tfl), Themus thermophilus (Tth), Thermus litoris (Tli) and Thermotoga maritime (Tma). These enzymes, modified version of these enzymes, and combination of enzymes, are commercially available from vendors including Roche, Invitrogen, Qiagen, Strategene, and Applied Biosystems. Representative enzymes include PHUSION (New England Biolabs, Ipswich , MA), Hot MasterTaem (Eppendorf), PHUSION
Mpx (Finnzymes), PyroStart (Fermentas), KOD (EMD Biosciences), Z-Taq (TAKARA), and CS3AC/LA (KlenTaq, University City , MO). A widely used enzyme for PCR
amplification for STR typing is the Taq polymerase, and the TaqGold variant is supplied with. the IdentifilerTm, Profiler, and COfilerTm kits.
In certain embodiments, the PCR conditions presented here can generate full STR
profiles from a human target nucleic acid with high efficiency, although production of a full profile is not required. A full profile for autosomal STR can comprise loci such as amelogenin, D8S1179, D21511, D7S820, CFSIPO, D351358, TH01, D13S317, DI6S539, D251338, D19S433, vWA, TPDX, D18S51, D5S818, FGA, or a plurality thereof.
Other STR
loci including mini-STRs, and Y-STR analysis. The criteria for optimization of the protocols include the generation of full profiles, signal strength, dynamic range, inter-locus signal strength balance, PHR, incomplete NTA, stutter, and total cycle time.
According one embodiment, protocols using the SpeedSTAR enzyme and the thermal cycler of the invention can reduce the total cycling time for biochip and tube reactions to 17.3 and 19.1 min respectively, to generate full STR profiles. In the protocol, the denaturing state is about 98 C for about 4 seconds, the annealing state is about 59 C for about 15 seconds, the extension state is about 72 C for about 7 seconds, and the final state is about 70 C for about 90 seconds.
In certain embodiments, the total cycling time for at least 10, 20, or 30 multiplexed PCR cycles can range from about 1 minute to about 90 minutes. Preferably, total cycling time for at least 10, 20, or 30 multiplexed PCR cycles ranges from about 1 minute to about 90 minutes; or from about I minute to about 85 minutes; or from about 1 minute to about 80 minutes; or from about 1 minute to about 75 minutes; or from about 1 minute to about 70 minutes; or from about 1 minute to about 65 minutes; or from about 1 minute to about 60 minutes; or from about 1 minute to about 55 minutes; or from about 1 minute to about 50 minutes; or from about 1 minute to about 45 minutes; or from about 1 minute to about 40 minutes; or from about 1 minute to about 35 minutes; or from about 1 minute to about 30 minutes; or from about 1 minute to about 25 minutes; or from about 1 minute to about 20 minutes; or from about 1 minute to about 15 minutes; or from about 1 minute to about 10 minutes or from about 1 minute to about 5 minutes. In other embodiments, the total cycling time for at least 10, 20, or 30 multiplexed PCR cycles is less than about 90 minutes.
Preferably, the total cycling time for at least 10, 20, or 30 multiplexed PCR
cycles is less than about 89, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 minute.
The invention contemplates an integrated biochip comprising one or a plurality of microfluidic systems, for performing the multiplexed PCR amplification of a plurality of loci within a nucleic acid sample as well as at least one other sample preparation and/or analysis method within the same biochip platform. For example, within each microfluidic system on a biochip, each having a flow direction from an inlet port to an outlet port, the system can comprise a plurality of reaction chambers, wherein a first reaction chamber of the plurality of reaction chambers is in fluid communication with the inlet port, and an ultimate reaction chamber of the plurality of reaction chambers is in fluid communication with the outlet port, and at least one microchannel fluidly connecting each consecutive pair of reaction chambers along the flow direction. At least one reaction chamber in each microfluidic system can be less than 200 Am from a contact surface of the biochip substrate to facilitate thermal communication with a thermal cycler of the invention for performing multiplexed PCR
within said reaction chamber.
Each of the remaining reaction chambers within each of the microfluidic systems of the biochip can be adapted for nucleic acid extraction, nucleic acid purification, nucleic acid hybridization, nucleic acid ligation, pre-PCR nucleic acid cleanup, post-PCR
cleanup, pre-sequencing cleanup, sequencing, post-sequencing cleanup, separation and detection, reverse transcription, pre-reverse transcription cleanup, and/or post-reverse transcription cleanup, electrophoretic separation, nucleic acid detection. The term "cleanup" as used herein means the removal of reaction components (including anions, cations, oligonucleotides, nucleotides, preservatives, enzymes, or inhibitors) that may interfere with any of the reaction chamber processes listed above.
The Examples which follow are illustrative of specific embodiments of the invention, and various uses thereof. They set forth for explanatory purposes only, and are not to be taken as limiting the invention.
EXAMPLES
Example 1 Custom Thermal Cycler and Microfluidic Biochip A thermal cycler of the inventionƵ as shown in Figure 1A, was used to perform fast cycling by allowing the PCR reaction solution temperatures to be heated and cooled rapidly, controllably, and reproducibly. This instrument accepts a 16-chamber microfluidic biochip and consists of a high output thermoelectric cooler/heater mounted to a high efficiency heat sink. Each of 16 PCR reaction solutions was placed into an individual chamber of the microfluidic biochip, coupled to the heat pump by applying a 0.2 MPa of compressive pressure with a clamping mechanism. Figure 1B shows a photograph of the 16-samp1e disposable plastic microfluidic biochip. Each PCR chamber is 500 vim deep and approximately 1 mm wide and holds 7 1 of PCR reaction solution.
Instrumentation and Temperature profiles In the following examples, all amplification reactions in tubes were performed with an Eppendorf MastercylerTm ep gradient S (Eppendorf North America, Westbury, NY).
Block temperature profiles of the above instrument were obtained using a 127 Am diameter type K thermocouple sensor which was attached directly to the block. For reaction solution profiles a 127 tim diameter type K thermocouple sensor was placed in the 20 pd_, reaction solution, within a thin-walled PCR tube. Data acquisition was performed with an Omega HH506RA Multilogger thermometer set to acquire data at a rate of 100 Hz.
Amplification reactions in biochips were performed using the thermal cycler of Example 1 with 16-sample plastic biochips as the reaction vessels. The solution temperature within the microfluidic biochip was monitored by inserting a thermocouple into a sensing chamber within the biochip.
PCRĀØ reaction mix components and cycling conditions Multiplex PCR reactions were performed with the AmpFESTRO Profiler Plus ID
PCR Amplification Kit (Profiler Plus ED kit) (Applied Biosystems, Foster City, CA) using 9947A genomic DNA (Promega, Madison, WI) as a template. Polymerases used for amplification were either AmpliTaq Gold DNA Polymerase (TaqGo1d1-11) supplied with the Profiler Plus ID kit or other polymerases: SpeedSTAR HS DNA Polymerase (SpeedSTAR) (Takara BIO USA Inc., Madison, WI), KOD Hot Start DNA Polymerase (KOD) (EMD
Biosciences Inc., Gibbstown, NJ), or PyrostartTM Fast PCR Master Mix (PyroStart) (Fermentas Inc., Glen Burnie, MD). Multiplex PCRs with other polymerases were carried out using the labeled multiplex primer set from the Profiler Plus II) kit in combination with the polymerase specific buffers and dNTPs. All tube PCRs were carried out in 0.2 mL
thin-walled PCR tubes (Eppendorf North America, Westbury, NY) using the Eppendorf MastercylerTm ep gradient S. All biochip reactions were amplified in the thermal cycler of Figure lA using 16-sample biochips.
The following PCR reaction mixtures were prepared and used for thermal cycling:
Standard TaqGoldTm reactions:
Standard TaqGoldmi multiplex reactions consisted of 9.55 AL Profiler Plus ID
reaction mix, 1 ng 9947A genomic DNA, 5 AL Profiler Plus ID Primer set and 2.25 U
TaqGoldTm in a 25 AL reaction volume. Cycling conditions (block temperatures and times) were chosen following the manufacturers recommendations and set to an initial 95 C for 11 min (hot start) followed by 28 cycles of 1 min at 94 C
(denaturing), 1 min at 59 C (annealing), 1 min at 72 C (extension) and a final extension of 45 min at 60 C.
Optimized TaqGoldTm reactions:
TaqGoldTm reactions optimized for fast cycling were carried out in a 10 AL
reaction volume containing 3.82 AL Profiler Plus ID reaction mix, 1 ng 9947A
genomic DNA, 2 AL Profiler Plus ID Primer set and 0.9 U TaqGoldTm. Reactions were cycled at 95 C for 11 min, 28 cycles 10 s, 98 C; 45 s, 59 C; 30 s, 72 C and a final extension of 15 min at 72 C.
SpeedSTAR tube reactions:
SpeedSTAR PCR mix components for tube PCR were: 2 AL Profiler Plus ID
primer set, 9947A genomic DNA, lx Fast Buffer I (Takara BIO USA Inc., Madison, WI), 200 AM dNTPs and 0.315 U SpeedSTAR in a 10 AL reaction volume. Cycling conditions for fast performance were set to: 1 min at 95 C (enzyme activation) followed by 28 cycles of 4 s at 98 C, 15 s at 59 C, 5 s at 72 C and a 1 min at 72 C
final extension.
SpeedSTAR biochip reactions:
For biochip PCR the 7 AL reaction mix contained 1.4 AL Profiler Plus ID
primer set, 9947A genomic DNA, lx Fast Buffer I buffer, 200 ktM dNTPs and 0.42 U
SpeedSTAR. Cycling parameters were set to 70 s at 95 C, 28 cycles of 4 s, 98 C; 15 s, 59 C; 7 s, 72 C and a final extension of 1:30 min at 70 C.
KOD reactions:
Amplification with KOD were performed with 2 AL Profiler Plus ID primer set, lx KOD buffer (EMD Biosciences Inc., Gibbstown, NJ), 200 ktM dNTPs, 1 ng 9947A genomic DNA, 1.5 mM MgSO4, 0.2 U KOD in a 10 AL reaction volume.
Cycling conditions were: 2 min, 95 C followed by 28 cycles of 4 s, 98 C; 30 s, 59 C; 10 s, 72 C with a final extension of 1 min, 72 C.
PyroStart reactions:
Reaction mixtures with PyroStart in a lx final concentration also contained 2 AL Profiler Plus ID primer set and 1 ng 9947A genomic DNA in a 10 ktI, reaction and were cycled at: 1 min, 95 C and 28 cycles of 4 s, 98 C; 20 s, 59 C; 30 s, followed by a final extension of 1 min at 72 C.
Multiplex PCR with other STR typing kits:
The suitability of SpeedSTAR to generate full STR profiles with other STR
typing kits (AmpFeSTR Identifiler (Identifiler), AmpHSTR COfiler PCR
Amplification Kit (COfiler), (Applied Biosystems) was tested in tube and biochip with the reaction conditions as described above for SpeedSTAR with the Profiler Plus ID kit. In these reactions, the Profiler Plus ID primer sets were replaced with the primer set from each of the kits.
Reproducibility Reproducibility studies in tube and biochip were performed with TaqGold-T-mĀØ
and SpeedSTAR using lng 9947A genomic DNA as a template. For tube reproducibility individual reactions were prepared. Biochip reproducibility was determined in 3 biochip PCR runs with 8 reactions each.
Sensitivity Sensitivity studies for SpeedSTAR amplification in tube and biochip were performed using the following amounts of 9947A template DNA: In tube: 4 ng, 2 ng, 1.5 ng, 1 ng, 0.5 ng, 0.25 ng, 0.125 ng, 0.1 ng, 0.05 ng, 0.03 ng, 0.02 ng, 0.01 ng, 0.006 ng;
in biochip: 4 ng, 2 ng, 1.5 ng, 1 ng, 0.5 ng, 0.25 ng, 0.1 ng, 0.05 ng, 0.025 ng, 0.02 ng,Ć015 ng, 0.01 ng, 0.006 ng. The reactions at each template level were performed in duplicate.
STR separation and detection instrumentation Amplified products were separated and detected using the Network Biosystem Genebench-FXTm Series 100 (Pyzowski and Tan, Advances in Biochip-Based Analysis: A
Rapid Field-Based Approach 59th Annual Meeting of the American Academy of Forensic Sciences San Antonio, TX, February 19-24, 2007). This instrument was developed and optimized specifically for STR analysis. To 2.7 AL of each amplified product 10.2 AL
Hi-Di Tm formamide and 0.1 AL of Genescan 500 LIZ internal lane standard (both Applied Biosystems, Foster City, CA) were added. After denaturation at 95 C for 3 min and snap cooling on ice, samples were loaded into the separation chip and electrophoretically moved into the separation channels by applying a 350 V/cm electric field for 90 seconds. This was followed by the application of a 150 V/cm electric field along the separation channel to separate the DNA fragments. All separations were carried out at 50 C.
Data analysis Data was analyzed with the GeneMarker HID STR Human Identification Software, Version 1.51 (SoftGenetics LLC, State College, PA). Signal strengths were normalized to the internal lane standard and the percentages of stutter, incomplete NTA as well as PHR
were determined. PHR is calculated by dividing the lower signal strength allele by the higher signal strength allele within the locus. The level of incomplete NTA is calculated by dividing the signal strength of the template fragment (-A) by the signal strength of the adenylated fragment (+A).
Example 2 Temperature Profiles of Thermal Cycling Instruments and Reaction Solutions in Conventional PCR Tubes and Microfluidic Biochips Amplification reactions were performed in thin-walled PCR tubes using a commercial thermal cycler and in microfluidic biochips using the thermal cycler of Example 1. For tube reactions, the Eppendorf MastercylerTm was utilized. Figure 2A shows the temperature of the block and the reaction solution within a tube for one of the 28 thermal cycles using a conventional STR cycling protocol. The MastercyclerTm heating and cooling system is based on a heat pump with an integrated block for tube insertion. The time and temperature setpoints are 1 minute at 98 C for denaturation, 1 minute at 59 C for annealing, and 1 minute at 72 C for extension. A comparison of the temperature profiles for the heat block and the reaction solution shows a lag in the response of the solution temperature relative to the block temperature. The measured heating and cooling rates of the block are 5.6 C/sec and 4.9 C/sec and of the solution are 4.8 C/sec and 3.3 C/sec. The block makes the temperature transition from extension (72 C) to denaturation (98 C) in 14 seconds, but the solution does not achieve the setpoint temperature for 39 seconds. Transitions between the denaturation and annealing steps (59 C) take 10 and 27 seconds and between the annealing and extension steps take 7 and 24 seconds for the block and solution respectively.
The temperature profiles of the Eppendorf MastercylerTM block and the reaction solution for one of the 28 thermal cycles under fast cycling conditions are shown in Figure 2B. The time and temperature setpoints are 5 seconds at 98 C for denaturation, 15 seconds=
at 59 C for annealing, and 5 seconds at 72 C for extension. However, the delayed and dampened response of the solution prevents it from achieving the desired setpoint temperatures.
_ The temperature profiles of the heat pump and the reaction solution for one of the 28 thermal cycles for the thermal cycler of the invention using fast cycling conditions were also determined (Figure 3). For the determination of the reaction solution temperature, a sensing chamber within the biochip was used. The time and temperature setpoints are 4 seconds at 95 C for denaturation, 15 seconds at 59 C for annealing, and 7 seconds at 72 C
for extension.
The measured heating and cooling rates of the heat pump are 21.5 C/sec and 21.7 C/sec, and the measured heating and cooling rates of the reaction solution are 14.8 C/sec and 15.4 C/sec.
Accordingly, the thermal cycler of the invention is capable of heating and cooling the reaction solution at a rate that is 3 to 5 times faster than the commercial block-based cycler.
The transition times between extension, denaturation, and annealing steps for the heat pump are 1.7, 2.1, and 0.7 seconds and for the solution 2.7, 4.5, and 2.2 seconds.
The thermal cycler of the invention allows the reaction solution to reach the required temperatures approximately 7-fold faster than the block-based cycler, resulting in defined and controlled incubation temperatures and times under fast cycling conditions.
Example 3 Evaluation of PCR Enzymes in Tubes A large number of polymerases were evaluated for potential use for fast, multiplexed STR analysis, and candidates were selected based in part on hot-start activation time and extension rate. The reported properties of the four polymerases selected for experimental evaluation compared with recommended conditions for TaqGoldT are presented in Table 1(A).
1 1 l TABLE 1A = Reported Polyrnerase characteristics 1 I l l 1ĀØ
Potymerase l ATG l SpeedSTAR PyroStart l KOD
3-5' Exonuclease activity No = Yes, <20% No Yes Generation of 3'-dA overhangs Yes Yes, >80% Yes No Hot Start mechanism Chemical modified Antibody Chemical modified Antibody initial activation 95*C / 11 min 95 C / 1 min 95*C / 1 min 95 C / 2 min Elongation rate (nucleotides/sec] 16.67 l 100-200 40 d 1 1B - Optimized performance of polymerases in tube reactions
Denaturing states can range generally include from about 90 to 99 C for times ranging from about 1 to 30 seconds. The actual times and temperatures are enzyme, primer and target dependent. For the Applied Biosystems (AB) multiplexed STR kit for amplifying human genomic DNA, about 95 C for about 5 sec. being preferred.
The annealing temperature and time influence the specificity and efficiency of primer binding to a particular locus within a target nucleic acid and are particularly important for multiplexed PCR reactions. The correct binding of a complete set of primer pairs during the annealing step can allow production of multiplexed amplification of a plurality of loci, for example, one or a plurality of full STR profiles with acceptable PI-IR and inter-locus signal strength balance. For a given primer pair, annealing states can range from about 50 C to 70 C and times from about 1 to 30 seconds. The actual times and temperatures are enzyme, primer, and target dependent. For the AB multiplexed STR kit for amplifying human genomic DNA, about 59 C for 15 seconds is preferred.
Extension temperature and time primarily impact the allele product yield and are an inherent property of the enzyme under study. It should be noted that the extension rates reported by the manufacturer are often provided for singleplex reactions;
extension rates for multiplex reactions can be much slower. For a given enzyme, extension states can range from about 60 to 75 C and times from about 1 to 30 seconds. The actual times and temperatures are enzyme, primer, and target dependent. For the AB multiplexed STR kit for amplifying human genomic DNA, about 72 C for about 5 seconds is preferred.
Preferably, for continuing a predetermined number of cycles, the reaction solution is heated from the extension state to the denaturing state at a third rate of about 1 to about 150 C/sec, or about 1 to about 100 C/sec; or about 1 to about 80 C/sec; or about 1 to about 60 C/sec; or about 1 to about 40 C/sec; or about 1 to about 30 C/sec; or about 1 to about 20 C/sec; 4 to about 150 C/sec, or about 4 to about 100 C/sec; or about 4 to about 80 C/sec; or about 4 to about 60 C/sec; or about 4 to about 40 C/sec; or about 4 to about 30 C/sec; or about 4 to about 20 C/sec; or about 10 to about 150 C/sec; or about 10 to about 100 C/sec; or about 10 to about 80 C/sec; or about 10 to about 60 C/sec; of about 10 to about 40 C/sec; or about 10 to about 30 C/sec; or about 10 to about 20 C/sec. Generally, the predetermined number of cycles is chosen to be about 10 to about 50 cycles, although fewer or more cycles may be used as necessary.
Final extension times can be reduced significantly until incomplete NTA begins to increase. For a given enzyme, final extension temperatures can range from about 60 to 75 C
and times from about 0 to 300 seconds. The actual times and temperatures are enzyme, primer, and target dependent. For the AB multiplexed STR kit for amplifying human genomic DNA, about 72 C for about 90 seconds is preferred.
In addition to the 3-step thermal cycling approach set forth above, this process is also amenable to 2-step thermal cycling approaches. In this approach, the reaction solutions are sequentially cycled between a denaturing state, and an annealing/extension state for a predetermined number of cycles. This approach utilizes primers designed to anneal at the extension temperature, allowing the annealing and extension steps to share the same temperature. The reduced number of temperature transition results in a further reduction in the cycle time.
In certain embodiments, a plurality of amplified nucleic acid products can be obtained in about 5 to about 20 minutes. In certain other embodiments, a plurality of amplified nucleic acid products can be obtained in about 5 to 10 minutes, about 1 to 5 minutes, or less than 5 minutes. Each amplified nucleic acid product can be generated starting from less than about ng of a target nucleic acid. Preferably, amplified nucleic acid products can be generated starting from less than about 5 ng or less than about 2 ng of nucleic acid, or less than about 1 ng of nucleic acid, or less than about 0.5 ng of nucleic acid, or less than about 0.2 ng of nucleic acid, or less than about 0.1 ng of nucleic acid, or less than about 0.05 ng of nucleic acid, or less than about 0.006 ng of nucleic acid.
In other embodiments, such as the identification of biological weapons agents in clinical or environmental samples or the diagnosis of bacterial, viral, or fungal infections in humans, plants, and animals, amplified nucleic acid products can be generated starting from at least one copy of a target nucleic acid. For example, a sample to be analyzed can comprise less than 1000 copies (e.g., 1 ĀØ 1000 copies), less than 400 copies, less than 200 copies, less than 100 copies, less than 50 copies, less than 30 copies, less than 10 copies or 1 copy of a target nucleic acid prior to the multiplexed amplification reaction.
In addition, less than a single genome equivalent of DNA can be utilized for amplification if the target nucleic acid locus is present in more than one copy in the genome.
In any of the preceding methods, the thermal cycling can be performed for a predetermined number of cycles to achieve sufficient amplification of the loci in the target nucleic acid as can be readily determined by one skilled in the art. For example, the predetermined number of cycles can range between about 10 and about 50 cycles, and preferably between about 20 and 50 cycles. Further, in any of the preceding methods, at least 2 loci of one or a plurality of nucleic acids can be simultaneously amplified.
Depending on the desired application, greater than four, 5 to 10, 10 to 20, 20 to 30 or about 10 to 250 loci are simultaneously amplified For example, for amplification of STR loci, 10-20 loci may be preferred.
Preferably, the temperature of the reaction solutions is cycled by a thermal cycler of the invention (supra). While it can be possible to utilize commercial block thermal cyclers for fast thermal cycling by the compensating for lagging response of the PCR
solution by setting the block temperature higher than the desired solution temperature on heating steps and setting the block temperature lower than the desired solution temperature on cooling steps, this mode of operation is cumbersome to implement as the temperature setpoints required to compensate for the slow ramping response must be determined empirically.
Furthermore, as feedback and control are still performed by the block and no monitoring of the solution temperature takes place, the repeatability and reproducibility of the profile can be influenced by external factors including the changes in the room temperature.
Hence, the temperature profile of the solution is not reproducible.
Many commercially available polymerases can be adapted for use in fast PCR
applications using the approaches described here. Typically, the nucleic acid polymerase has an extension rate of at least 100 bases/sec. A large number of polymerases available for PCR
amplification including Thermus aquaticus (Taq), Pyrococcus furiosus (Pfu), Pyrococcus woesei (Pwo), Thermas flavus (Tfl), Themus thermophilus (Tth), Thermus litoris (Tli) and Thermotoga maritime (Tma). These enzymes, modified version of these enzymes, and combination of enzymes, are commercially available from vendors including Roche, Invitrogen, Qiagen, Strategene, and Applied Biosystems. Representative enzymes include PHUSION (New England Biolabs, Ipswich , MA), Hot MasterTaem (Eppendorf), PHUSION
Mpx (Finnzymes), PyroStart (Fermentas), KOD (EMD Biosciences), Z-Taq (TAKARA), and CS3AC/LA (KlenTaq, University City , MO). A widely used enzyme for PCR
amplification for STR typing is the Taq polymerase, and the TaqGold variant is supplied with. the IdentifilerTm, Profiler, and COfilerTm kits.
In certain embodiments, the PCR conditions presented here can generate full STR
profiles from a human target nucleic acid with high efficiency, although production of a full profile is not required. A full profile for autosomal STR can comprise loci such as amelogenin, D8S1179, D21511, D7S820, CFSIPO, D351358, TH01, D13S317, DI6S539, D251338, D19S433, vWA, TPDX, D18S51, D5S818, FGA, or a plurality thereof.
Other STR
loci including mini-STRs, and Y-STR analysis. The criteria for optimization of the protocols include the generation of full profiles, signal strength, dynamic range, inter-locus signal strength balance, PHR, incomplete NTA, stutter, and total cycle time.
According one embodiment, protocols using the SpeedSTAR enzyme and the thermal cycler of the invention can reduce the total cycling time for biochip and tube reactions to 17.3 and 19.1 min respectively, to generate full STR profiles. In the protocol, the denaturing state is about 98 C for about 4 seconds, the annealing state is about 59 C for about 15 seconds, the extension state is about 72 C for about 7 seconds, and the final state is about 70 C for about 90 seconds.
In certain embodiments, the total cycling time for at least 10, 20, or 30 multiplexed PCR cycles can range from about 1 minute to about 90 minutes. Preferably, total cycling time for at least 10, 20, or 30 multiplexed PCR cycles ranges from about 1 minute to about 90 minutes; or from about I minute to about 85 minutes; or from about 1 minute to about 80 minutes; or from about 1 minute to about 75 minutes; or from about 1 minute to about 70 minutes; or from about 1 minute to about 65 minutes; or from about 1 minute to about 60 minutes; or from about 1 minute to about 55 minutes; or from about 1 minute to about 50 minutes; or from about 1 minute to about 45 minutes; or from about 1 minute to about 40 minutes; or from about 1 minute to about 35 minutes; or from about 1 minute to about 30 minutes; or from about 1 minute to about 25 minutes; or from about 1 minute to about 20 minutes; or from about 1 minute to about 15 minutes; or from about 1 minute to about 10 minutes or from about 1 minute to about 5 minutes. In other embodiments, the total cycling time for at least 10, 20, or 30 multiplexed PCR cycles is less than about 90 minutes.
Preferably, the total cycling time for at least 10, 20, or 30 multiplexed PCR
cycles is less than about 89, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 minute.
The invention contemplates an integrated biochip comprising one or a plurality of microfluidic systems, for performing the multiplexed PCR amplification of a plurality of loci within a nucleic acid sample as well as at least one other sample preparation and/or analysis method within the same biochip platform. For example, within each microfluidic system on a biochip, each having a flow direction from an inlet port to an outlet port, the system can comprise a plurality of reaction chambers, wherein a first reaction chamber of the plurality of reaction chambers is in fluid communication with the inlet port, and an ultimate reaction chamber of the plurality of reaction chambers is in fluid communication with the outlet port, and at least one microchannel fluidly connecting each consecutive pair of reaction chambers along the flow direction. At least one reaction chamber in each microfluidic system can be less than 200 Am from a contact surface of the biochip substrate to facilitate thermal communication with a thermal cycler of the invention for performing multiplexed PCR
within said reaction chamber.
Each of the remaining reaction chambers within each of the microfluidic systems of the biochip can be adapted for nucleic acid extraction, nucleic acid purification, nucleic acid hybridization, nucleic acid ligation, pre-PCR nucleic acid cleanup, post-PCR
cleanup, pre-sequencing cleanup, sequencing, post-sequencing cleanup, separation and detection, reverse transcription, pre-reverse transcription cleanup, and/or post-reverse transcription cleanup, electrophoretic separation, nucleic acid detection. The term "cleanup" as used herein means the removal of reaction components (including anions, cations, oligonucleotides, nucleotides, preservatives, enzymes, or inhibitors) that may interfere with any of the reaction chamber processes listed above.
The Examples which follow are illustrative of specific embodiments of the invention, and various uses thereof. They set forth for explanatory purposes only, and are not to be taken as limiting the invention.
EXAMPLES
Example 1 Custom Thermal Cycler and Microfluidic Biochip A thermal cycler of the inventionƵ as shown in Figure 1A, was used to perform fast cycling by allowing the PCR reaction solution temperatures to be heated and cooled rapidly, controllably, and reproducibly. This instrument accepts a 16-chamber microfluidic biochip and consists of a high output thermoelectric cooler/heater mounted to a high efficiency heat sink. Each of 16 PCR reaction solutions was placed into an individual chamber of the microfluidic biochip, coupled to the heat pump by applying a 0.2 MPa of compressive pressure with a clamping mechanism. Figure 1B shows a photograph of the 16-samp1e disposable plastic microfluidic biochip. Each PCR chamber is 500 vim deep and approximately 1 mm wide and holds 7 1 of PCR reaction solution.
Instrumentation and Temperature profiles In the following examples, all amplification reactions in tubes were performed with an Eppendorf MastercylerTm ep gradient S (Eppendorf North America, Westbury, NY).
Block temperature profiles of the above instrument were obtained using a 127 Am diameter type K thermocouple sensor which was attached directly to the block. For reaction solution profiles a 127 tim diameter type K thermocouple sensor was placed in the 20 pd_, reaction solution, within a thin-walled PCR tube. Data acquisition was performed with an Omega HH506RA Multilogger thermometer set to acquire data at a rate of 100 Hz.
Amplification reactions in biochips were performed using the thermal cycler of Example 1 with 16-sample plastic biochips as the reaction vessels. The solution temperature within the microfluidic biochip was monitored by inserting a thermocouple into a sensing chamber within the biochip.
PCRĀØ reaction mix components and cycling conditions Multiplex PCR reactions were performed with the AmpFESTRO Profiler Plus ID
PCR Amplification Kit (Profiler Plus ED kit) (Applied Biosystems, Foster City, CA) using 9947A genomic DNA (Promega, Madison, WI) as a template. Polymerases used for amplification were either AmpliTaq Gold DNA Polymerase (TaqGo1d1-11) supplied with the Profiler Plus ID kit or other polymerases: SpeedSTAR HS DNA Polymerase (SpeedSTAR) (Takara BIO USA Inc., Madison, WI), KOD Hot Start DNA Polymerase (KOD) (EMD
Biosciences Inc., Gibbstown, NJ), or PyrostartTM Fast PCR Master Mix (PyroStart) (Fermentas Inc., Glen Burnie, MD). Multiplex PCRs with other polymerases were carried out using the labeled multiplex primer set from the Profiler Plus II) kit in combination with the polymerase specific buffers and dNTPs. All tube PCRs were carried out in 0.2 mL
thin-walled PCR tubes (Eppendorf North America, Westbury, NY) using the Eppendorf MastercylerTm ep gradient S. All biochip reactions were amplified in the thermal cycler of Figure lA using 16-sample biochips.
The following PCR reaction mixtures were prepared and used for thermal cycling:
Standard TaqGoldTm reactions:
Standard TaqGoldmi multiplex reactions consisted of 9.55 AL Profiler Plus ID
reaction mix, 1 ng 9947A genomic DNA, 5 AL Profiler Plus ID Primer set and 2.25 U
TaqGoldTm in a 25 AL reaction volume. Cycling conditions (block temperatures and times) were chosen following the manufacturers recommendations and set to an initial 95 C for 11 min (hot start) followed by 28 cycles of 1 min at 94 C
(denaturing), 1 min at 59 C (annealing), 1 min at 72 C (extension) and a final extension of 45 min at 60 C.
Optimized TaqGoldTm reactions:
TaqGoldTm reactions optimized for fast cycling were carried out in a 10 AL
reaction volume containing 3.82 AL Profiler Plus ID reaction mix, 1 ng 9947A
genomic DNA, 2 AL Profiler Plus ID Primer set and 0.9 U TaqGoldTm. Reactions were cycled at 95 C for 11 min, 28 cycles 10 s, 98 C; 45 s, 59 C; 30 s, 72 C and a final extension of 15 min at 72 C.
SpeedSTAR tube reactions:
SpeedSTAR PCR mix components for tube PCR were: 2 AL Profiler Plus ID
primer set, 9947A genomic DNA, lx Fast Buffer I (Takara BIO USA Inc., Madison, WI), 200 AM dNTPs and 0.315 U SpeedSTAR in a 10 AL reaction volume. Cycling conditions for fast performance were set to: 1 min at 95 C (enzyme activation) followed by 28 cycles of 4 s at 98 C, 15 s at 59 C, 5 s at 72 C and a 1 min at 72 C
final extension.
SpeedSTAR biochip reactions:
For biochip PCR the 7 AL reaction mix contained 1.4 AL Profiler Plus ID
primer set, 9947A genomic DNA, lx Fast Buffer I buffer, 200 ktM dNTPs and 0.42 U
SpeedSTAR. Cycling parameters were set to 70 s at 95 C, 28 cycles of 4 s, 98 C; 15 s, 59 C; 7 s, 72 C and a final extension of 1:30 min at 70 C.
KOD reactions:
Amplification with KOD were performed with 2 AL Profiler Plus ID primer set, lx KOD buffer (EMD Biosciences Inc., Gibbstown, NJ), 200 ktM dNTPs, 1 ng 9947A genomic DNA, 1.5 mM MgSO4, 0.2 U KOD in a 10 AL reaction volume.
Cycling conditions were: 2 min, 95 C followed by 28 cycles of 4 s, 98 C; 30 s, 59 C; 10 s, 72 C with a final extension of 1 min, 72 C.
PyroStart reactions:
Reaction mixtures with PyroStart in a lx final concentration also contained 2 AL Profiler Plus ID primer set and 1 ng 9947A genomic DNA in a 10 ktI, reaction and were cycled at: 1 min, 95 C and 28 cycles of 4 s, 98 C; 20 s, 59 C; 30 s, followed by a final extension of 1 min at 72 C.
Multiplex PCR with other STR typing kits:
The suitability of SpeedSTAR to generate full STR profiles with other STR
typing kits (AmpFeSTR Identifiler (Identifiler), AmpHSTR COfiler PCR
Amplification Kit (COfiler), (Applied Biosystems) was tested in tube and biochip with the reaction conditions as described above for SpeedSTAR with the Profiler Plus ID kit. In these reactions, the Profiler Plus ID primer sets were replaced with the primer set from each of the kits.
Reproducibility Reproducibility studies in tube and biochip were performed with TaqGold-T-mĀØ
and SpeedSTAR using lng 9947A genomic DNA as a template. For tube reproducibility individual reactions were prepared. Biochip reproducibility was determined in 3 biochip PCR runs with 8 reactions each.
Sensitivity Sensitivity studies for SpeedSTAR amplification in tube and biochip were performed using the following amounts of 9947A template DNA: In tube: 4 ng, 2 ng, 1.5 ng, 1 ng, 0.5 ng, 0.25 ng, 0.125 ng, 0.1 ng, 0.05 ng, 0.03 ng, 0.02 ng, 0.01 ng, 0.006 ng;
in biochip: 4 ng, 2 ng, 1.5 ng, 1 ng, 0.5 ng, 0.25 ng, 0.1 ng, 0.05 ng, 0.025 ng, 0.02 ng,Ć015 ng, 0.01 ng, 0.006 ng. The reactions at each template level were performed in duplicate.
STR separation and detection instrumentation Amplified products were separated and detected using the Network Biosystem Genebench-FXTm Series 100 (Pyzowski and Tan, Advances in Biochip-Based Analysis: A
Rapid Field-Based Approach 59th Annual Meeting of the American Academy of Forensic Sciences San Antonio, TX, February 19-24, 2007). This instrument was developed and optimized specifically for STR analysis. To 2.7 AL of each amplified product 10.2 AL
Hi-Di Tm formamide and 0.1 AL of Genescan 500 LIZ internal lane standard (both Applied Biosystems, Foster City, CA) were added. After denaturation at 95 C for 3 min and snap cooling on ice, samples were loaded into the separation chip and electrophoretically moved into the separation channels by applying a 350 V/cm electric field for 90 seconds. This was followed by the application of a 150 V/cm electric field along the separation channel to separate the DNA fragments. All separations were carried out at 50 C.
Data analysis Data was analyzed with the GeneMarker HID STR Human Identification Software, Version 1.51 (SoftGenetics LLC, State College, PA). Signal strengths were normalized to the internal lane standard and the percentages of stutter, incomplete NTA as well as PHR
were determined. PHR is calculated by dividing the lower signal strength allele by the higher signal strength allele within the locus. The level of incomplete NTA is calculated by dividing the signal strength of the template fragment (-A) by the signal strength of the adenylated fragment (+A).
Example 2 Temperature Profiles of Thermal Cycling Instruments and Reaction Solutions in Conventional PCR Tubes and Microfluidic Biochips Amplification reactions were performed in thin-walled PCR tubes using a commercial thermal cycler and in microfluidic biochips using the thermal cycler of Example 1. For tube reactions, the Eppendorf MastercylerTm was utilized. Figure 2A shows the temperature of the block and the reaction solution within a tube for one of the 28 thermal cycles using a conventional STR cycling protocol. The MastercyclerTm heating and cooling system is based on a heat pump with an integrated block for tube insertion. The time and temperature setpoints are 1 minute at 98 C for denaturation, 1 minute at 59 C for annealing, and 1 minute at 72 C for extension. A comparison of the temperature profiles for the heat block and the reaction solution shows a lag in the response of the solution temperature relative to the block temperature. The measured heating and cooling rates of the block are 5.6 C/sec and 4.9 C/sec and of the solution are 4.8 C/sec and 3.3 C/sec. The block makes the temperature transition from extension (72 C) to denaturation (98 C) in 14 seconds, but the solution does not achieve the setpoint temperature for 39 seconds. Transitions between the denaturation and annealing steps (59 C) take 10 and 27 seconds and between the annealing and extension steps take 7 and 24 seconds for the block and solution respectively.
The temperature profiles of the Eppendorf MastercylerTM block and the reaction solution for one of the 28 thermal cycles under fast cycling conditions are shown in Figure 2B. The time and temperature setpoints are 5 seconds at 98 C for denaturation, 15 seconds=
at 59 C for annealing, and 5 seconds at 72 C for extension. However, the delayed and dampened response of the solution prevents it from achieving the desired setpoint temperatures.
_ The temperature profiles of the heat pump and the reaction solution for one of the 28 thermal cycles for the thermal cycler of the invention using fast cycling conditions were also determined (Figure 3). For the determination of the reaction solution temperature, a sensing chamber within the biochip was used. The time and temperature setpoints are 4 seconds at 95 C for denaturation, 15 seconds at 59 C for annealing, and 7 seconds at 72 C
for extension.
The measured heating and cooling rates of the heat pump are 21.5 C/sec and 21.7 C/sec, and the measured heating and cooling rates of the reaction solution are 14.8 C/sec and 15.4 C/sec.
Accordingly, the thermal cycler of the invention is capable of heating and cooling the reaction solution at a rate that is 3 to 5 times faster than the commercial block-based cycler.
The transition times between extension, denaturation, and annealing steps for the heat pump are 1.7, 2.1, and 0.7 seconds and for the solution 2.7, 4.5, and 2.2 seconds.
The thermal cycler of the invention allows the reaction solution to reach the required temperatures approximately 7-fold faster than the block-based cycler, resulting in defined and controlled incubation temperatures and times under fast cycling conditions.
Example 3 Evaluation of PCR Enzymes in Tubes A large number of polymerases were evaluated for potential use for fast, multiplexed STR analysis, and candidates were selected based in part on hot-start activation time and extension rate. The reported properties of the four polymerases selected for experimental evaluation compared with recommended conditions for TaqGoldT are presented in Table 1(A).
1 1 l TABLE 1A = Reported Polyrnerase characteristics 1 I l l 1ĀØ
Potymerase l ATG l SpeedSTAR PyroStart l KOD
3-5' Exonuclease activity No = Yes, <20% No Yes Generation of 3'-dA overhangs Yes Yes, >80% Yes No Hot Start mechanism Chemical modified Antibody Chemical modified Antibody initial activation 95*C / 11 min 95 C / 1 min 95*C / 1 min 95 C / 2 min Elongation rate (nucleotides/sec] 16.67 l 100-200 40 d 1 1B - Optimized performance of polymerases in tube reactions
11 k Standard ATG Optimized ATG SpeedSTAR PyroStart KOD
Cycling conditions 95 C / 11 min 95 C / 11 min 95 C 1 1 min 95 C / 1 min 1 95 C / 2 min 94 C / 1 min 98 C / 10sec 98 C / 4 sec __ 98 C / 4 sec 98 C /
4 sec 59 C / 1 min x 28 59 C I 45 sec x 28 59 C I 15 sec x 28 59 C / 20 sec x 28 59 C / 30 sec x 28 72 C / 1 min 72 C / 30 sec 72 C / 5 sec 72 C / 30 sec 72 C
/ 10 sec 60 C / 45 min 72=C/ 15min 72 C / 1 min 72=C/ 1 min 72 C i 1 min Amplthcation time 145.1 min 71.67 min 19.13 min 33.12 min 29.47.min Signal Strength range pail 561-1655 600-3876 945-3669 Stutter range 4.18.11.16% 3.91-13.77% 6.49-13.56% 6 21-15 91% 4.46-23.61%
NTA range 1.54-7.67% 1.93-20.13%
3.07.19.68% 3.01-23.09%
PHR 0.88-0.93% 0.74-0.96% 0.83-0.93% 0.71-0.94% 0.61-0.94%
I
The evaluated enzymes have reported extension rates ranging from approximately nucleotides/second; in general, the reported extension rates are based on singleplex amplifications and may be somewhat lower for multiplex applications.
PCR conditions in tubes were initially investigated for these four enzymes with the goal of achieving full STR profiles in the least amount of time. For all reactions, 1 ng of human genomic DNA was amplified using primer pairs from the Profiler Plus lD
kit and vendor recommended buffers and enzyme concentrations, and resulting profiles were separated, detected, sized, and quantified using Genebench-FX11" Series 100.
Various times and temperatures for the denaturation, annealing, and extension steps were determined to give total times for PCR amplification with signal strengths suitable for STR
interpretation ranging from 19.13 minutes for SpeedSTAR to 71.7 minutes for TaqGoldill [Table 1(B)].
Method conditions of the invention allow amplification to be performed 2-10 fold more rapidly than recommended conditions for TaqGoldTm.
Further evaluation of the enzymes for forensically relevant performance includes signal strength, levels of stutter and incomplete NTA and PFIR [Table 1(B)].
All enzymes are capable of performing highly multiplexed amplification using the Profiler Plus ID
primers. Signal strengths for SpeedSTAR, Pyrostart, KOD, and optimized TaqGoldlil reactions are all either approximately the same or higher than those generated using standard TaqGoldrĀØm- PCR conditions.
With respect to incomplete NTA, both SpeedSTAR and PyroStart as well as optimized TaqGoldTm reactions exhibited levels that are up to three times higher than that of standard TaqGoldi'm reactions. For most alleles, levels fall below the 15%
interpretation threshold. Those alleles having higher levels of incomplete NTA can be decreased to below the 15% interpretation threshold as discussed below. The KOD polymerase possesses 3'-5' exonuclease activity and does not generate fragments with A-overhangs;
accordingly, all alleles were 1 nucleotide shorter than their allelic ladder counterpart.
The relative levels of stutter observed for optimized TaqGoldTm, SpeedSTAR and PyroStart reactions are similar to the range of stutter produced with standard TaqGoldTm reactions; the range of stutter generated with KOD is slightly higher than the stutter for standard TaqGoldTm.
Example 4a Fast PCR Protocol Using SpeedSTAR Polymerase in Tubes and Biochips Based on the results presented above, the SpeedSTAR polymerase was selected for further evaluation in biochips with the goal of minimizing the total cycling time and achieving full STR profiles that satisfy signal strength, PHR, incomplete NTA
and stutter interpretation requirements.
The time and temperature setpoints for amplification using SpeedSTAR in the microfluidic 16-sample biochip on the thermal cycler of the invention are 70 seconds 95 C
for hot-start activation followed by 28 cycles of 4 seconds at 95 C for denaturation, 15 seconds at 59 C for annealing, and 7 seconds at 72 C for extension. A final extension of 90 seconds at 72 C is performed for a total protocol time of 17.3 minutes. Tube reactions in the Eppendorf Mastercycler were performed in 19.13 minutes comprising of block times and temperatures set to an initial activation time of 1 minute at 95 C, 28 cycles of 4 seconds at 98 C, 15 seconds at 59 C and 5 seconds at 72 C followed by a final extension of 1 minute at 72 C.
Figures 4A and 4B show STR profiles generated with the preceding SpeedSTAR
cycling conditions in (Figure 4A) 7 AL biochip and (Figure 4B) 10 AL tube reactions using 0.5 ng of DNA and Table 2 presents signal strengths for all Profiler Plus ID
alleles from the SpeedSTAR biochip and tube reactions as well as TaqGoldTm in tubes using the standard protocol. Signal strengths of the 0.5 ng SpeedSTAR biochip reactions are on average approximately 2 times higher than those of the lng standard TaqGoldmi reactions, while the signal strengths of the 0.5 ng SpeedSTAR tube reactions are on average approximately the same as those of the TaqGoldTm reactions.
TABLE 2 - Con;parison of' signal strengĀ¶ th, PHR. NTA and stutter for S4eedSTAR'b;ochip and (ube reactions and ATG standard reactions' I I
SpeedSTAR biochip reaction SpeedSTAR tube reaction I I
Standard ATG reactions Locus Allele -1 Signai 1 PHR 1 NIA (%) Stutter Signal - PHR NTA (%) Stutter I
1 Signal strength PHR NTA (%) Stutter ______________ strength (%) strength (%) 11 Averac-S-TDEV Average 1 STDEV Average I STDEV Average I STDEV
03S1358 14 1404.218 9.08 727.11 9.74 I 831.69 167.25 1 1.88 0.52 0.79 0.81 0.92 0.04 D3S1358 15 1110.915 8.05 10.35 895.12 10.50 8.14 1 802.99 141.78 1.54 0.34 5.31 0.23 vWA 17 2338.633 6.14 1346.81 6.62 1 765.61 83.69 0.95 0.65 4.22 0.44 vWA 0.90 1 18 2216.64 6 83 12.87 875.84 6.78 11.96 1 736.85 88.40 "8 4 23 0.19 7.38 948 _ FGA 23 747.5319007 4.21 877.22 2.54 1 735.41 130 32 a 1 2.14 0.45 FGA 24 648.8992 3.34 9.72 840.03 8..-a 2.30 8.32 1 727.02 122.82 -.. n 1 -a, 1.98 0.44 7.19 0.43 Amelogenin X 5645.423 I 4.04 1324.78 2.02 1 1655.65 343.77 3.35 0.49 D8S1179 13 3784.38 5.62 1 10.70 1012.17 5.47 11 56 1 1405.57 105 18 I 4.52 0.58 I 651 062 1321S11 30 2008.992 3.15 I 13.05 787.70 3.45 l 13.29 1 1280.31 81.30 I 300 0.66 7.33 0.60 018551 l 15 1655.991 6.90 11.44 924.04 5.48 9.09 1 879.42 137.76 4.68 0.74 7.89 0.80 0.70 0.72 0.88 0.05 068 11.16 0.52 1191 21910457643973 97: 5358 184:53 16:017466 I
= 83:9827 183.7903 1 1858148.1084 m125:7758 D5S818 3.71 0.17 4.94 0.44 013S317 11 3906.373 3.32 6.78 1867.36 I
3.21 7.74 h 1643486.9560 119613:4827 0.89 - 2.33 0.28 4.18 0.47 075820 10 1232.908 0.03 7.23 647.24 0 73 8.01 1 n n. 4.69 0.99 ,D7S820 , 11 , 1149 849. . 10.16 , 7.37 , , 469.59 , = 10.00 , 5.96 I I 561.37 , 92.47 1 0.08 7 0.72 , 4 57 , 0.62 , Example 4b Allele Characterization of Fast PCR Using SpeedSTAR Polymerase in Tubes and Biochips In order to characterize the products of fast PCR reactions from Example 4a, quantification of PHR, incomplete NTA and stutter was performed. Biochip and tube reactions using the SpeedSTAR polymerase show more inter-locus peak height imbalance compared to that for the TaqGoldTm reactions. The PHR for alleles generated in biochip reactions is between 0.70 and 0.95 and is approximately the same in tubes; all fall within acceptable interpretation guidelines. Reactions using SpeedSTAR have PHR that are approximately 10% lower than those determined for standard TaqGoldTm reactions.
Similarly, the level of incomplete NTA for most alleles in both biochip and tube reactions using SpeedSTAR are approximately the same (2.0 and 10.6%); both are approximately 2 times higher than for TaqGoldTm control reactions. The exception is incomplete NTA for the D3S1358 alleles, which is 4.8 to 7 times higher with SpeedSTAR than with TaqGoldTm; even in this case, the level of incomplete NTA is below 12% for the SpeedSTAR
enzyme. Finally, the level of stutter in both biochip and tube based reactions using SpeedSTAR
is between approximately 6.0 and 14.1%, on average approximately 1.6-fold higher than that for standard TaqGoldTm tube reactions.
The microfluidic biochip reactions using 0.5 ng template DNA generate signal strengths that are approximately 2 times higher than those for standard TaqGoldTm reactions using 1 ng template. This result suggests that the SpeedSTAR enzyme in the biochip and the TaqGoldTm enzyme in the conventional reaction act with similar efficiencies;
the DNA
.
concentration in the biochip is approximately 1.8-fold that in the tube, which corresponds to the 2 fold greater in signal strength. In contrast, the fast tube based reactions are less efficient than the control TaqGoldTm reactions; the approximately 40% reduction in product yield is likely the consequence of the poor cycling profile that results when commercial thermal cyclers are used for fast thermal cycling. Even in this circumstance, signal strengths are well over the levels required for interpretation and can be raised significantly by increasing the extension time by a few seconds per cycle (data not shown).
Repeatability and reproducibility of the signal strength for fast PCR reactions in biochips and tubes are similar to those in conventional reactions.
The inter-locus allele signal strength for the fast biochip and tube reactions shows a higher level of imbalance as compared to the TaqGoldTm reaction. The inter-loci signal strength balance is influenced by numerous factors including primer concentration, annealing temperature and time, and molecular weight of the loci. The STR amplification kit used for these experiments has a set of primer concentrations that are optimized for the TaqGoldTm enzyme and the recommended cycling protocols. The signal strengths of the loci can be modified by adjusting the primer concentrations utilized in the amplification reactions (Henegariu et al., Biotechniques 1997, 23, 504-11).
The relationship between signal strength and template level for fast biochip and tube reactions is as expected with signal strength generally increasing with template. Good peak morphology is observed for all alleles at high template levels of 4 ng (which generate alleles with signal strengths of greater than 12000 RFU). At template levels of 0.03 ng and below some allele drop-out occurs. This effect is observed when amplification reactions are carried out with limited number of template DNA strands in the solution leading to stochastic amplification (Walsh et al., PCR Methods Appl. 1992, 1, 241-250). The presence of readily detectable signal for both the high-signal strength alleles and low-signal strength alleles at a template level of 0.006 ng, demonstrates the high sensitivity of the fast biochip and tube reaction coupled with Genebench-FX-rm Series 100 separation and detection, demonstrating the utility of this system for low copy number analysis. Taken together, this data also suggests that the fast PCR approach and the thermal cycler of the invention and Genebench instrumentation have a high template dynamic range.
Example 4c DNA Template Levels and Allele Characteristics in Fast PCR Reactions The effects of template DNA on signal strength for fast PCR reactions using SpeedSTAR polymerase in (Figure 5A) biochip and (Figure 5B) tube reactions are presented in Figures 5A and 5B. The alleles selected for analysis were Amelogenin, the allele with the highest signal level in the STR profile and FGA 23 and 24 and D7S820 10 and 11, the alleles with the lowest signal levels in the profile. Signal strengths for all alleles increase as the DNA template level increases from 0.006 ng to 4 ng in both SpeedSTAR biochip and tube reactions. At a template level of 0.006 ng, signal strengths for the amelogenin peak of 111 RFU for biochip and 58 RFU for tube reactions were observed. At a template level of 4 ng, signal strengths of 12680 RFU were seen for biochip and 5570 RFU for tube reactions. All alleles observed in both reaction types showed good peak morphology.
For fast biochip reactions (Figure 6A), PHR is between 0.6 and 1.0 for template levels ranging from 0.05 to 4.0 ng. For template levels below 0.05 ng, PHR
decreases until 0.025 ng, when instances of allelic dropouts occur and PHR of zero are observed. Similar results are observed for fast tube reactions, although they generally exhibit somewhat lower PHR than biochips reactions (Figure 6B). For biochip reactions, the level of incomplete NTA is 15% or less for template levels of 2.0 ng and below. For tube reactions, the incomplete NTA levels surpass 15% at template levels of 1 ng and increase dramatically by 4 ng.
Two major differences between biochip and tube reactions are the temperature profiles of the reaction solutions and the relative concentration of template and polymerase.
The level of incomplete NTA decreases as more polymerase is available. For biochip reactions experimental data show that over a DNA template range from 0.5 - 4.0 ng the level of incomplete NTA decreases by approximately 50% as the amount of SpeedSTAR
polymerase increases from 0.3U to 1.2U (Figures 7A and 7B). The level of stutter for fast biochip and tube reactions was relatively constant and generally less than 15%
for all alleles over a template level range of 0.25 ĀØ 4.0 ng (Figures 8A and 8B).
The speed of an STR amplification reaction is only relevant if the reaction itself generates actionable data that meets forensic interpretation guidelines. The FBI has general guidelines that are used for STR interpretation, and individual laboratories set thresholds that must be met before a profile can be considered acceptable based on their validation work (Holt et al., i Forensic Sci. 2002, 47(1), p. 66-96; LaFountain et al., J.
Forensic Sci., 2001, 46(5), 1191-8).
The conditions presented herein can generate fast STR profiles that meet these guidelines. PHR for 0.5 ng template in biochip and tube reactions meet with the interpretation guidelines that state a level of 0.6 or greater is required and are consistent with previously reported results (Leclair et al., J. Forensic Sci. 2004, 49, 968-80). For higher DNA template amounts, PHR remain relatively constant but are lower than those for the lng TaqGoldTv.1 reactions. For low copy numbers, the PHR is dominated by amplification due to stochastic fluctuations.
The level of incomplete NTA is based on the ability of the polymerase to fully adenylate all STR amplicons. For conventional amplification, this is accomplished by attaching a "pigtail" to the primer and increasing the final extension time.
The level of incomplete NTA for 0.5 ng biochips and tube reactions described herein are within interpretation guidelines.
Levels of incomplete NTA increase with increasing DNA template (a consequence of the increasing ratio of DNA to polymerase) and can be reduced by increasing the amount of polymerase, extension time per cycle, and final extension time. The later two approaches are not well-suited to fast multiplexed amplification, as they increase the reaction time.
Increasing polymerase concentration is effective and compatible with fast PCR.
Stutter is a result of DNA strand slippage during extension (Walsh et al., Nucleic Acids Res. 1996, 24(14), 2807-12). The level of stutter described here for the 0.5 ng biochip and tube reactions fall within the interpretational guidelines and are also consistent with previously cited reports. As expected, the level of stutter appears to be independent of the DNA
template level.
Example 4d Repeatability and Reproducibility Studies The repeatability and reproducibility of the fast biochip (Table 3A) and tube (Table 3B) reactions using the SpeedSTAR polymerase were evaluated by performing 24 identical PCR reactions in 3 PCR biochips and by performing 5 identical tube reactions.
For biochip reactions, the confidence value (CV) for signal strength ranges from 17 to 24%
and for tube reactions from 15 to 34%. The CV for standard TaqGo1dn'71 reactions is between 6 and 21%.
=
= TABLE 3 = Re. ..ucibili of = STAR, biochi. 3A and tube 38 reactions 1111111.11.1111.1111111.111.1.1011111MINIMIMENNIMill A: SpeeraSTAR biochip reactions 1.111111111111 .111.111.11111..MME11.1 Allele Signal Strength (FtFU) PHR
NIA (%) Stutter (%) _ IMMINIUMERWERIZI Max Min Avera. e STDEV Max IIIMMIZMILEIZIIIMINWAMM Avera e STDEV Max Min 03S135814 l 1235.40 27143 1963.95 781.79 0.85 0.11 1.00 0.63 9.11 1.77 11.86 6.64 MEIMMINE
CERBENZIEMENEXIMIIIIEEKI 689.23 11111.111.1.111111M111.11111.130.1.4'MIEMIRMI
576 MUM 9=84 2.62 raglii11111111111=1117firEll 3818.46 MEM 0.81 MENNINWEEBEECEMEEE11111=1111111111111111111=1111=11111111111MIZEKEEMMEEMINEDEEN
NEEMEINBI 11.78 MIERIIMILEIIIIIIIIBBINIERE111=1111111MMICOM 0.99 K131111=33MINCE1111110011111111311111=111111=1111111111111M
MEM. 794.52 SM. 1109.30 11E13 11111111=111M1111.12311 0.48 MiliEllIECERI
0.95 12.18 8.63 1=1.11. 5085 29 IIECIIIIIIEMIEMilmmill111111111111111M1M1111111111111/111111 0,40I'6 =IIIMIEUEMEin 5200 08 IECEIONIMEM111111111=1111111111111MINEIMIIIMENWERMILIEMIDEINIIICIBIIME1311 10.01 D31111111LIIIIZEINEEIMIEMB111111111111111111111.11111=11111118001111111:13:1111 11111:1111IXEMEEEMIlarel 10.73 IXERE1211111EIMICEEDIEMOINIEEMEE=MINIIIIIIM111111111111=11111011101111113011111 rENI 000 10.61 0.64 5M4 9.04 D18551.19 IMIMERIER 2549.69 111=11110EEIIIIME1111113111111111111=10111111E161111M011 0.00 III8E1111113133111111131311 12.96 CIERIMIIERIECI 500.56 IEMEEIIIEEEEMIIMIIIMIIIIMMIIIOMMIIIIIIIIMIILM 1.88 RECEIMINXIM 8.90 EZIEM 9.89 8.35 MEW1 4097.95 EIZIENICEIMEMINI11111111=1111111111111=1=113111111:131111K9IENIEUEN3E5111111XEM
2.95 6.09 D7S320,10 MEMEENIMEM 3262.80 IMMIIIIMIN 0.09 MEM 0.69 6.68 0.60 Egimulimmommionmm.
D75820.11 MOEN 309 99 FIE*1II1MELIMM1111111111111=111111111=1=11101111111333111111aMMEEMENEINIXIMMEN
6.42 CV Min: 4%
CV Max: 24% CV Max: 14% CV Max: 28%
CV Max: 9%
.-1101111111=1M11111.1111111.11111.1.1111M111.110.111.11111111111.111111.1MMIMMII
B. S.eedSTAR tube reactions 11111111111111111111111111111111M11111111=MINIM1111111111MMIIIIIMIIIIII
Melo Si=nal Strength (RFU PHR
NTA (%) Stutter (%
_1.11122ThEEIZIIIIIIMMUNIMEMI=IIKIEMIEMEMZEIIMMEERThEMI Auera.e STDEV Max Min 03S1358 14 I 1718.86 464.62 2321.62 1249.71 0.86 0.03 0.94 1.3311.1321. 0.44 I 20.04 18.84 IMEME 1455.28 285.03 Naill 1110 96 11=E=.1111.11111111111M.11 19 68 0.78 20.71 Mignmum 0.49 Elm 7.65 1934,44 299 00 2150 18 EOM 0 83 Nam 0 98 mffloinimmum 12.32 11161EEMIIIIM
1722.47 450.99 2439.38 EMI
11111111111111111111111111111111E111111113111111 12.29 1E111311111EIMMiJ.1'III 13.37 12.18 firMallillEfOR 269.29 EMEEMEMEMIKEIMNIIIIIII 0.99 0.80 MillME:16011111311111111111111111111111=11111111111 8.90 3669.80 844.56 EMI 2799.39 111111111111111111111111111111111111111111111=2111111111:12111 5.41 4.68 D8S1179,13 2447.48 658.60 NEM 1820.49 ..11111111111111111111111.1111.1NEEMNI 8.61 aminirnimmis 10.86 9.72 MOE= 1628.98 436.18 5.26 4.46 11011.111110E31111=11 11.84 oamnarisminommunniml 1066.52 111131111111131111111101111MEMEMKEIMEMMICINI 8.67 0.31 10.09 9.30 OMEIBMINEEKIETEDIIMEI 963.18
Cycling conditions 95 C / 11 min 95 C / 11 min 95 C 1 1 min 95 C / 1 min 1 95 C / 2 min 94 C / 1 min 98 C / 10sec 98 C / 4 sec __ 98 C / 4 sec 98 C /
4 sec 59 C / 1 min x 28 59 C I 45 sec x 28 59 C I 15 sec x 28 59 C / 20 sec x 28 59 C / 30 sec x 28 72 C / 1 min 72 C / 30 sec 72 C / 5 sec 72 C / 30 sec 72 C
/ 10 sec 60 C / 45 min 72=C/ 15min 72 C / 1 min 72=C/ 1 min 72 C i 1 min Amplthcation time 145.1 min 71.67 min 19.13 min 33.12 min 29.47.min Signal Strength range pail 561-1655 600-3876 945-3669 Stutter range 4.18.11.16% 3.91-13.77% 6.49-13.56% 6 21-15 91% 4.46-23.61%
NTA range 1.54-7.67% 1.93-20.13%
3.07.19.68% 3.01-23.09%
PHR 0.88-0.93% 0.74-0.96% 0.83-0.93% 0.71-0.94% 0.61-0.94%
I
The evaluated enzymes have reported extension rates ranging from approximately nucleotides/second; in general, the reported extension rates are based on singleplex amplifications and may be somewhat lower for multiplex applications.
PCR conditions in tubes were initially investigated for these four enzymes with the goal of achieving full STR profiles in the least amount of time. For all reactions, 1 ng of human genomic DNA was amplified using primer pairs from the Profiler Plus lD
kit and vendor recommended buffers and enzyme concentrations, and resulting profiles were separated, detected, sized, and quantified using Genebench-FX11" Series 100.
Various times and temperatures for the denaturation, annealing, and extension steps were determined to give total times for PCR amplification with signal strengths suitable for STR
interpretation ranging from 19.13 minutes for SpeedSTAR to 71.7 minutes for TaqGoldill [Table 1(B)].
Method conditions of the invention allow amplification to be performed 2-10 fold more rapidly than recommended conditions for TaqGoldTm.
Further evaluation of the enzymes for forensically relevant performance includes signal strength, levels of stutter and incomplete NTA and PFIR [Table 1(B)].
All enzymes are capable of performing highly multiplexed amplification using the Profiler Plus ID
primers. Signal strengths for SpeedSTAR, Pyrostart, KOD, and optimized TaqGoldlil reactions are all either approximately the same or higher than those generated using standard TaqGoldrĀØm- PCR conditions.
With respect to incomplete NTA, both SpeedSTAR and PyroStart as well as optimized TaqGoldTm reactions exhibited levels that are up to three times higher than that of standard TaqGoldi'm reactions. For most alleles, levels fall below the 15%
interpretation threshold. Those alleles having higher levels of incomplete NTA can be decreased to below the 15% interpretation threshold as discussed below. The KOD polymerase possesses 3'-5' exonuclease activity and does not generate fragments with A-overhangs;
accordingly, all alleles were 1 nucleotide shorter than their allelic ladder counterpart.
The relative levels of stutter observed for optimized TaqGoldTm, SpeedSTAR and PyroStart reactions are similar to the range of stutter produced with standard TaqGoldTm reactions; the range of stutter generated with KOD is slightly higher than the stutter for standard TaqGoldTm.
Example 4a Fast PCR Protocol Using SpeedSTAR Polymerase in Tubes and Biochips Based on the results presented above, the SpeedSTAR polymerase was selected for further evaluation in biochips with the goal of minimizing the total cycling time and achieving full STR profiles that satisfy signal strength, PHR, incomplete NTA
and stutter interpretation requirements.
The time and temperature setpoints for amplification using SpeedSTAR in the microfluidic 16-sample biochip on the thermal cycler of the invention are 70 seconds 95 C
for hot-start activation followed by 28 cycles of 4 seconds at 95 C for denaturation, 15 seconds at 59 C for annealing, and 7 seconds at 72 C for extension. A final extension of 90 seconds at 72 C is performed for a total protocol time of 17.3 minutes. Tube reactions in the Eppendorf Mastercycler were performed in 19.13 minutes comprising of block times and temperatures set to an initial activation time of 1 minute at 95 C, 28 cycles of 4 seconds at 98 C, 15 seconds at 59 C and 5 seconds at 72 C followed by a final extension of 1 minute at 72 C.
Figures 4A and 4B show STR profiles generated with the preceding SpeedSTAR
cycling conditions in (Figure 4A) 7 AL biochip and (Figure 4B) 10 AL tube reactions using 0.5 ng of DNA and Table 2 presents signal strengths for all Profiler Plus ID
alleles from the SpeedSTAR biochip and tube reactions as well as TaqGoldTm in tubes using the standard protocol. Signal strengths of the 0.5 ng SpeedSTAR biochip reactions are on average approximately 2 times higher than those of the lng standard TaqGoldmi reactions, while the signal strengths of the 0.5 ng SpeedSTAR tube reactions are on average approximately the same as those of the TaqGoldTm reactions.
TABLE 2 - Con;parison of' signal strengĀ¶ th, PHR. NTA and stutter for S4eedSTAR'b;ochip and (ube reactions and ATG standard reactions' I I
SpeedSTAR biochip reaction SpeedSTAR tube reaction I I
Standard ATG reactions Locus Allele -1 Signai 1 PHR 1 NIA (%) Stutter Signal - PHR NTA (%) Stutter I
1 Signal strength PHR NTA (%) Stutter ______________ strength (%) strength (%) 11 Averac-S-TDEV Average 1 STDEV Average I STDEV Average I STDEV
03S1358 14 1404.218 9.08 727.11 9.74 I 831.69 167.25 1 1.88 0.52 0.79 0.81 0.92 0.04 D3S1358 15 1110.915 8.05 10.35 895.12 10.50 8.14 1 802.99 141.78 1.54 0.34 5.31 0.23 vWA 17 2338.633 6.14 1346.81 6.62 1 765.61 83.69 0.95 0.65 4.22 0.44 vWA 0.90 1 18 2216.64 6 83 12.87 875.84 6.78 11.96 1 736.85 88.40 "8 4 23 0.19 7.38 948 _ FGA 23 747.5319007 4.21 877.22 2.54 1 735.41 130 32 a 1 2.14 0.45 FGA 24 648.8992 3.34 9.72 840.03 8..-a 2.30 8.32 1 727.02 122.82 -.. n 1 -a, 1.98 0.44 7.19 0.43 Amelogenin X 5645.423 I 4.04 1324.78 2.02 1 1655.65 343.77 3.35 0.49 D8S1179 13 3784.38 5.62 1 10.70 1012.17 5.47 11 56 1 1405.57 105 18 I 4.52 0.58 I 651 062 1321S11 30 2008.992 3.15 I 13.05 787.70 3.45 l 13.29 1 1280.31 81.30 I 300 0.66 7.33 0.60 018551 l 15 1655.991 6.90 11.44 924.04 5.48 9.09 1 879.42 137.76 4.68 0.74 7.89 0.80 0.70 0.72 0.88 0.05 068 11.16 0.52 1191 21910457643973 97: 5358 184:53 16:017466 I
= 83:9827 183.7903 1 1858148.1084 m125:7758 D5S818 3.71 0.17 4.94 0.44 013S317 11 3906.373 3.32 6.78 1867.36 I
3.21 7.74 h 1643486.9560 119613:4827 0.89 - 2.33 0.28 4.18 0.47 075820 10 1232.908 0.03 7.23 647.24 0 73 8.01 1 n n. 4.69 0.99 ,D7S820 , 11 , 1149 849. . 10.16 , 7.37 , , 469.59 , = 10.00 , 5.96 I I 561.37 , 92.47 1 0.08 7 0.72 , 4 57 , 0.62 , Example 4b Allele Characterization of Fast PCR Using SpeedSTAR Polymerase in Tubes and Biochips In order to characterize the products of fast PCR reactions from Example 4a, quantification of PHR, incomplete NTA and stutter was performed. Biochip and tube reactions using the SpeedSTAR polymerase show more inter-locus peak height imbalance compared to that for the TaqGoldTm reactions. The PHR for alleles generated in biochip reactions is between 0.70 and 0.95 and is approximately the same in tubes; all fall within acceptable interpretation guidelines. Reactions using SpeedSTAR have PHR that are approximately 10% lower than those determined for standard TaqGoldTm reactions.
Similarly, the level of incomplete NTA for most alleles in both biochip and tube reactions using SpeedSTAR are approximately the same (2.0 and 10.6%); both are approximately 2 times higher than for TaqGoldTm control reactions. The exception is incomplete NTA for the D3S1358 alleles, which is 4.8 to 7 times higher with SpeedSTAR than with TaqGoldTm; even in this case, the level of incomplete NTA is below 12% for the SpeedSTAR
enzyme. Finally, the level of stutter in both biochip and tube based reactions using SpeedSTAR
is between approximately 6.0 and 14.1%, on average approximately 1.6-fold higher than that for standard TaqGoldTm tube reactions.
The microfluidic biochip reactions using 0.5 ng template DNA generate signal strengths that are approximately 2 times higher than those for standard TaqGoldTm reactions using 1 ng template. This result suggests that the SpeedSTAR enzyme in the biochip and the TaqGoldTm enzyme in the conventional reaction act with similar efficiencies;
the DNA
.
concentration in the biochip is approximately 1.8-fold that in the tube, which corresponds to the 2 fold greater in signal strength. In contrast, the fast tube based reactions are less efficient than the control TaqGoldTm reactions; the approximately 40% reduction in product yield is likely the consequence of the poor cycling profile that results when commercial thermal cyclers are used for fast thermal cycling. Even in this circumstance, signal strengths are well over the levels required for interpretation and can be raised significantly by increasing the extension time by a few seconds per cycle (data not shown).
Repeatability and reproducibility of the signal strength for fast PCR reactions in biochips and tubes are similar to those in conventional reactions.
The inter-locus allele signal strength for the fast biochip and tube reactions shows a higher level of imbalance as compared to the TaqGoldTm reaction. The inter-loci signal strength balance is influenced by numerous factors including primer concentration, annealing temperature and time, and molecular weight of the loci. The STR amplification kit used for these experiments has a set of primer concentrations that are optimized for the TaqGoldTm enzyme and the recommended cycling protocols. The signal strengths of the loci can be modified by adjusting the primer concentrations utilized in the amplification reactions (Henegariu et al., Biotechniques 1997, 23, 504-11).
The relationship between signal strength and template level for fast biochip and tube reactions is as expected with signal strength generally increasing with template. Good peak morphology is observed for all alleles at high template levels of 4 ng (which generate alleles with signal strengths of greater than 12000 RFU). At template levels of 0.03 ng and below some allele drop-out occurs. This effect is observed when amplification reactions are carried out with limited number of template DNA strands in the solution leading to stochastic amplification (Walsh et al., PCR Methods Appl. 1992, 1, 241-250). The presence of readily detectable signal for both the high-signal strength alleles and low-signal strength alleles at a template level of 0.006 ng, demonstrates the high sensitivity of the fast biochip and tube reaction coupled with Genebench-FX-rm Series 100 separation and detection, demonstrating the utility of this system for low copy number analysis. Taken together, this data also suggests that the fast PCR approach and the thermal cycler of the invention and Genebench instrumentation have a high template dynamic range.
Example 4c DNA Template Levels and Allele Characteristics in Fast PCR Reactions The effects of template DNA on signal strength for fast PCR reactions using SpeedSTAR polymerase in (Figure 5A) biochip and (Figure 5B) tube reactions are presented in Figures 5A and 5B. The alleles selected for analysis were Amelogenin, the allele with the highest signal level in the STR profile and FGA 23 and 24 and D7S820 10 and 11, the alleles with the lowest signal levels in the profile. Signal strengths for all alleles increase as the DNA template level increases from 0.006 ng to 4 ng in both SpeedSTAR biochip and tube reactions. At a template level of 0.006 ng, signal strengths for the amelogenin peak of 111 RFU for biochip and 58 RFU for tube reactions were observed. At a template level of 4 ng, signal strengths of 12680 RFU were seen for biochip and 5570 RFU for tube reactions. All alleles observed in both reaction types showed good peak morphology.
For fast biochip reactions (Figure 6A), PHR is between 0.6 and 1.0 for template levels ranging from 0.05 to 4.0 ng. For template levels below 0.05 ng, PHR
decreases until 0.025 ng, when instances of allelic dropouts occur and PHR of zero are observed. Similar results are observed for fast tube reactions, although they generally exhibit somewhat lower PHR than biochips reactions (Figure 6B). For biochip reactions, the level of incomplete NTA is 15% or less for template levels of 2.0 ng and below. For tube reactions, the incomplete NTA levels surpass 15% at template levels of 1 ng and increase dramatically by 4 ng.
Two major differences between biochip and tube reactions are the temperature profiles of the reaction solutions and the relative concentration of template and polymerase.
The level of incomplete NTA decreases as more polymerase is available. For biochip reactions experimental data show that over a DNA template range from 0.5 - 4.0 ng the level of incomplete NTA decreases by approximately 50% as the amount of SpeedSTAR
polymerase increases from 0.3U to 1.2U (Figures 7A and 7B). The level of stutter for fast biochip and tube reactions was relatively constant and generally less than 15%
for all alleles over a template level range of 0.25 ĀØ 4.0 ng (Figures 8A and 8B).
The speed of an STR amplification reaction is only relevant if the reaction itself generates actionable data that meets forensic interpretation guidelines. The FBI has general guidelines that are used for STR interpretation, and individual laboratories set thresholds that must be met before a profile can be considered acceptable based on their validation work (Holt et al., i Forensic Sci. 2002, 47(1), p. 66-96; LaFountain et al., J.
Forensic Sci., 2001, 46(5), 1191-8).
The conditions presented herein can generate fast STR profiles that meet these guidelines. PHR for 0.5 ng template in biochip and tube reactions meet with the interpretation guidelines that state a level of 0.6 or greater is required and are consistent with previously reported results (Leclair et al., J. Forensic Sci. 2004, 49, 968-80). For higher DNA template amounts, PHR remain relatively constant but are lower than those for the lng TaqGoldTv.1 reactions. For low copy numbers, the PHR is dominated by amplification due to stochastic fluctuations.
The level of incomplete NTA is based on the ability of the polymerase to fully adenylate all STR amplicons. For conventional amplification, this is accomplished by attaching a "pigtail" to the primer and increasing the final extension time.
The level of incomplete NTA for 0.5 ng biochips and tube reactions described herein are within interpretation guidelines.
Levels of incomplete NTA increase with increasing DNA template (a consequence of the increasing ratio of DNA to polymerase) and can be reduced by increasing the amount of polymerase, extension time per cycle, and final extension time. The later two approaches are not well-suited to fast multiplexed amplification, as they increase the reaction time.
Increasing polymerase concentration is effective and compatible with fast PCR.
Stutter is a result of DNA strand slippage during extension (Walsh et al., Nucleic Acids Res. 1996, 24(14), 2807-12). The level of stutter described here for the 0.5 ng biochip and tube reactions fall within the interpretational guidelines and are also consistent with previously cited reports. As expected, the level of stutter appears to be independent of the DNA
template level.
Example 4d Repeatability and Reproducibility Studies The repeatability and reproducibility of the fast biochip (Table 3A) and tube (Table 3B) reactions using the SpeedSTAR polymerase were evaluated by performing 24 identical PCR reactions in 3 PCR biochips and by performing 5 identical tube reactions.
For biochip reactions, the confidence value (CV) for signal strength ranges from 17 to 24%
and for tube reactions from 15 to 34%. The CV for standard TaqGo1dn'71 reactions is between 6 and 21%.
=
= TABLE 3 = Re. ..ucibili of = STAR, biochi. 3A and tube 38 reactions 1111111.11.1111.1111111.111.1.1011111MINIMIMENNIMill A: SpeeraSTAR biochip reactions 1.111111111111 .111.111.11111..MME11.1 Allele Signal Strength (FtFU) PHR
NIA (%) Stutter (%) _ IMMINIUMERWERIZI Max Min Avera. e STDEV Max IIIMMIZMILEIZIIIMINWAMM Avera e STDEV Max Min 03S135814 l 1235.40 27143 1963.95 781.79 0.85 0.11 1.00 0.63 9.11 1.77 11.86 6.64 MEIMMINE
CERBENZIEMENEXIMIIIIEEKI 689.23 11111.111.1.111111M111.11111.130.1.4'MIEMIRMI
576 MUM 9=84 2.62 raglii11111111111=1117firEll 3818.46 MEM 0.81 MENNINWEEBEECEMEEE11111=1111111111111111111=1111=11111111111MIZEKEEMMEEMINEDEEN
NEEMEINBI 11.78 MIERIIMILEIIIIIIIIBBINIERE111=1111111MMICOM 0.99 K131111=33MINCE1111110011111111311111=111111=1111111111111M
MEM. 794.52 SM. 1109.30 11E13 11111111=111M1111.12311 0.48 MiliEllIECERI
0.95 12.18 8.63 1=1.11. 5085 29 IIECIIIIIIEMIEMilmmill111111111111111M1M1111111111111/111111 0,40I'6 =IIIMIEUEMEin 5200 08 IECEIONIMEM111111111=1111111111111MINEIMIIIMENWERMILIEMIDEINIIICIBIIME1311 10.01 D31111111LIIIIZEINEEIMIEMB111111111111111111111.11111=11111118001111111:13:1111 11111:1111IXEMEEEMIlarel 10.73 IXERE1211111EIMICEEDIEMOINIEEMEE=MINIIIIIIM111111111111=11111011101111113011111 rENI 000 10.61 0.64 5M4 9.04 D18551.19 IMIMERIER 2549.69 111=11110EEIIIIME1111113111111111111=10111111E161111M011 0.00 III8E1111113133111111131311 12.96 CIERIMIIERIECI 500.56 IEMEEIIIEEEEMIIMIIIMIIIIMMIIIOMMIIIIIIIIMIILM 1.88 RECEIMINXIM 8.90 EZIEM 9.89 8.35 MEW1 4097.95 EIZIENICEIMEMINI11111111=1111111111111=1=113111111:131111K9IENIEUEN3E5111111XEM
2.95 6.09 D7S320,10 MEMEENIMEM 3262.80 IMMIIIIMIN 0.09 MEM 0.69 6.68 0.60 Egimulimmommionmm.
D75820.11 MOEN 309 99 FIE*1II1MELIMM1111111111111=111111111=1=11101111111333111111aMMEEMENEINIXIMMEN
6.42 CV Min: 4%
CV Max: 24% CV Max: 14% CV Max: 28%
CV Max: 9%
.-1101111111=1M11111.1111111.11111.1.1111M111.110.111.11111111111.111111.1MMIMMII
B. S.eedSTAR tube reactions 11111111111111111111111111111111M11111111=MINIM1111111111MMIIIIIMIIIIII
Melo Si=nal Strength (RFU PHR
NTA (%) Stutter (%
_1.11122ThEEIZIIIIIIMMUNIMEMI=IIKIEMIEMEMZEIIMMEERThEMI Auera.e STDEV Max Min 03S1358 14 I 1718.86 464.62 2321.62 1249.71 0.86 0.03 0.94 1.3311.1321. 0.44 I 20.04 18.84 IMEME 1455.28 285.03 Naill 1110 96 11=E=.1111.11111111111M.11 19 68 0.78 20.71 Mignmum 0.49 Elm 7.65 1934,44 299 00 2150 18 EOM 0 83 Nam 0 98 mffloinimmum 12.32 11161EEMIIIIM
1722.47 450.99 2439.38 EMI
11111111111111111111111111111111E111111113111111 12.29 1E111311111EIMMiJ.1'III 13.37 12.18 firMallillEfOR 269.29 EMEEMEMEMIKEIMNIIIIIII 0.99 0.80 MillME:16011111311111111111111111111111=11111111111 8.90 3669.80 844.56 EMI 2799.39 111111111111111111111111111111111111111111111=2111111111:12111 5.41 4.68 D8S1179,13 2447.48 658.60 NEM 1820.49 ..11111111111111111111111.1111.1NEEMNI 8.61 aminirnimmis 10.86 9.72 MOE= 1628.98 436.18 5.26 4.46 11011.111110E31111=11 11.84 oamnarisminommunniml 1066.52 111131111111131111111101111MEMEMKEIMEMMICINI 8.67 0.31 10.09 9.30 OMEIBMINEEKIETEDIIMEI 963.18
12.28 055818.11 3.112,19 111371=115MUI1sIEIM11111111111111111111=11=IIIIIIIIIMEE111111001111 6.47 6.02 1111130111M1111 8,86 8.03 MEM= 3093 19 WEIECNIEBEINCIEN1111111111111=11=111111MMIZEIMIENEITIMMIIIIMIIIIIINNIIIMIN 6 D75820.10 1009.46 BENIESEKII 780 76 .111111=111111111111311111111:01111111131111KITINKJ.8 6.86 D75820.11 6.15 CV Min: 2%
CV Max: 34% CV Max: 21% CV Max: 13%
CV Max: 6%
The CV for PHR is up to 14% for biochips and 21% for tube reactions, compared to the 5% to 10% range observed for standard TaqGoldTm reactions. CVs for incomplete NTA
in biochip reactions vary between 6% and 28%, and for tube reactions between 2 to 13%.
Again, these variations are similar to the 4 to 28% range observed for standard TaqGoldTm reactions. The CVs for stutter in biochips are 4 to 9%, in tubes 2 to 6%, and are also similar to the range of 4-13% observed for standard TaqGoldTm reactions.
Example 4e Compatibility with Other Commercially Available STR Kits Using the same fast biochip and tube conditions described above, a series of samples were evaluated using primer sets from the COfilerml and IdentifilerTm kits.
Figures 9A and 9B show the achievement of full profiles using these primer sets using the thermal cycler of the invention, the SpeedSTAR enzyme, and the protocols described herein. Each is suitable for these commercially available kits as well. Although full profiles were achieved, imbalance in the signal strengths across the loci was observed.
Example 5 Fast Sequencing With the Thermal Cycler The thermal cycling instrument and methodology can also be applied to fast DNA
sequencing reactions. In this implementation of the fast thermal cycler, the instrumentation and biochip are the same as that used for PCR. Different reaction solutions, polymerase and cycling temperatures are applied for the sequencing reaction. The currently commercially available sequencing reactions take 49 min (for GE Amersham DYEnamicTm ET
Terminato Cycle Sequencing Kit) and 2.25 hr (for AB Big Dye V3.1. Utilizing the NetBio thermal cycler, with conventional reagents, allowed the sequencing reaction time to be reduced to 21 minutes.
Fast sequencing has been achieved using the thermocycler disclosed herein and biochip comprising 16 lanes. The final reaction volume in the chips was 7 L.
Half strength sequencing reactions were set up with the DYEnamicTm ET Terminator Cycle Sequencing Kit from GE Healthcare following the manufacturer's protocol. All volumes were scaled down accordingly to accommodate the 7 AL final volume. Template for the reaction was 0.1 pmol B. subtilus with a fragment size of 343 bp.
Three cycling protocols were demonstrated with the first protocol consisting of 30 cycles of (20 s at 95 C, 15 s at 50 C and 60 s at 60 C) (total cycling time is 51.7 min), the second protocol consisting of 30 cycles of 5 s at 95 C, 15 s at 50 C and 30 s at 60 C (total cycling time is 29 min) and a third protocol consisting of 30 cycles of 5 s at 95 C, 10 s at 50 C and 20 s at 60 C (total cycling time of 21.6 min). Each sequencing reaction was cleaned-up with ethanol precipitated, and separated on Genebench FX Series 100. The average PHRED scores for sequencing a 343 bp PCR product for the 3 cycling protocols were 282, 287, and 279 respectively; demonstrating that sequencing of a 343 bp product can be achieved in chip in less than 22 min. Figure 10 shows the DNA sequence of the fast DNA
sequencing protocol.
In general, biochip based multiplexed amplification of one or more nucleic acids utilizing the systems and methods described herein have the advantage of providing amplified nucleic acid products in significantly shorter overall reaction times with respect to reactions run in thin-walled tubes and utilizing presently commercialized thermal cycling units.
CV Max: 34% CV Max: 21% CV Max: 13%
CV Max: 6%
The CV for PHR is up to 14% for biochips and 21% for tube reactions, compared to the 5% to 10% range observed for standard TaqGoldTm reactions. CVs for incomplete NTA
in biochip reactions vary between 6% and 28%, and for tube reactions between 2 to 13%.
Again, these variations are similar to the 4 to 28% range observed for standard TaqGoldTm reactions. The CVs for stutter in biochips are 4 to 9%, in tubes 2 to 6%, and are also similar to the range of 4-13% observed for standard TaqGoldTm reactions.
Example 4e Compatibility with Other Commercially Available STR Kits Using the same fast biochip and tube conditions described above, a series of samples were evaluated using primer sets from the COfilerml and IdentifilerTm kits.
Figures 9A and 9B show the achievement of full profiles using these primer sets using the thermal cycler of the invention, the SpeedSTAR enzyme, and the protocols described herein. Each is suitable for these commercially available kits as well. Although full profiles were achieved, imbalance in the signal strengths across the loci was observed.
Example 5 Fast Sequencing With the Thermal Cycler The thermal cycling instrument and methodology can also be applied to fast DNA
sequencing reactions. In this implementation of the fast thermal cycler, the instrumentation and biochip are the same as that used for PCR. Different reaction solutions, polymerase and cycling temperatures are applied for the sequencing reaction. The currently commercially available sequencing reactions take 49 min (for GE Amersham DYEnamicTm ET
Terminato Cycle Sequencing Kit) and 2.25 hr (for AB Big Dye V3.1. Utilizing the NetBio thermal cycler, with conventional reagents, allowed the sequencing reaction time to be reduced to 21 minutes.
Fast sequencing has been achieved using the thermocycler disclosed herein and biochip comprising 16 lanes. The final reaction volume in the chips was 7 L.
Half strength sequencing reactions were set up with the DYEnamicTm ET Terminator Cycle Sequencing Kit from GE Healthcare following the manufacturer's protocol. All volumes were scaled down accordingly to accommodate the 7 AL final volume. Template for the reaction was 0.1 pmol B. subtilus with a fragment size of 343 bp.
Three cycling protocols were demonstrated with the first protocol consisting of 30 cycles of (20 s at 95 C, 15 s at 50 C and 60 s at 60 C) (total cycling time is 51.7 min), the second protocol consisting of 30 cycles of 5 s at 95 C, 15 s at 50 C and 30 s at 60 C (total cycling time is 29 min) and a third protocol consisting of 30 cycles of 5 s at 95 C, 10 s at 50 C and 20 s at 60 C (total cycling time of 21.6 min). Each sequencing reaction was cleaned-up with ethanol precipitated, and separated on Genebench FX Series 100. The average PHRED scores for sequencing a 343 bp PCR product for the 3 cycling protocols were 282, 287, and 279 respectively; demonstrating that sequencing of a 343 bp product can be achieved in chip in less than 22 min. Figure 10 shows the DNA sequence of the fast DNA
sequencing protocol.
In general, biochip based multiplexed amplification of one or more nucleic acids utilizing the systems and methods described herein have the advantage of providing amplified nucleic acid products in significantly shorter overall reaction times with respect to reactions run in thin-walled tubes and utilizing presently commercialized thermal cycling units.
Claims (3)
1. A thermal cycler system comprising:
a temperature control element (TCE) having a first surface;
a substrate comprising a sample chamber comprising a solution, said sample chamber positioned in thermal communication with said first surface, and a sensing chamber comprising a thermosensor, wherein the sensing chamber is fabricated to have the same material stack-up as the sample chamber, and configured and positioned in the substrate at an analogous position to that of the sample in the sample chamber so as to simulate conditions within said sample chamber; and a controller configured to receive input from said thermosensor, wherein said thermosensor provides feedback to heat or cool the TCE to set or maintain the solution at a desired temperature.
a temperature control element (TCE) having a first surface;
a substrate comprising a sample chamber comprising a solution, said sample chamber positioned in thermal communication with said first surface, and a sensing chamber comprising a thermosensor, wherein the sensing chamber is fabricated to have the same material stack-up as the sample chamber, and configured and positioned in the substrate at an analogous position to that of the sample in the sample chamber so as to simulate conditions within said sample chamber; and a controller configured to receive input from said thermosensor, wherein said thermosensor provides feedback to heat or cool the TCE to set or maintain the solution at a desired temperature.
2. The thermal cycler system of claim 1, wherein said substrate is a biochip and wherein said sample chamber is a reaction chamber of said biochip.
3. An integrated biochip system comprising:
a biochip comprising:
(i) a cover layer having a thickness of less than 500 um; and (ii) at least one reaction chamber formed therein and further comprising a solution, each of said reaction chambers in contact with said cover layer and further comprising a microfluidic inlet channel and a microfluidic outlet channel; and (iii) at least one sensing chamber comprising a thermosensor, each of said sensing chambers fabricated to have the same material stack-up as the reaction chamber, and configured and positioned within the biochip at an analogous position to that of the solution in the reaction chamber so as to simulate the conditions within at least one reaction chamber; and a thermal cycler system, comprising:
a temperature control element (TCE) having a first surface,wherein the first surface of said TCE is in thermal communication with the cover layer of the biochip, and;
a controller configured to receive input from said thermosensor, said thermosensor providing feedback to heat or cool the TCE to set or maintain a desired temperature of the solution contained within said at least one reaction chamber.
a biochip comprising:
(i) a cover layer having a thickness of less than 500 um; and (ii) at least one reaction chamber formed therein and further comprising a solution, each of said reaction chambers in contact with said cover layer and further comprising a microfluidic inlet channel and a microfluidic outlet channel; and (iii) at least one sensing chamber comprising a thermosensor, each of said sensing chambers fabricated to have the same material stack-up as the reaction chamber, and configured and positioned within the biochip at an analogous position to that of the solution in the reaction chamber so as to simulate the conditions within at least one reaction chamber; and a thermal cycler system, comprising:
a temperature control element (TCE) having a first surface,wherein the first surface of said TCE is in thermal communication with the cover layer of the biochip, and;
a controller configured to receive input from said thermosensor, said thermosensor providing feedback to heat or cool the TCE to set or maintain a desired temperature of the solution contained within said at least one reaction chamber.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2894945A CA2894945C (en) | 2007-04-04 | 2008-04-04 | Methods for rapid multiplexed amplification of target nucleic acids |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92180207P | 2007-04-04 | 2007-04-04 | |
US60/921,802 | 2007-04-04 | ||
US96450207P | 2007-08-13 | 2007-08-13 | |
US60/964,502 | 2007-08-13 | ||
US2807308P | 2008-02-12 | 2008-02-12 | |
US61/028,073 | 2008-02-12 | ||
PCT/US2008/004487 WO2008124116A1 (en) | 2007-04-04 | 2008-04-04 | Methods for rapid multiplexed amplification of target nucleic acids |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2894945A Division CA2894945C (en) | 2007-04-04 | 2008-04-04 | Methods for rapid multiplexed amplification of target nucleic acids |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2682761A1 CA2682761A1 (en) | 2008-10-16 |
CA2682761C true CA2682761C (en) | 2015-10-13 |
Family
ID=39591889
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2984820A Active CA2984820C (en) | 2007-04-04 | 2008-04-04 | Plastic microfluidic separation and detection platforms |
CA2682758A Active CA2682758C (en) | 2007-04-04 | 2008-04-04 | Integrated nucleic acid analysis |
CA2682761A Active CA2682761C (en) | 2007-04-04 | 2008-04-04 | Methods for rapid multiplexed amplification of target nucleic acids |
CA2682734A Active CA2682734C (en) | 2007-04-04 | 2008-04-04 | Plastic microfluidic separation and detection platforms |
CA3135182A Active CA3135182C (en) | 2007-04-04 | 2008-04-04 | Plastic microfluidic separation and detection platforms |
CA2894945A Active CA2894945C (en) | 2007-04-04 | 2008-04-04 | Methods for rapid multiplexed amplification of target nucleic acids |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2984820A Active CA2984820C (en) | 2007-04-04 | 2008-04-04 | Plastic microfluidic separation and detection platforms |
CA2682758A Active CA2682758C (en) | 2007-04-04 | 2008-04-04 | Integrated nucleic acid analysis |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2682734A Active CA2682734C (en) | 2007-04-04 | 2008-04-04 | Plastic microfluidic separation and detection platforms |
CA3135182A Active CA3135182C (en) | 2007-04-04 | 2008-04-04 | Plastic microfluidic separation and detection platforms |
CA2894945A Active CA2894945C (en) | 2007-04-04 | 2008-04-04 | Methods for rapid multiplexed amplification of target nucleic acids |
Country Status (9)
Country | Link |
---|---|
US (12) | US8425861B2 (en) |
EP (7) | EP3032251B1 (en) |
JP (9) | JP2010523115A (en) |
KR (4) | KR101523260B1 (en) |
AU (5) | AU2008236612B2 (en) |
CA (6) | CA2984820C (en) |
ES (3) | ES2748134T3 (en) |
NZ (5) | NZ602697A (en) |
WO (4) | WO2009011942A2 (en) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101073002B (en) | 2004-09-15 | 2012-08-08 | č±ē¹åŗå ęéå ¬åø | Microfluidic devices |
GB0421529D0 (en) | 2004-09-28 | 2004-10-27 | Landegren Gene Technology Ab | Microfluidic structure |
WO2008030631A2 (en) * | 2006-02-03 | 2008-03-13 | Microchip Biotechnologies, Inc. | Microfluidic devices |
WO2008012550A2 (en) | 2006-07-28 | 2008-01-31 | Diagnostics For The Real World, Ltd. | Device, system and method for processing a sample |
EP2109666A4 (en) | 2007-02-05 | 2011-09-14 | Integenx Inc | Microfluidic and nanofluidic devices, systems, and applications |
ES2748134T3 (en) * | 2007-04-04 | 2020-03-13 | Ande Corp | Systems for rapid multiple amplification of target nucleic acids |
WO2009024773A1 (en) | 2007-08-17 | 2009-02-26 | Diagnostics For The Real World, Ltd | Device, system and method for processing a sample |
US20090253181A1 (en) * | 2008-01-22 | 2009-10-08 | Microchip Biotechnologies, Inc. | Universal sample preparation system and use in an integrated analysis system |
EP2280905B1 (en) | 2008-04-11 | 2016-07-06 | Fluidigm Corporation | Multilevel microfluidic systems and methods |
GB0818609D0 (en) | 2008-10-10 | 2008-11-19 | Univ Hull | apparatus and method |
CN102341691A (en) * | 2008-12-31 | 2012-02-01 | å°¹ē¹ę ¹åå ęÆęéå ¬åø | Instrument with microfluidic chip |
US8058630B2 (en) * | 2009-01-16 | 2011-11-15 | Fluidigm Corporation | Microfluidic devices and methods |
NZ620826A (en) * | 2009-02-03 | 2015-09-25 | Netbio Inc | Nucleic acid purification |
US8388908B2 (en) | 2009-06-02 | 2013-03-05 | Integenx Inc. | Fluidic devices with diaphragm valves |
GB2483402B (en) | 2009-06-04 | 2014-04-09 | Lockheed Corp | Multiple-sample microfluidic chip for DNA analysis |
CA2764464A1 (en) | 2009-06-05 | 2010-12-09 | Integenx Inc. | Universal sample preparation system and use in an integrated analysis system |
US9550985B2 (en) | 2009-06-15 | 2017-01-24 | Netbio, Inc. | Methods for forensic DNA quantitation |
US8584703B2 (en) | 2009-12-01 | 2013-11-19 | Integenx Inc. | Device with diaphragm valve |
AU2011208946B2 (en) | 2010-01-28 | 2014-10-02 | Ellume Pty Ltd | Sampling and testing device for the human or animal body |
ITMI20100163A1 (en) * | 2010-02-03 | 2011-08-04 | Consiglio Nazionale Ricerche | PROCEDURE FOR IDENTIFICATION AND TRACEABILITY OF PLANT COMPONENTS |
AU2013204367A1 (en) * | 2010-03-09 | 2013-05-16 | Netbio, Inc. | Unitary biochip providing sample-in to results-out processing and methods of manufacture |
US8720036B2 (en) | 2010-03-09 | 2014-05-13 | Netbio, Inc. | Unitary biochip providing sample-in to results-out processing and methods of manufacture |
WO2011112746A2 (en) * | 2010-03-09 | 2011-09-15 | Netbio, Inc. | Unitary biochip providing sample-in to results-out processing and methods of manufacture |
JP5841315B2 (en) | 2010-04-28 | 2016-01-13 | ć½ćć¼ę Ŗå¼ä¼ē¤¾ | Fine particle analyzer |
US8512538B2 (en) | 2010-05-28 | 2013-08-20 | Integenx Inc. | Capillary electrophoresis device |
US20110312793A1 (en) * | 2010-06-17 | 2011-12-22 | Geneasys Pty Ltd | Microfluidic test module with low mass of probes |
EP2606154B1 (en) | 2010-08-20 | 2019-09-25 | Integenx Inc. | Integrated analysis system |
US8763642B2 (en) | 2010-08-20 | 2014-07-01 | Integenx Inc. | Microfluidic devices with mechanically-sealed diaphragm valves |
US10114020B2 (en) * | 2010-10-11 | 2018-10-30 | Mbio Diagnostics, Inc. | System and device for analyzing a fluidic sample |
MX2013004184A (en) | 2010-10-15 | 2013-07-29 | Lockheed Corp | Micro fluidic optic design. |
EP2707509A4 (en) * | 2011-05-12 | 2014-11-26 | Netbio Inc | Methods and compositions for rapid multiplex amplification of str loci |
CA2835654A1 (en) | 2011-06-01 | 2012-12-06 | Streck, Inc. | Rapid thermocycler system for rapid amplification of nucleic acids and related methods |
US20130048487A1 (en) * | 2011-08-25 | 2013-02-28 | The University Of British Columbia | Systems and methods for enrichment and detection of particles |
US9207690B2 (en) * | 2011-09-23 | 2015-12-08 | Analogic Corporation | Thermal cycling |
US10865440B2 (en) | 2011-10-21 | 2020-12-15 | IntegenX, Inc. | Sample preparation, processing and analysis systems |
US20150136604A1 (en) | 2011-10-21 | 2015-05-21 | Integenx Inc. | Sample preparation, processing and analysis systems |
CN103160430A (en) | 2011-12-13 | 2013-06-19 | äøęēµåę Ŗå¼ä¼ē¤¾ | Cell capturing filter having high aspect ratio |
TWI470224B (en) * | 2011-12-22 | 2015-01-21 | Univ Chang Gung | Detecting system and detecting method |
US9322054B2 (en) | 2012-02-22 | 2016-04-26 | Lockheed Martin Corporation | Microfluidic cartridge |
JP6027321B2 (en) * | 2012-03-06 | 2016-11-16 | å ¬ēč²”å£ę³äŗŗē„å„å·ē§å¦ęč”ć¢ć«ććć¼ | High-speed gene amplification detector |
WO2013169915A1 (en) * | 2012-05-08 | 2013-11-14 | Brian Root | Self-coating sieving copolymers and plastic devices for nucleic acid separations on such devices |
KR102054678B1 (en) * | 2012-07-12 | 2020-01-22 | ģ¼ģ±ģ ģģ£¼ģķģ¬ | Fluid analysis cartridge |
CN104704357A (en) * | 2012-07-30 | 2015-06-10 | å å©ē¦å°¼äŗ大å¦č£äŗä¼ | Biomolecular detection test strip design |
US20140200167A1 (en) | 2012-08-01 | 2014-07-17 | Nanomdx, Inc. | Functionally integrated device for multiplex genetic identification |
EP2883039A1 (en) | 2012-08-10 | 2015-06-17 | Streck Inc. | Real-time optical system for polymerase chain reaction |
US10890590B2 (en) | 2012-09-27 | 2021-01-12 | Ellume Limited | Diagnostic devices and methods |
US9739714B2 (en) | 2012-10-29 | 2017-08-22 | Mbio Diagnostics, Inc. | Particle identification system, cartridge and associated methods |
EP2932266A4 (en) | 2012-12-17 | 2016-11-30 | Leukodx Ltd | Systems and methods for determining a chemical state |
JP6257148B2 (en) * | 2013-02-20 | 2018-01-10 | ćć¤ćć³ę Ŗå¼ä¼ē¤¾ | Image forming apparatus |
RU2662932C2 (en) | 2013-03-14 | 2018-07-31 | ŠŠ°ŃŠøŠ±Š¾ ŠŠøŠ¾ŃŠ°Š¹ŠµŠ½ŃŠøŠ·, ŠŠ½Šŗ. | Compositions and methods with use of nucleic acids targeted at nucleic acids |
US9146248B2 (en) | 2013-03-14 | 2015-09-29 | Intelligent Bio-Systems, Inc. | Apparatus and methods for purging flow cells in nucleic acid sequencing instruments |
US9591268B2 (en) | 2013-03-15 | 2017-03-07 | Qiagen Waltham, Inc. | Flow cell alignment methods and systems |
WO2014210593A1 (en) | 2013-06-28 | 2014-12-31 | Streck, Inc. | Devices for real-time polymerase chain reaction |
US9259823B2 (en) | 2013-08-26 | 2016-02-16 | Lawrence Livermore National Security, Llc | Boron nitride composites |
JP2015053893A (en) * | 2013-09-11 | 2015-03-23 | å ¬ēč²”å£ę³äŗŗē„å„å·ē§å¦ęč”ć¢ć«ććć¼ | High-speed gene amplification detection device |
JP6605454B2 (en) * | 2013-09-24 | 2019-11-13 | ć¶ ćŖć¼ćøć§ć³ć ćŖć ć¶ ć¦ććć¼ć·ćć£ ćŖć ć«ćŖćć©ć«ćć¢ | Generation of separation media using grayscale mask |
WO2015073999A1 (en) | 2013-11-18 | 2015-05-21 | Integenx Inc. | Cartridges and instruments for sample analysis |
US9827566B2 (en) * | 2013-11-19 | 2017-11-28 | IDEA machine development design AND production ltd. | Multi-well plates and methods of use thereof |
US9630182B2 (en) | 2013-12-04 | 2017-04-25 | Leidos Innovations Technology, Inc. | Non-contact infrared thermocycling |
WO2015103326A1 (en) * | 2013-12-31 | 2015-07-09 | Canon U.S. Life Sciences, Inc. | Field deployable small format fast first result microfluidic system |
US20150203893A1 (en) * | 2014-01-22 | 2015-07-23 | Analogic Corporation | Concurrently Evaluating Multiple Disease States Via Processing A Bio-Sample With A Single Multi-Channel Micro-Channel Device |
US10195610B2 (en) | 2014-03-10 | 2019-02-05 | Click Diagnostics, Inc. | Cartridge-based thermocycler |
GB2526520B (en) * | 2014-04-04 | 2021-08-18 | It Is Int Ltd | Biochemical reaction system |
SG11201608600YA (en) | 2014-04-14 | 2016-11-29 | Stanford Res Inst Int | Portable nucleic acid analysis system and high-performance microfluidic electroactive polymer actuators |
WO2015179098A1 (en) | 2014-05-21 | 2015-11-26 | Integenx Inc. | Fluidic cartridge with valve mechanism |
CN105277725B (en) * | 2014-07-01 | 2017-03-29 | ęø åå¤§å¦ | A kind of integrated micro-flow control system for foranalysis of nucleic acids detection |
CN107106983B (en) * | 2014-10-22 | 2021-04-16 | å°¹ē¹ę ¹åå ęÆęéå ¬åø | Systems and methods for sample preparation, processing, and analysis |
GB201419879D0 (en) | 2014-11-07 | 2014-12-24 | Ibm | Self-limited, anisotropic wet etching of transverse vias in microfluidic chips |
EP4029606A1 (en) | 2014-12-31 | 2022-07-20 | Visby Medical, Inc. | Molecular diagnostic testing |
EP3248001B1 (en) | 2015-01-22 | 2019-09-18 | Ellume Pty Ltd. | Diagnostic devices and methods for mitigating hook effect and use thereof |
GB2531616B (en) * | 2015-02-02 | 2017-11-22 | Atlas Genetics Ltd | Instrument for performing a diagnostic test on a fluidic cartridge |
DE112015005925B4 (en) * | 2015-02-23 | 2023-06-15 | Hitachi High-Tech Corporation | Nucleic Acid Analyzer |
EP3764093B1 (en) * | 2015-05-20 | 2022-07-06 | ProteinSimple | System and methods for electrophoretic separation and analysis of analytes |
US10233491B2 (en) | 2015-06-19 | 2019-03-19 | IntegenX, Inc. | Valved cartridge and system |
JP2017009435A (en) * | 2015-06-22 | 2017-01-12 | åÆ士é»ę©ę Ŗå¼ä¼ē¤¾ | Heating/cooling mechanism and heating/cooling system |
KR101751913B1 (en) * | 2015-09-08 | 2017-07-03 | (ģ£¼) ķģė°ģ“ģ¤ķ | A PCR-based point of care testing device coupled with electrophoretic microfluidic chip |
CN108139354A (en) * | 2015-09-22 | 2018-06-08 | ēē©č¾å°å®éŖ室č”份ęéå ¬åø | Electrophoresis vessel and method |
WO2017066485A1 (en) | 2015-10-13 | 2017-04-20 | Landers James P | Devices and methods for extraction, separation and thermocycling |
CN116083530A (en) * | 2016-01-29 | 2023-05-09 | ę®ēēēē©ē³»ē»å ¬åø | Isotachophoresis for nucleic acid purification |
US20170282178A1 (en) * | 2016-03-30 | 2017-10-05 | Credo Biomedical Pte Ltd. | Portable qpcr and qrt-pcr apparatus |
US10987674B2 (en) | 2016-04-22 | 2021-04-27 | Visby Medical, Inc. | Printed circuit board heater for an amplification module |
WO2017197040A1 (en) | 2016-05-11 | 2017-11-16 | Click Diagnostics, Inc. | Devices and methods for nucleic acid extraction |
KR101913208B1 (en) * | 2016-05-17 | 2018-10-30 | ģøģ°ėķźµ ģ°ķķė „ėØ | Extracting method of nucleic acid using solid phase object |
CN106066303B (en) * | 2016-05-24 | 2019-04-19 | äøå½ē§å¦é¢éåŗē»æč²ęŗč½ęęÆē ē©¶é¢ | Biomolecule Terahertz characteristic signal receives runner prisms waveguide and preparation method thereof in a kind of enhancing solution |
CN110325652A (en) | 2016-06-29 | 2019-10-11 | ęę·ä»ŖåØčÆęč”份ęéå ¬åø | Use the device and method of flow cell detection molecules |
USD800331S1 (en) | 2016-06-29 | 2017-10-17 | Click Diagnostics, Inc. | Molecular diagnostic device |
USD800914S1 (en) | 2016-06-30 | 2017-10-24 | Click Diagnostics, Inc. | Status indicator for molecular diagnostic device |
USD800913S1 (en) | 2016-06-30 | 2017-10-24 | Click Diagnostics, Inc. | Detection window for molecular diagnostic device |
EP3269444A1 (en) * | 2016-07-14 | 2018-01-17 | Base4 Innovation Ltd | Method of identifying droplets in a stack and an associated sequencer |
DE102016222035A1 (en) * | 2016-11-10 | 2018-05-17 | Robert Bosch Gmbh | Microfluidic device and method for analyzing samples |
DE102017100189A1 (en) * | 2017-01-06 | 2018-07-12 | Technische UniversitƤt Braunschweig | Method for two-dimensional protein separation and protein separation device |
JP2020507344A (en) | 2017-02-15 | 2020-03-12 | ć¢ć³ćć£ć»ć³ć¼ćć¬ć¤ć·ć§ć³ļ¼”ļ¼®ļ¼¤ļ¼„ ļ¼£ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ | Systems and methods for rapid nucleic acid extraction, purification and analysis |
US11602750B2 (en) * | 2017-05-30 | 2023-03-14 | Roche Molecular Systems, Inc. | Customizable sample processing device |
CA3069668A1 (en) | 2017-07-12 | 2019-01-17 | Ande Corporation | Pattern recognition system |
AU2018364741B2 (en) | 2017-11-09 | 2021-03-25 | Visby Medical, Inc. | Portable molecular diagnostic device and methods for the detection of target viruses |
KR102114148B1 (en) * | 2018-01-03 | 2020-05-22 | ģ¬ėØė²ģø źµ¬ėÆøģ ģģ ė³“źø°ģ ģ | Method for Detecting Foodborne Microorganism |
CN108220412B (en) * | 2018-01-03 | 2021-10-01 | äŗ¬äøę¹ē§ęéå¢č”份ęéå ¬åø | Gene sequencing substrate, preparation method thereof and gene sequencing device |
US11150180B1 (en) * | 2018-01-16 | 2021-10-19 | Redshift Bioanalytics Inc. | Actuated multi-chamber cells for fluid analysis |
JP6937851B2 (en) * | 2018-01-30 | 2021-09-22 | äŗ¬ć»ć©ę Ŗå¼ä¼ē¤¾ | Measuring device |
US10046322B1 (en) * | 2018-03-22 | 2018-08-14 | Talis Biomedical Corporation | Reaction well for assay device |
US20200347437A1 (en) * | 2018-03-23 | 2020-11-05 | Hewlett-Packard Development Company, L.P. | Nucleic acid tests with temporal fluorescent signals |
US11752500B2 (en) | 2018-04-27 | 2023-09-12 | Corning Incorporated | Microfluidic devices and methods for manufacturing microfluidic devices |
CN108645850A (en) * | 2018-05-24 | 2018-10-12 | ę å·ę³č·Æęŗåŗå ē§ęęéå ¬åø | A kind of swab and its preparation method and application |
US20220177980A1 (en) | 2018-07-30 | 2022-06-09 | Ande Corporation | Multiplexed Fuel Analysis |
DK3833466T3 (en) * | 2018-08-06 | 2023-12-18 | Siemens Healthcare Diagnostics Inc | METHOD AND DEVICE FOR DETERMINING THE CONCENTRATION OF ANALYTES IN WHOLE BLOOD |
WO2020033183A1 (en) * | 2018-08-06 | 2020-02-13 | Corning Incorporated | Microfluidic devices and methods for manufacturing microfluidic devices |
CN109813434B (en) * | 2018-12-19 | 2020-07-10 | å¦éØčµ¢ē§å ēµęéå ¬åø | Human body identification method and device based on temperature detection and terminal equipment |
US11684916B2 (en) * | 2019-01-09 | 2023-06-27 | Beijing Boe Optoelectronics Technology Co., Ltd. | Chip for polymerase chain reaction, method of operation chip, and reaction device |
RU2703776C9 (en) * | 2019-01-25 | 2020-02-18 | Š Š¾ŃŃŠøŠ¹ŃŠŗŠ°Ń Š¤ŠµŠ“ŠµŃŠ°ŃŠøŃ Š² Š»ŠøŃŠµ ŠŠøŠ½ŠøŃŃŠµŃŃŃŠ²Š° Š·Š“ŃŠ°Š²Š¾Š¾Ń ŃŠ°Š½ŠµŠ½ŠøŃ | One-time chip for pcr analysis |
JP6741100B2 (en) * | 2019-02-28 | 2020-08-19 | ć½ćć¼ę Ŗå¼ä¼ē¤¾ | Microparticle analyzer and microparticle analysis method |
US20200299672A1 (en) * | 2019-03-18 | 2020-09-24 | Cellular Research, Inc. | Precise delivery of components into fluids |
US20220112453A1 (en) * | 2019-04-30 | 2022-04-14 | Hewlett-Packard Development Company, L.P. | Cell lysis with a microbead and thermal resistor |
US11352675B2 (en) | 2020-01-03 | 2022-06-07 | Visby Medical, Inc. | Devices and methods for antibiotic susceptability testing |
WO2021188877A1 (en) * | 2020-03-19 | 2021-09-23 | Mayo Foundation For Medical Education And Research | Point-of-care digital microfluidics for sepsis diagnosis |
KR102288369B1 (en) * | 2020-12-23 | 2021-08-10 | ģ£¼ģķģ¬ ėÆøģ½ė°ģ“ģ¤ė©ė | Integrated chip with lysis and amplifying nucleic acids, lysis module having the same, apparatus for point-of-care-testing having the same, and method for lysis and amplifying nucleic acids using the same |
CN112782395B (en) | 2020-12-30 | 2021-11-09 | åäŗ¬äøē§ēä»Ŗē§ęęéå ¬åø | PCR detector and method thereof |
CN113278509B (en) * | 2021-01-15 | 2022-04-26 | åäŗ¬äøē§ēä»Ŗē§ęęéå ¬åø | Chip device for nucleic acid detection |
CN112903613B (en) * | 2021-02-24 | 2022-11-08 | åęå¤§å¦ | Labview-based transient absorption spectrum control system design method |
WO2023019105A1 (en) * | 2021-08-08 | 2023-02-16 | Keydev Inc. | Cartridge gel electrophoresis device for separating biomolecules |
CN113702317B (en) * | 2021-08-30 | 2023-10-27 | äøå½åäøē§å¦é¢åäøäæ”ęÆē ē©¶ę | River basin non-point source pollution component sensor, monitoring system and method |
CN114231401B (en) * | 2022-02-21 | 2022-05-03 | åäŗ¬čÆčæå¾®ēē©ęęÆęéå ¬åø | Nucleic acid detection kit and detection method |
WO2023168085A1 (en) * | 2022-03-04 | 2023-09-07 | Catalog Technologies, Inc. | Dna microarrays and component level sequencing for nucleic acid-based data storage and processing |
KR20230155183A (en) * | 2022-05-03 | 2023-11-10 | ź²½ė¶ėķźµ ģ°ķķė „ėØ | A portable device for isolationg nucleic acids in blood |
Family Cites Families (292)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2817264A (en) | 1953-10-19 | 1957-12-24 | Beckman Instruments Inc | Electrophoresis apparatus |
US4170616A (en) | 1978-05-30 | 1979-10-09 | Rca Corporation | Method of fabrication of a Fresnel lens |
US5821058A (en) | 1984-01-16 | 1998-10-13 | California Institute Of Technology | Automated DNA sequencing technique |
US5171534A (en) | 1984-01-16 | 1992-12-15 | California Institute Of Technology | Automated DNA sequencing technique |
US5038852A (en) * | 1986-02-25 | 1991-08-13 | Cetus Corporation | Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps |
DE3531570A1 (en) * | 1985-09-04 | 1987-03-05 | Glotur Trust | IGNITION DEVICE FOR INTERNAL COMBUSTION ENGINES |
US4855225A (en) | 1986-02-07 | 1989-08-08 | Applied Biosystems, Inc. | Method of detecting electrophoretically separated oligonucleotides |
US4811218A (en) * | 1986-06-02 | 1989-03-07 | Applied Biosystems, Inc. | Real time scanning electrophoresis apparatus for DNA sequencing |
CA1340806C (en) * | 1986-07-02 | 1999-11-02 | James Merrill Prober | Method, system and reagents for dna sequencing |
US5112460A (en) * | 1986-10-21 | 1992-05-12 | Northeastern University | High performance microcapillary gel electrophoresis |
US4865707A (en) | 1986-10-21 | 1989-09-12 | Northeastern University | Capillary gel electrophoresis columns |
JPH0799353B2 (en) * | 1987-03-31 | 1995-10-25 | ę Ŗå¼ä¼ē¤¾å³¶ę“„č£½ä½ę | Nucleotide sequencer |
JP2550106B2 (en) * | 1987-10-30 | 1996-11-06 | ę Ŗå¼ä¼ē¤¾ę„ē«č£½ä½ę | Optical dispersion detection type electrophoretic device |
GB8807297D0 (en) * | 1988-03-26 | 1988-04-27 | Dean P D G | Intelligent heating block |
US4945135A (en) * | 1988-07-25 | 1990-07-31 | California Institute Of Technology | Ring opening metathesis polymerization of strained cyclic ethers |
US5281516A (en) | 1988-08-02 | 1994-01-25 | Gene Tec Corporation | Temperature control apparatus and method |
CA1339731C (en) | 1988-10-12 | 1998-03-17 | Charles T. Caskey | Multiplex genomic dna amplification for deletion detection |
US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
FR2654552A1 (en) * | 1989-11-14 | 1991-05-17 | Radiotechnique Compelec | SEGMENTED PHOTOMULTIPLIER TUBE WITH HIGH COLLECTION EFFICIENCY AND LIMITED DIAPHYT. |
US5164055A (en) | 1990-01-29 | 1992-11-17 | Applied Biosystems, Inc. | High-viscosity polymer matrix and methods |
US5126022A (en) * | 1990-02-28 | 1992-06-30 | Soane Tecnologies, Inc. | Method and device for moving molecules by the application of a plurality of electrical fields |
US5858188A (en) * | 1990-02-28 | 1999-01-12 | Aclara Biosciences, Inc. | Acrylic microchannels and their use in electrophoretic applications |
US5750015A (en) * | 1990-02-28 | 1998-05-12 | Soane Biosciences | Method and device for moving molecules by the application of a plurality of electrical fields |
US5770029A (en) * | 1996-07-30 | 1998-06-23 | Soane Biosciences | Integrated electrophoretic microdevices |
US5307148A (en) * | 1990-04-05 | 1994-04-26 | Hitachi, Ltd. | Fluorescence detection type electrophoresis apparatus |
JP2826366B2 (en) * | 1990-04-12 | 1998-11-18 | ę Ŗå¼ä¼ē¤¾ę„ē«č£½ä½ę | Fluorescence detection type electrophoresis device |
US5085756A (en) * | 1990-08-21 | 1992-02-04 | Hewlett-Packard Company | Column separation system for electrophoresis with sample pretreatment |
KR100236506B1 (en) * | 1990-11-29 | 2000-01-15 | ķ¼ķØ-ģėØøģķ°ģ¤ģøģ¤ķøė£Øėؼģø | Apparatus for polymerase chain reaction |
US5332481A (en) * | 1991-01-29 | 1994-07-26 | Beckman Instruments, Inc. | Capillary electrophoresis using replaceable gels |
US5994056A (en) | 1991-05-02 | 1999-11-30 | Roche Molecular Systems, Inc. | Homogeneous methods for nucleic acid amplification and detection |
WO1992022590A1 (en) | 1991-06-11 | 1992-12-23 | Nippon Zeon Co., Ltd. | Hydrogenated thermoplastic norbornene polymer, production thereof, and optical element base, optical element and lens molded therefrom |
US5334424A (en) | 1991-06-17 | 1994-08-02 | Nippon Zeon Co., Ltd. | Thermoplastic norbornene resin formed articles and sustrates for liquid crystal display |
US5273638A (en) * | 1991-09-30 | 1993-12-28 | Beckman Instruments, Inc. | Nucleotide sequence determination employing matched dideoxynucleotide terminator concentrations |
US5274602A (en) * | 1991-10-22 | 1993-12-28 | Florida Atlantic University | Large capacity solid-state memory |
US5198511A (en) * | 1991-12-20 | 1993-03-30 | Minnesota Mining And Manufacturing Company | Polymerizable compositions containing olefin metathesis catalysts and cocatalysts, and methods of use therefor |
US5468803A (en) | 1992-03-03 | 1995-11-21 | Nippon Zeon Co. Ltd. | Medical implement, polymer composition, and optical material |
WO1993019205A1 (en) * | 1992-03-19 | 1993-09-30 | The Regents Of The University Of California | Multiple tag labeling method for dna sequencing |
US5312940A (en) | 1992-04-03 | 1994-05-17 | California Institute Of Technology | Ruthenium and osmium metal carbene complexes for olefin metathesis polymerization |
US5587128A (en) | 1992-05-01 | 1996-12-24 | The Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification devices |
US5290418A (en) * | 1992-09-24 | 1994-03-01 | Applied Biosystems, Inc. | Viscous electrophoresis polymer medium and method |
CA2110463C (en) * | 1992-12-17 | 2005-02-08 | Jacob Emert | Gel-free ethylene interpolymer dispersant additives useful in oleaginous compositions |
US5364790A (en) | 1993-02-16 | 1994-11-15 | The Perkin-Elmer Corporation | In situ PCR amplification system |
EP1296134B1 (en) | 1993-04-15 | 2013-05-29 | Bayer Intellectual Property GmbH | Sampling device and its use for controlling sample introduction in microcolumn separation techniques |
EP0635994B1 (en) * | 1993-07-08 | 1998-09-23 | Canon Kabushiki Kaisha | Method and apparatus for separating particles |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
US6403367B1 (en) | 1994-07-07 | 2002-06-11 | Nanogen, Inc. | Integrated portable biological detection system |
US5840338A (en) | 1994-07-18 | 1998-11-24 | Roos; Eric J. | Loading of biologically active solutes into polymer gels |
US6001229A (en) * | 1994-08-01 | 1999-12-14 | Lockheed Martin Energy Systems, Inc. | Apparatus and method for performing microfluidic manipulations for chemical analysis |
US5596226A (en) * | 1994-09-06 | 1997-01-21 | International Business Machines Corporation | Semiconductor chip having a chip metal layer and a transfer metal and corresponding electronic module |
US7008771B1 (en) | 1994-09-30 | 2006-03-07 | Promega Corporation | Multiplex amplification of short tandem repeat loci |
US6479235B1 (en) * | 1994-09-30 | 2002-11-12 | Promega Corporation | Multiplex amplification of short tandem repeat loci |
US5843660A (en) * | 1994-09-30 | 1998-12-01 | Promega Corporation | Multiplex amplification of short tandem repeat loci |
CA2118048C (en) | 1994-09-30 | 2003-04-08 | James W. Schumm | Multiplex amplification of short tandem repeat loci |
US6017434A (en) * | 1995-05-09 | 2000-01-25 | Curagen Corporation | Apparatus and method for the generation, separation, detection, and recognition of biopolymer fragments |
US6485625B1 (en) * | 1995-05-09 | 2002-11-26 | Curagen Corporation | Apparatus and method for the generation, separation, detection, and recognition of biopolymer fragments |
US5882856A (en) * | 1995-06-07 | 1999-03-16 | Genzyme Corporation | Universal primer sequence for multiplex DNA amplification |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5994066A (en) | 1995-09-11 | 1999-11-30 | Infectio Diagnostic, Inc. | Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
US20020068357A1 (en) * | 1995-09-28 | 2002-06-06 | Mathies Richard A. | Miniaturized integrated nucleic acid processing and analysis device and method |
US6709869B2 (en) | 1995-12-18 | 2004-03-23 | Tecan Trading Ag | Devices and methods for using centripetal acceleration to drive fluid movement in a microfluidics system |
US5830657A (en) * | 1996-05-01 | 1998-11-03 | Visible Genetics Inc. | Method for single-tube sequencing of nucleic acid polymers |
US5723294A (en) * | 1996-03-05 | 1998-03-03 | Gull Laboratories | Methods for detection and discrimination of multiple analytes using fluorescent technology |
AU713667B2 (en) | 1996-04-12 | 1999-12-09 | Phri Properties, Inc. | Detection probes, kits and assays |
US5885470A (en) * | 1997-04-14 | 1999-03-23 | Caliper Technologies Corporation | Controlled fluid transport in microfabricated polymeric substrates |
US5942443A (en) | 1996-06-28 | 1999-08-24 | Caliper Technologies Corporation | High throughput screening assay systems in microscale fluidic devices |
US6706875B1 (en) * | 1996-04-17 | 2004-03-16 | Affyemtrix, Inc. | Substrate preparation process |
US5994064A (en) | 1996-04-24 | 1999-11-30 | Identigene, Inc. | Simple and complex tandem repeats with DNA typing method |
US5847162A (en) | 1996-06-27 | 1998-12-08 | The Perkin Elmer Corporation | 4, 7-Dichlororhodamine dyes |
US5800996A (en) | 1996-05-03 | 1998-09-01 | The Perkin Elmer Corporation | Energy transfer dyes with enchanced fluorescence |
WO1997043611A1 (en) * | 1996-05-16 | 1997-11-20 | Affymetrix, Inc. | Systems and methods for detection of labeled materials |
US6156512A (en) | 1996-05-23 | 2000-12-05 | Promega Corp | Allelic ladders for short tandem repeat loci |
US6361672B1 (en) * | 1996-06-10 | 2002-03-26 | Transgenomic, Inc. | Multiple laser diode electromagnetic radiation source in multiple electrophoresis channel systems |
BR9710054A (en) | 1996-06-28 | 2000-01-11 | Caliper Techn Corp | Apparatus for separating test compounds for an effect on a biochemical system and for detecting a effect of a test compound on a biochemical system, procedures for determining whether a sample contains a compound capable of affecting a biochemical system, for separating a plurality of test compounds for an effect on a biochemical system and uses of a microfluidic system and a test substrate. |
US5779868A (en) * | 1996-06-28 | 1998-07-14 | Caliper Technologies Corporation | Electropipettor and compensation means for electrophoretic bias |
US5858187A (en) * | 1996-09-26 | 1999-01-12 | Lockheed Martin Energy Systems, Inc. | Apparatus and method for performing electrodynamic focusing on a microchip |
WO1998017992A2 (en) * | 1996-10-25 | 1998-04-30 | Applied Imaging, Inc. | Multifluor-fluorescence in situ hybridization (m-fish) imaging techniques using multiple multiband filters with image registration |
US6372142B1 (en) * | 1996-11-13 | 2002-04-16 | Transgenomic, Inc. | Column for DNA separation by matched ion polynucleotide chromatography |
US6312886B1 (en) | 1996-12-06 | 2001-11-06 | The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Reaction vessels |
EP0854362A3 (en) | 1997-01-16 | 2000-12-20 | Japan Science and Technology Corporation | Multi-capillary electrophoresis apparatus |
JPH10239278A (en) * | 1997-02-24 | 1998-09-11 | Hitachi Ltd | Cataphoresis device |
US6074868A (en) | 1997-03-03 | 2000-06-13 | Regents Of The University Of Minnesota | Alumina plate method and device for controlling temperature |
US6391622B1 (en) * | 1997-04-04 | 2002-05-21 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
JP2001521394A (en) | 1997-04-22 | 2001-11-06 | ćććŖć¢ć³ć»ćć«ćć£ććÆć»ćŖćµć¼ćć»ć¤ć³ć¹ćć£ćć„ć¼ćć»ć¢ćÆćć£ć¼ć¼ć«ć¹ć«ć | TaqMan ā¢ upper TM ā¢ -PCR for detection of pathogenic E. coli strains |
DE19717085C2 (en) | 1997-04-23 | 1999-06-17 | Bruker Daltonik Gmbh | Processes and devices for extremely fast DNA multiplication using polymerase chain reactions (PCR) |
KR100351531B1 (en) | 1997-04-25 | 2002-09-11 | ģŗė¦¬ķ¼ ķ ķ¬ėė”ģ§ģ¤ ģ½ķ¬ė ģ“ģ | Microfludic devices incorporating improved channel geometries |
US7033474B1 (en) * | 1997-04-25 | 2006-04-25 | Caliper Life Sciences, Inc. | Microfluidic devices incorporating improved channel geometries |
US5976336A (en) * | 1997-04-25 | 1999-11-02 | Caliper Technologies Corp. | Microfluidic devices incorporating improved channel geometries |
US6410275B1 (en) | 1997-05-02 | 2002-06-25 | Biomerieux, Inc. | Disposable test devices for performing nucleic acid amplification reactions |
US5989499A (en) | 1997-05-02 | 1999-11-23 | Biomerieux, Inc. | Dual chamber disposable reaction vessel for amplification reactions |
US6429007B1 (en) | 1997-05-02 | 2002-08-06 | BIOMĆ©RIEUX, INC. | Nucleic acid amplification reaction station for disposable test devices |
US5786182A (en) | 1997-05-02 | 1998-07-28 | Biomerieux Vitek, Inc. | Dual chamber disposable reaction vessel for amplification reactions, reaction processing station therefor, and methods of use |
US6632619B1 (en) * | 1997-05-16 | 2003-10-14 | The Governors Of The University Of Alberta | Microfluidic system and methods of use |
JP3469585B2 (en) | 1997-05-23 | 2003-11-25 | ć¬ć”ć© ćć¤ćŖćµć¤ćØć³ć¹ ć³ć¼ćć¬ć¤ć·ć§ć³ | Apparatus and method for using centripetal acceleration to drive flow motion in microfluidics systems |
US5876675A (en) * | 1997-08-05 | 1999-03-02 | Caliper Technologies Corp. | Microfluidic devices and systems |
US6207031B1 (en) | 1997-09-15 | 2001-03-27 | Whitehead Institute For Biomedical Research | Methods and apparatus for processing a sample of biomolecular analyte using a microfabricated device |
AU1517999A (en) | 1997-10-15 | 1999-05-03 | Aclara Biosciences, Inc. | Laminate microstructure device and method for making same |
US6143152A (en) | 1997-11-07 | 2000-11-07 | The Regents Of The University Of California | Microfabricated capillary array electrophoresis device and method |
EP1179585B1 (en) * | 1997-12-24 | 2008-07-09 | Cepheid | Device and method for lysis |
US6826524B1 (en) | 1998-01-08 | 2004-11-30 | Purdue Research Foundation | Sample-adaptive product quantization |
US6167910B1 (en) * | 1998-01-20 | 2001-01-02 | Caliper Technologies Corp. | Multi-layer microfluidic devices |
US6857449B1 (en) * | 1998-01-20 | 2005-02-22 | Caliper Life Sciences, Inc. | Multi-layer microfluidic devices |
US6080868A (en) * | 1998-01-23 | 2000-06-27 | The Perkin-Elmer Corporation | Nitro-substituted non-fluorescent asymmetric cyanine dye compounds |
US6210882B1 (en) * | 1998-01-29 | 2001-04-03 | Mayo Foundation For Medical Education And Reseach | Rapid thermocycling for sample analysis |
US6420143B1 (en) | 1998-02-13 | 2002-07-16 | Caliper Technologies Corp. | Methods and systems for performing superheated reactions in microscale fluidic systems |
US6100541A (en) | 1998-02-24 | 2000-08-08 | Caliper Technologies Corporation | Microfluidic devices and systems incorporating integrated optical elements |
CA2230653A1 (en) | 1998-02-27 | 1999-08-27 | The Governors Of The University Of Alberta | Microchip based enzymatic analysis |
US6251247B1 (en) * | 1998-04-01 | 2001-06-26 | Hitachi Chemical Co., Ltd. | Detection of degradation of RNA using microchannel electrophoresis |
US6200531B1 (en) * | 1998-05-11 | 2001-03-13 | Igen International, Inc. | Apparatus for carrying out electrochemiluminescence test measurements |
US6172997B1 (en) | 1998-06-16 | 2001-01-09 | Aculight Corporation | Integrated semiconductor diode laser pumped solid state laser |
WO2000009758A1 (en) | 1998-08-14 | 2000-02-24 | The Regents Of The University Of California | NOVEL AMPLICON IN THE 20q13 REGION OF HUMAN CHROMOSOME 20 AND USES THEREOF |
US6605472B1 (en) | 1998-10-09 | 2003-08-12 | The Governors Of The University Of Alberta | Microfluidic devices connected to glass capillaries with minimal dead volume |
JP3613032B2 (en) * | 1998-10-26 | 2005-01-26 | ę Ŗå¼ä¼ē¤¾ę„ē«č£½ä½ę | Capillary array electrophoresis device |
DE19856064C2 (en) | 1998-12-04 | 2000-11-30 | Invitek Gmbh | Universal method for the isolation of DNA from any starting material |
US6431476B1 (en) * | 1999-12-21 | 2002-08-13 | Cepheid | Apparatus and method for rapid ultrasonic disruption of cells or viruses |
US6261431B1 (en) | 1998-12-28 | 2001-07-17 | Affymetrix, Inc. | Process for microfabrication of an integrated PCR-CE device and products produced by the same |
US7261859B2 (en) * | 1998-12-30 | 2007-08-28 | Gyros Ab | Microanalysis device |
US6249341B1 (en) * | 1999-01-25 | 2001-06-19 | Amnis Corporation | Imaging and analyzing parameters of small moving objects such as cells |
CA2297352A1 (en) | 1999-02-05 | 2000-08-05 | Robert J. Lipshutz | Multiplex genotyping of populations of individuals |
US6558945B1 (en) * | 1999-03-08 | 2003-05-06 | Aclara Biosciences, Inc. | Method and device for rapid color detection |
US6225061B1 (en) * | 1999-03-10 | 2001-05-01 | Sequenom, Inc. | Systems and methods for performing reactions in an unsealed environment |
US6303343B1 (en) | 1999-04-06 | 2001-10-16 | Caliper Technologies Corp. | Inefficient fast PCR |
US6235479B1 (en) * | 1999-04-13 | 2001-05-22 | Bio Merieux, Inc. | Methods and devices for performing analysis of a nucleic acid sample |
US20050181440A1 (en) | 1999-04-20 | 2005-08-18 | Illumina, Inc. | Nucleic acid sequencing using microsphere arrays |
JP3597729B2 (en) * | 1999-05-11 | 2004-12-08 | ę„ē«ć½ććć¦ćØć¢ćØć³ćøćć¢ćŖć³ć°ę Ŗå¼ä¼ē¤¾ | Fluorescence metering method and fluorescence meter |
AU782343B2 (en) | 1999-05-28 | 2005-07-21 | Cepheid | Apparatus and method for analyzing a fluid sample |
US6472155B1 (en) | 1999-06-08 | 2002-10-29 | The Regents Of The University Of California | Species specific identification of spore-producing microbes using the gene sequence of small acid-soluble spore coat proteins for amplification based diagnostics |
US6706519B1 (en) * | 1999-06-22 | 2004-03-16 | Tecan Trading Ag | Devices and methods for the performance of miniaturized in vitro amplification assays |
US6664104B2 (en) * | 1999-06-25 | 2003-12-16 | Cepheid | Device incorporating a microfluidic chip for separating analyte from a sample |
GB9917307D0 (en) * | 1999-07-23 | 1999-09-22 | Sec Dep Of The Home Department | Improvements in and relating to analysis of DNA |
US6864050B2 (en) * | 1999-07-30 | 2005-03-08 | Affymetrix, Inc. | Single-phase amplification of nucleic acids |
US6472156B1 (en) * | 1999-08-30 | 2002-10-29 | The University Of Utah | Homogeneous multiplex hybridization analysis by color and Tm |
US6633785B1 (en) | 1999-08-31 | 2003-10-14 | Kabushiki Kaisha Toshiba | Thermal cycler and DNA amplifier method |
GB9922971D0 (en) | 1999-09-29 | 1999-12-01 | Secr Defence | Reaction system |
DE19947495C2 (en) | 1999-10-01 | 2003-05-28 | Agilent Technologies Inc | Microfluidic microchip |
US6630063B1 (en) | 1999-10-06 | 2003-10-07 | I. Reich Family Limited Partnership | Uniform laser excitation and detection in capillary array electrophoresis system and method |
ATE408141T1 (en) | 1999-10-20 | 2008-09-15 | Shigeori Takenaka | GENE DETECTION CHIP, SENSOR AND DETECTION METHOD |
US6471916B1 (en) * | 1999-11-09 | 2002-10-29 | Packard Instrument Company | Apparatus and method for calibration of a microarray scanning system |
US6875619B2 (en) | 1999-11-12 | 2005-04-05 | Motorola, Inc. | Microfluidic devices comprising biochannels |
CA2290731A1 (en) | 1999-11-26 | 2001-05-26 | D. Jed Harrison | Apparatus and method for trapping bead based reagents within microfluidic analysis system |
US6432290B1 (en) | 1999-11-26 | 2002-08-13 | The Governors Of The University Of Alberta | Apparatus and method for trapping bead based reagents within microfluidic analysis systems |
US6497977B1 (en) * | 1999-11-30 | 2002-12-24 | Ballard Power Systems Inc. | Method of making stripped porous polymer films |
CA2393690A1 (en) * | 1999-12-09 | 2001-06-14 | Huinan Yu | Multilayered microfluidic devices for analyte reactions |
US6884395B2 (en) | 2000-05-12 | 2005-04-26 | Gyros Ab | Integrated microfluidic disc |
ATE412774T1 (en) * | 2000-02-16 | 2008-11-15 | Illumina Inc | PARALLEL GENOTYPING OF MULTIPLE PATIENT SAMPLES |
US6407395B1 (en) * | 2000-02-29 | 2002-06-18 | The University Of Chicago | Portable biochip scanner device |
US6329661B1 (en) * | 2000-02-29 | 2001-12-11 | The University Of Chicago | Biochip scanner device |
ITCA20000004A1 (en) | 2000-03-07 | 2001-09-07 | Mario Raimondo Caria | METHOD AND SYSTEM FOR SIMULTANEOUS AND MULTIPLE DETECTION WITH QUANTIFICATION OF THE HYBRIDIZATION OF MOLECULAR COMPOUNDS SUCH AS CORE ACIDS |
US8288128B2 (en) * | 2004-11-18 | 2012-10-16 | Eppendorf Array Technologies S.A. | Real-time quantification of multiple targets on a micro-array |
US6358387B1 (en) * | 2000-03-27 | 2002-03-19 | Caliper Technologies Corporation | Ultra high throughput microfluidic analytical systems and methods |
EP1142544B1 (en) * | 2000-04-04 | 2008-03-26 | Link Spine Group, Inc. | Intervertebral implant |
US6734420B2 (en) | 2000-04-06 | 2004-05-11 | Quantum Dot Corporation | Differentiable spectral bar code methods and systems |
US7306924B2 (en) | 2000-04-17 | 2007-12-11 | Purdue Research Foundation | Biosensor and related method |
US6733645B1 (en) * | 2000-04-18 | 2004-05-11 | Caliper Technologies Corp. | Total analyte quantitation |
US6448014B2 (en) | 2000-04-19 | 2002-09-10 | Research Development Foundation | PCR-hybridization assays specific for integrated retroviruses |
US6787016B2 (en) * | 2000-05-01 | 2004-09-07 | Aclara Biosciences, Inc. | Dynamic coating with linear polymer mixture for electrophoresis |
US6777184B2 (en) * | 2000-05-12 | 2004-08-17 | Caliper Life Sciences, Inc. | Detection of nucleic acid hybridization by fluorescence polarization |
AU2001259770A1 (en) | 2000-05-15 | 2001-11-26 | Biomicro Systems, Inc. | Air flow regulation in microfluidic circuits for pressure control and gaseous exchange |
US6635487B1 (en) * | 2000-05-17 | 2003-10-21 | Caliper Technologies Corp. | Fluorescence standard for use in microfluidic instruments |
US6531282B1 (en) | 2000-05-30 | 2003-03-11 | Oligotrail, Llc | Multiplex amplification and analysis of selected STR loci |
CA2352639A1 (en) * | 2000-07-14 | 2002-01-14 | John Joseph Cullen | A method and apparatus for monitoring a condition in chlorophyll containing matter |
JP4896349B2 (en) * | 2000-07-21 | 2012-03-14 | ć¢ćÆć©ć© ćć¤ćŖćµć¤ćØć³ć·ć¼ćŗļ¼ ć¤ć³ć³ć¼ćć¬ć¤ććć | Methods and devices for capillary electrophoresis using a norbornene-based surface coating. |
US7008769B2 (en) * | 2000-08-15 | 2006-03-07 | Bioforce Nanosciences, Inc. | Nanoscale molecular arrayer |
WO2002018660A2 (en) | 2000-08-31 | 2002-03-07 | Mayo Foundation For Medical Education And Research | Detection of varicella-zoster virus |
DE50012114D1 (en) * | 2000-09-05 | 2006-04-13 | Zeltz Patrick | Method for the specific determination of DNA sequences by means of parallel amplification |
US6939451B2 (en) | 2000-09-19 | 2005-09-06 | Aclara Biosciences, Inc. | Microfluidic chip having integrated electrodes |
US6482641B2 (en) * | 2000-10-02 | 2002-11-19 | Boris Chen | DNA-based integrated circuit |
US7150815B2 (en) | 2000-10-05 | 2006-12-19 | E. I. Du Pont De Nemours And Company | Polymeric microfabricated fluidic device suitable for ultraviolet detection |
WO2002035223A1 (en) * | 2000-10-25 | 2002-05-02 | Xiamen University | Electrophoretic separating device and method for using the device |
US7033475B2 (en) * | 2000-10-25 | 2006-04-25 | Shimadzu Corporation | Electrophoretic apparatus |
WO2002061387A2 (en) | 2000-10-25 | 2002-08-08 | Exiqon A/S | Open substrate platforms suitable for analysis of biomolecules |
US6824024B2 (en) | 2000-11-17 | 2004-11-30 | Tecan Trading Ag | Device for the take-up and/or release of liquid samples |
JP3663125B2 (en) | 2000-11-28 | 2005-06-22 | ę„ē«ć½ććć¦ćØć¢ćØć³ćøćć¢ćŖć³ć°ę Ŗå¼ä¼ē¤¾ | Fluorescence reading method and fluorescence reading apparatus |
US6630680B2 (en) * | 2000-12-25 | 2003-10-07 | Fuji Photo Film Co., Ltd. | Scanner having confocal optical system, method for producing focus position data of confocal optical system of scanner having confocal optical system and method for producing digital data of scanner having confocal optical system |
US6800438B2 (en) * | 2000-12-28 | 2004-10-05 | Xerox Corporation | Imager for DNA sequencer |
WO2002056004A2 (en) | 2001-01-12 | 2002-07-18 | Syngenta Participations Ag | Thin film electrophoresis apparatus and method |
ES2344594T3 (en) | 2001-01-31 | 2010-09-01 | Mayo Foundation For Medical Education And Research | DETECTION OF THE SIMPLEX HERPES VIRUS. |
WO2002063288A1 (en) | 2001-01-31 | 2002-08-15 | Sau Lan Tang Staats | Microfluidic devices |
CA2438130A1 (en) | 2001-02-13 | 2002-08-22 | Children's Hospital Research Foundation | Quantitative epstein barr virus pcr rapid assay |
EP2089413A4 (en) | 2001-02-21 | 2009-10-28 | Amnis Corp | Method and apparatus for labeling and analyzing cellular components |
DE10111457B4 (en) | 2001-03-09 | 2006-12-14 | Siemens Ag | diagnostic device |
DE10116674C2 (en) | 2001-04-04 | 2003-08-14 | Eppendorf Ag | Device for the detection of fluids in a microfluidic component |
US6598545B2 (en) | 2001-04-10 | 2003-07-29 | Newport Corporation | Vibration damper for optical tables and other structures |
DK1392814T3 (en) | 2001-04-25 | 2007-09-24 | Cornell Res Foundation Inc | Devices and Methods for Pharmacokinetic Based Cell Culture System |
FR2823999B1 (en) | 2001-04-27 | 2003-06-27 | Commissariat Energie Atomique | MINIATURE DEVICE FOR SEPARATING AND ISOLATING BIOLOGICAL OBJECTS AND USES |
US6929730B2 (en) * | 2001-05-01 | 2005-08-16 | Cheng Sheng Lee | Two dimensional microfluidic gene scanner |
US6596140B2 (en) * | 2001-05-01 | 2003-07-22 | Applera Corporation | Multi-channel capillary electrophoresis device and method |
US20030007895A1 (en) * | 2001-06-19 | 2003-01-09 | Fuji Photo Film Co., Ltd. | Biochemical analysis unit |
US7179423B2 (en) | 2001-06-20 | 2007-02-20 | Cytonome, Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
US6762049B2 (en) * | 2001-07-05 | 2004-07-13 | Institute Of Microelectronics | Miniaturized multi-chamber thermal cycler for independent thermal multiplexing |
WO2003004982A1 (en) * | 2001-07-05 | 2003-01-16 | Hamamatsu Photonics K.K. | Spectroscopic device |
JP2003028797A (en) * | 2001-07-11 | 2003-01-29 | Hitachi Software Eng Co Ltd | Fluorescence reader |
US20030021016A1 (en) * | 2001-07-27 | 2003-01-30 | Grier David G. | Parallel scanned laser confocal microscope |
US20040175299A1 (en) * | 2001-08-03 | 2004-09-09 | Alexei Belenky | Microscale affinity purification system |
US6919058B2 (en) | 2001-08-28 | 2005-07-19 | Gyros Ab | Retaining microfluidic microcavity and other microfluidic structures |
US6995841B2 (en) * | 2001-08-28 | 2006-02-07 | Rice University | Pulsed-multiline excitation for color-blind fluorescence detection |
US6617137B2 (en) | 2001-10-15 | 2003-09-09 | Molecular Staging Inc. | Method of amplifying whole genomes without subjecting the genome to denaturing conditions |
DE60235485D1 (en) | 2001-10-15 | 2010-04-08 | Nissin Foods Holdings Co Ltd | PRIMER AND METHOD FOR DETECTING BACTERIA |
WO2003044221A1 (en) | 2001-10-19 | 2003-05-30 | West Virginia University Research Corporation | Microfluidic system for proteome analysis |
US7069952B1 (en) | 2001-11-14 | 2006-07-04 | Caliper Life Sciences, Inc. | Microfluidic devices and methods of their manufacture |
US6960298B2 (en) | 2001-12-10 | 2005-11-01 | Nanogen, Inc. | Mesoporous permeation layers for use on active electronic matrix devices |
JP3537802B2 (en) * | 2001-12-18 | 2004-06-14 | ę Ŗå¼ä¼ē¤¾ę„ē«č£½ä½ę | Electrophoresis chip |
JP2003180350A (en) | 2001-12-21 | 2003-07-02 | Terumo Corp | Temperature control device |
JP2003194775A (en) | 2001-12-28 | 2003-07-09 | Japan Science & Technology Corp | Electrophoresis method of protein |
US7141372B2 (en) | 2002-01-18 | 2006-11-28 | Health Research Incorporated | Universal RT-coupled PCR method for the specific amplification of mRNA |
US7846315B2 (en) * | 2002-01-28 | 2010-12-07 | Qiagen Sciences, Llc | Integrated bio-analysis and sample preparation system |
US20040109793A1 (en) * | 2002-02-07 | 2004-06-10 | Mcneely Michael R | Three-dimensional microfluidics incorporating passive fluid control structures |
US20030155966A1 (en) | 2002-02-20 | 2003-08-21 | Harrison Reid R. | Low-power, low-noise CMOS amplifier |
DE10208770A1 (en) | 2002-02-28 | 2003-09-04 | Febit Ag | Increasing the sensitivity and specificity of hybridization experiments with nucleic acid chips |
KR100459896B1 (en) | 2002-03-06 | 2004-12-04 | ģ¼ģ±ģ ģģ£¼ģķģ¬ | Thermostatic control Method and apparatus for Driving a PCR(polymerize chain reaction) chip |
JP2003271735A (en) | 2002-03-12 | 2003-09-26 | Yokogawa Electric Corp | Gene diagnosing and analyzing device, and gene diagnosis support system using the same |
WO2003078586A2 (en) | 2002-03-12 | 2003-09-25 | The Regents Of The University Of California | Vascularized tissue for transplantation |
US7419784B2 (en) * | 2002-04-02 | 2008-09-02 | Dubrow Robert S | Methods, systems and apparatus for separation and isolation of one or more sample components of a sample biological material |
US6606273B1 (en) | 2002-04-11 | 2003-08-12 | Advanced Micro Devices, Inc. | Methods and systems for flash memory tunnel oxide reliability testing |
US20040009518A1 (en) * | 2002-05-14 | 2004-01-15 | The Chinese University Of Hong Kong | Methods for evaluating a disease condition by nucleic acid detection and fractionation |
JP2006501860A (en) * | 2002-05-22 | 2006-01-19 | ćć©ćć£ćć¹ ććÆćććøć¼ćŗ ćØć«ćØć«ć·ć¼ | Substrates, devices and methods for assaying cells |
US6806460B2 (en) | 2002-05-31 | 2004-10-19 | Agilent Technologies, Inc. | Fluorescence detection with increased dynamic range |
EP1509760A1 (en) | 2002-05-31 | 2005-03-02 | Gyros AB | Detector arrangement based on surface plasmon resonance |
US6952651B2 (en) * | 2002-06-17 | 2005-10-04 | Intel Corporation | Methods and apparatus for nucleic acid sequencing by signal stretching and data integration |
US20040018611A1 (en) * | 2002-07-23 | 2004-01-29 | Ward Michael Dennis | Microfluidic devices for high gradient magnetic separation |
US7452507B2 (en) | 2002-08-02 | 2008-11-18 | Sandia Corporation | Portable apparatus for separating sample and detecting target analytes |
US20040197845A1 (en) | 2002-08-30 | 2004-10-07 | Arjang Hassibi | Methods and apparatus for pathogen detection, identification and/or quantification |
US7364848B2 (en) * | 2002-09-02 | 2008-04-29 | Pamgene B.V. | Integrated microarray analysis |
US6923895B2 (en) * | 2002-09-09 | 2005-08-02 | Beckman Coulter, Inc. | Coated capillary electrophoresis tubes and system |
US6737742B2 (en) | 2002-09-11 | 2004-05-18 | International Business Machines Corporation | Stacked package for integrated circuits |
JPWO2004029241A1 (en) * | 2002-09-24 | 2006-01-26 | ę¾äøé»åØē£ę„ę Ŗå¼ä¼ē¤¾ | Method for amplifying nucleic acid by electromagnetic induction heating, reaction vessel and reaction apparatus used therefor |
US7074598B2 (en) | 2002-09-25 | 2006-07-11 | Mayo Foundation For Medical Education And Research | Detection of vancomycin-resistant enterococcus spp. |
US7074599B2 (en) | 2002-09-27 | 2006-07-11 | Mayo Foundation For Medical Education And Research | Detection of mecA-containing Staphylococcus spp. |
TWI230257B (en) * | 2002-10-01 | 2005-04-01 | Univ Nat Cheng Kung | Integrated analytical biochip and manufacturing method thereof |
EP1546412B1 (en) * | 2002-10-02 | 2014-05-21 | California Institute Of Technology | Microfluidic nucleic acid analysis |
JP3813566B2 (en) * | 2002-10-15 | 2006-08-23 | ę Ŗå¼ä¼ē¤¾ćØć³ćć©ć¹ | Resin chip |
DE10258398A1 (en) | 2002-12-11 | 2004-08-12 | Hans-Knƶll-Institut fĆ¼r Naturstoff-Forschung e.V. | DNA amplification method |
US20050042639A1 (en) * | 2002-12-20 | 2005-02-24 | Caliper Life Sciences, Inc. | Single molecule amplification and detection of DNA length |
AU2003303594A1 (en) | 2002-12-30 | 2004-07-29 | The Regents Of The University Of California | Methods and apparatus for pathogen detection and analysis |
WO2004065995A2 (en) * | 2003-01-23 | 2004-08-05 | Alpha Innotech Corporation | Identifying indicia and focusing target |
US20040178971A1 (en) | 2003-03-10 | 2004-09-16 | Goodart Joseph Edgar | Enhanced brightness, color and contrast control for cathode ray tube monitor |
DE10315074A1 (en) * | 2003-04-02 | 2004-10-14 | Clondiag Chip Technologies Gmbh | Device for the duplication and detection of nucleic acids |
RU2005141456A (en) * | 2003-06-06 | 2006-06-10 | ŠŠ°Š¹ŠŗŃŠ¾Š½ŠøŠŗŃ, ŠŠ½Šŗ. (Us) | SYSTEM AND METHOD OF HEATING, COOLING AND THERMAL CYCLING IN A MICRO-LIQUID DEVICE |
US6864571B2 (en) * | 2003-07-07 | 2005-03-08 | Gelcore Llc | Electronic devices and methods for making same using nanotube regions to assist in thermal heat-sinking |
US7205111B2 (en) | 2003-07-24 | 2007-04-17 | Marshfield Clinic | Rapid identification of bacteria from positive blood cultures |
US7150299B2 (en) | 2003-09-12 | 2006-12-19 | Air Products And Chemicals, Inc. | Assembly and method for containing, receiving and storing fluids and for dispensing gas from a fluid control and gas delivery assembly having an integrated fluid flow restrictor |
US7541166B2 (en) * | 2003-09-19 | 2009-06-02 | Microfluidic Systems, Inc. | Sonication to selectively lyse different cell types |
WO2005029062A2 (en) | 2003-09-22 | 2005-03-31 | Shimadzu Corporation | Electrophoretic member electrophoretic device electrophoretic method and sample dispensing probe |
US20050074784A1 (en) * | 2003-10-07 | 2005-04-07 | Tuan Vo-Dinh | Integrated biochip with continuous sampling and processing (CSP) system |
JP2005117988A (en) * | 2003-10-17 | 2005-05-12 | Thermogen Kk | Device for amplifying dna |
US20050109621A1 (en) * | 2003-11-26 | 2005-05-26 | Peter C. Hauser | Method and apparatus for performing high-voltage contactless conductivity (HV-CCD) electrophoresis |
GB2416030B (en) | 2004-01-28 | 2008-07-23 | Norchip As | A diagnostic system for carrying out a nucleic acid sequence amplification and detection process |
WO2005080606A1 (en) * | 2004-02-18 | 2005-09-01 | Xiaochuan Zhou | Fluidic devices and methods for multiplex chemical and biochemical reactions |
US7312036B2 (en) | 2004-03-22 | 2007-12-25 | Isis Pharmaceuticals, Inc. | Compositions for use in identification of viral hemorrhagic fever viruses |
WO2005104323A2 (en) | 2004-03-30 | 2005-11-03 | Purdue Research Foundation | Improved microchannel heat sink |
US7280204B2 (en) * | 2004-04-08 | 2007-10-09 | Purdue Research Foundation | Multi-spectral detector and analysis system |
US7741042B2 (en) | 2004-04-19 | 2010-06-22 | Genomictree, Inc. | Method for preparing a DNA chip and use thereof |
US20060009106A1 (en) * | 2004-05-20 | 2006-01-12 | Daiwbo Co., Ltd. | Wiping sheet |
US7799553B2 (en) | 2004-06-01 | 2010-09-21 | The Regents Of The University Of California | Microfabricated integrated DNA analysis system |
CN103884698B (en) * | 2004-06-07 | 2017-04-12 | å éēē©ē§ęč”份ęéå ¬åø | Optical lens system and method for microfluidic devices |
EP1614466A3 (en) | 2004-07-08 | 2006-05-10 | Tecan Trading AG | System and method to prevent air bubbles in a hybridization chamber |
US7611840B2 (en) * | 2004-08-03 | 2009-11-03 | Agency For Science, Technology And Research | Method and device for the treatment of biological samples |
JP4483469B2 (en) * | 2004-08-05 | 2010-06-16 | ę„ē«é»ē·ę Ŗå¼ä¼ē¤¾ | Electrophoresis device |
WO2006018044A1 (en) | 2004-08-18 | 2006-02-23 | Agilent Technologies, Inc. | Microfluidic assembly with coupled microfluidic devices |
US8053214B2 (en) | 2004-09-09 | 2011-11-08 | Microfluidic Systems, Inc. | Apparatus and method of extracting and optically analyzing an analyte from a fluid-based sample |
CN101073002B (en) * | 2004-09-15 | 2012-08-08 | č±ē¹åŗå ęéå ¬åø | Microfluidic devices |
KR100668304B1 (en) | 2004-09-16 | 2007-01-12 | ģ¼ģ±ģ ģģ£¼ģķģ¬ | A device for the injection of PCR solution into a PCR channel and a PCR chip unit comprising the device |
TWI273240B (en) | 2004-09-27 | 2007-02-11 | Univ Nat Cheng Kung | Reverse transcription polymerase chain reaction chip |
US20060166223A1 (en) | 2005-01-26 | 2006-07-27 | Reed Michael W | DNA purification and analysis on nanoengineered surfaces |
US20060216737A1 (en) * | 2005-03-10 | 2006-09-28 | John Bodeau | Methods for multiplex amplification |
US20060207880A1 (en) * | 2005-03-15 | 2006-09-21 | Joyce Timothy H | Microfluidic devices and methods of using microfluidic devices |
US7275682B2 (en) | 2005-03-24 | 2007-10-02 | Varian, Inc. | Sample identification utilizing RFID tags |
TWI252920B (en) * | 2005-03-25 | 2006-04-11 | Ind Tech Res Inst | Method of fabricating an integral device of a biochip integrated with micro thermo-electric elements and the apparatus thereof |
EP1710017B1 (en) | 2005-04-04 | 2012-12-19 | Roche Diagnostics GmbH | Thermocycling of a block comprising multiple samples |
TW200637919A (en) * | 2005-04-21 | 2006-11-01 | Tang Chun Nan | With an intelligent controller PCR reactor |
US9599611B2 (en) | 2005-04-25 | 2017-03-21 | Trustees Of Boston University | Structured substrates for optical surface profiling |
KR100695148B1 (en) | 2005-05-02 | 2007-03-14 | ģ¼ģ±ģ ģģ£¼ģķģ¬ | Module for polymerase chain reaction and multiple polymerase chain reaction system |
US20060257958A1 (en) * | 2005-05-13 | 2006-11-16 | Pronucleotein Biotechnologies, Llc | Magnetically-assisted test strip cartridge and method for using same |
US8206974B2 (en) | 2005-05-19 | 2012-06-26 | Netbio, Inc. | Ruggedized apparatus for analysis of nucleic acid and proteins |
CN101203744B (en) | 2005-06-02 | 2011-06-29 | åå„„ēē©ęéå ¬åø | Laser micro array chip scanner |
US7939252B2 (en) * | 2005-06-17 | 2011-05-10 | University Of South Carolina | Direct quantification of gene expression using capillary electrophoresis with laser-induced fluorescence |
US20070014699A1 (en) * | 2005-06-23 | 2007-01-18 | Beckman Coulter, Inc, | Methods and apparatus for improving the sensitivity of capillary zone electrophoresis |
US20070009382A1 (en) * | 2005-07-05 | 2007-01-11 | William Bedingham | Heating element for a rotating multiplex fluorescence detection device |
US20090148348A1 (en) | 2005-08-11 | 2009-06-11 | Eksigent Technologies, Llc | Plastic surfaces and apparatuses for reduced adsorption of solutes and methods of preparing the same |
WO2007021809A2 (en) * | 2005-08-11 | 2007-02-22 | Eksigent Technologies, Llc | Microfluidic systems, devices and methods for reducing background autofluorescence and the effects thereof |
JP2009511059A (en) | 2005-10-11 | 2009-03-19 | ćć³ćć£ć¼ć©ć ć¤ć³ć³ć¼ćć¬ć¤ććć | Polynucleotide sample preparation device |
US20070116607A1 (en) * | 2005-11-23 | 2007-05-24 | Pharmacom Microlelectronics, Inc. | Microsystems that integrate three-dimensional microarray and multi-layer microfluidics for combinatorial detection of bioagent at single molecule level |
US8097421B2 (en) | 2005-12-29 | 2012-01-17 | Intel Corporation | Method for performing a multiplex immunoassay using label disassociation and an integrated substrate |
US20070154895A1 (en) | 2005-12-30 | 2007-07-05 | Caliper Life Sciences, Inc. | Multi-assay microfluidic chips |
US7715001B2 (en) | 2006-02-13 | 2010-05-11 | Pacific Biosciences Of California, Inc. | Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources |
TW200808975A (en) * | 2006-04-28 | 2008-02-16 | Basf Ag | Molecular beacons for DNA-photography |
US7629124B2 (en) * | 2006-06-30 | 2009-12-08 | Canon U.S. Life Sciences, Inc. | Real-time PCR in micro-channels |
ES2748134T3 (en) | 2007-04-04 | 2020-03-13 | Ande Corp | Systems for rapid multiple amplification of target nucleic acids |
JP5523327B2 (en) | 2007-10-12 | 2014-06-18 | ć¬ćŖćććÆć¹ļ¼ć¤ć³ć³ć¼ćć¬ć¤ććć | Integrated microfluidic device and method |
US20090253181A1 (en) * | 2008-01-22 | 2009-10-08 | Microchip Biotechnologies, Inc. | Universal sample preparation system and use in an integrated analysis system |
NZ620826A (en) | 2009-02-03 | 2015-09-25 | Netbio Inc | Nucleic acid purification |
US9550985B2 (en) * | 2009-06-15 | 2017-01-24 | Netbio, Inc. | Methods for forensic DNA quantitation |
WO2011112746A2 (en) | 2010-03-09 | 2011-09-15 | Netbio, Inc. | Unitary biochip providing sample-in to results-out processing and methods of manufacture |
-
2008
- 2008-04-04 ES ES08742602T patent/ES2748134T3/en active Active
- 2008-04-04 EP EP15191406.6A patent/EP3032251B1/en active Active
- 2008-04-04 JP JP2010502152A patent/JP2010523115A/en active Pending
- 2008-04-04 AU AU2008236612A patent/AU2008236612B2/en active Active
- 2008-04-04 WO PCT/US2008/059508 patent/WO2009011942A2/en not_active Application Discontinuation
- 2008-04-04 CA CA2984820A patent/CA2984820C/en active Active
- 2008-04-04 US US12/080,746 patent/US8425861B2/en active Active
- 2008-04-04 ES ES08727302T patent/ES2797951T3/en active Active
- 2008-04-04 WO PCT/US2008/004487 patent/WO2008124116A1/en active Application Filing
- 2008-04-04 WO PCT/US2008/004405 patent/WO2008124064A1/en active Application Filing
- 2008-04-04 EP EP17179620.4A patent/EP3284538A1/en not_active Withdrawn
- 2008-04-04 KR KR1020097022842A patent/KR101523260B1/en active IP Right Grant
- 2008-04-04 EP EP20157682.4A patent/EP3677905A1/en active Pending
- 2008-04-04 AU AU2008236691A patent/AU2008236691B2/en active Active
- 2008-04-04 CA CA2682758A patent/CA2682758C/en active Active
- 2008-04-04 CA CA2682761A patent/CA2682761C/en active Active
- 2008-04-04 EP EP08742557A patent/EP2137523A1/en not_active Ceased
- 2008-04-04 NZ NZ602697A patent/NZ602697A/en unknown
- 2008-04-04 KR KR1020097022841A patent/KR20100021565A/en not_active Application Discontinuation
- 2008-04-04 US US12/080,745 patent/US8858770B2/en active Active
- 2008-04-04 ES ES15191406.6T patent/ES2674101T3/en active Active
- 2008-04-04 AU AU2008236739A patent/AU2008236739B2/en active Active
- 2008-04-04 JP JP2010502139A patent/JP5557733B2/en active Active
- 2008-04-04 EP EP19194060.0A patent/EP3626345A1/en not_active Withdrawn
- 2008-04-04 NZ NZ605885A patent/NZ605885A/en unknown
- 2008-04-04 WO PCT/US2008/004462 patent/WO2008124104A1/en active Application Filing
- 2008-04-04 NZ NZ580374A patent/NZ580374A/en unknown
- 2008-04-04 CA CA2682734A patent/CA2682734C/en active Active
- 2008-04-04 NZ NZ580373A patent/NZ580373A/en unknown
- 2008-04-04 JP JP2010502155A patent/JP5675338B2/en active Active
- 2008-04-04 EP EP08727302.5A patent/EP2137522B1/en active Active
- 2008-04-04 KR KR1020097023091A patent/KR101530943B1/en active IP Right Grant
- 2008-04-04 EP EP08742602.9A patent/EP2155393B1/en active Active
- 2008-04-04 CA CA3135182A patent/CA3135182C/en active Active
- 2008-04-04 NZ NZ580375A patent/NZ580375A/en unknown
- 2008-04-04 KR KR1020157033925A patent/KR20150143860A/en not_active Application Discontinuation
- 2008-04-04 CA CA2894945A patent/CA2894945C/en active Active
- 2008-04-04 US US12/080,751 patent/US8018593B2/en active Active
-
2011
- 2011-03-03 US US13/040,156 patent/US9494519B2/en active Active
- 2011-07-27 US US13/191,952 patent/US9366631B2/en active Active
-
2012
- 2012-08-08 US US13/569,971 patent/US8961765B2/en active Active
-
2013
- 2013-04-22 JP JP2013089612A patent/JP2013215195A/en active Pending
- 2013-10-21 JP JP2013218594A patent/JP2014039562A/en active Pending
-
2014
- 2014-07-15 AU AU2014204426A patent/AU2014204426B2/en active Active
- 2014-08-06 JP JP2014160681A patent/JP6105525B2/en active Active
- 2014-12-04 AU AU2014271310A patent/AU2014271310B2/en active Active
-
2015
- 2015-01-13 US US14/595,785 patent/US9994895B2/en active Active
- 2015-07-23 JP JP2015146045A patent/JP6265948B2/en active Active
-
2016
- 2016-05-10 US US15/151,147 patent/US9889449B2/en active Active
- 2016-11-14 US US15/350,605 patent/US20170225164A1/en not_active Abandoned
-
2017
- 2017-08-17 JP JP2017157619A patent/JP2018029586A/en active Pending
-
2018
- 2018-02-12 US US15/894,630 patent/US11110461B2/en active Active
- 2018-06-07 US US16/002,079 patent/US11052398B2/en active Active
-
2019
- 2019-05-14 US US16/411,908 patent/US20200070173A1/en not_active Abandoned
- 2019-12-26 JP JP2019236739A patent/JP2020078301A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2682761C (en) | Methods for rapid multiplexed amplification of target nucleic acids | |
TWI504750B (en) | Methods for rapid multiplexed amplification of target nucleic acids | |
US20220315996A1 (en) | Optical Instruments and Systems for Forensic DNA Quantitation | |
JP2022130735A (en) | Method and apparatus for sequential amplification reaction | |
CN104662160A (en) | Extreme PCR | |
WO2008061129A2 (en) | Methods and compositions related to continuous flow thermal gradient pcr | |
JP2008148690A (en) | Nucleic acid amplification method using microchip and microchip, and nucleic acid amplification system using the same | |
Wang et al. | Towards a portable microchip system with integrated thermal control and polymer waveguides for realātime PCR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20130328 |